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“To explain the mind, we have to show how minds are built from mindless stuff, 
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PARKINSON’S DISEASE 
 
Parkinson’s disease (PD) is a neurodegenerative movement disorder, first (officially) 
described by James Parkinson in ‘An Essay on the Shaking Palsy’ published in 1817.
1
 This 
essay was based on merely six cases he had observed in his own practice as well as on 
walks around his London neighbourhood. Parkinson coined the term paralysis agitans 
(shaking palsy) and described the affected individuals as “having involuntary tremulous 
motion, with lessened muscular power, in parts not in action and even when supported; 
with a propensity to bend the trunk forwards, and to pass from a walking to a running 
pace: The senses and intellect being uninjured”. The French neurologist Jean-Martin 
Charcot recognized the importance of Parkinson’s work four decades later. He emphasized 
that tremor need not be present in the disorder, added a fourth symptom, muscular 
rigidity, to the clinical picture and suggested that the disease be named ‘Parkinson’s 
disease’.
2
 In current clinical practice, tremor, rigidity, brady/hypokinesia and loss of 
postural reflexes are still regarded as the four cardinal motor symptoms of PD. This 
symptom complex is commonly known under the name of parkinsonism.  
It was many years after Parkinson’s essay before the basal ganglia were first recognized by 
Meynert in 1871 as being involved in disorders of abnormal movement.
3
 In 1913, the 
German neurologist Lewy reported specific abnormalities in the brains of individuals with 
PD.
4
 At autopsy, he found cytoplasmic inclusions, now widely recognized as the 
pathological hallmark of the disorder and referred to as Lewy bodies. Soon thereafter, the 
Russian pathologist Tretiakoff was the first to emphasize the importance of the substantia 
nigra when he reported a loss of pigmented cells in this midbrain nucleus in PD patients.
5
 
Although involvement of other brain stem nuclei such as the locus coeruleus was reported 
in studies in the ensuing decades,
6;7
 pathology in the substantia nigra was regarded to be 
most constant and severe.
8
 In 1958, Carlsson and colleagues observed high dopamine 
concentrations in the basal ganglia, and suggested that PD might be associated with a 
dopamine deficiency in the striatum.
9;10
 This speculation was confirmed by the studies of 
Hornykiewicz 
11
 and Sourkes 
12
 in PD patients, and in the mid-1960s considerable evidence 
was gathering in favour of the existence of a nigrostriatal dopaminergic pathway, involved 
in the regulation of motor behaviour. Up to then, pharmacological treatment was largely 
limited to the administration of anticholinergic agents, but now introduction of the first 
exceptionally successful pharmacological treatment of PD followed closely; Birkmayer and 
Hornykiewicz,
13
 and almost concurrently Sourkes and Barbeau,
12
 conceived the idea of 
administering levodopa, a precursor of dopamine, to patients with PD, with spectacular 
results. The treatment of PD evolved in the following years, with optimization of 
administration regimens by Cotzias et al.,
14
 as well as with the introduction of 
decarboxylase inhibitors. By then, the concept of dopamine as a neurotransmitter had
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reached mainstream status and the nigrostriatal pathway had even become a model for 
the study of central synapses.  
The prevailing view of PD over the rest of the 20
th
 century was that of a movement 
disorder of unknown aetiology, principally associated with the degeneration of 
dopaminergic neurons in the substantia nigra and resulting in low levels of dopamine in its 
projection areas in the basal ganglia. Yet, in the meantime, evidence was accumulating 
that PD is actually a multisystem disorder, clinically characterized not only by motor 
deficits, but also by a wide range of non-motor disturbances such as autonomic 
dysfunction, sleep disturbances, cognitive deficits and olfactory dysfunction.
15
  
 
Neuropathology of Parkinson’s disease 
The concept of PD as a multisystem disorder was strongly driven by novel 
neuropathological insights gained from a meticulous study by Braak and co-workers (see 
Figure 1). According to their neuropathological PD staging system,
16
 brain pathology 
evolves following a predictable topographical sequence over the course of the disease. 
The neuropathology of PD is characterized by Lewy bodies and Lewy neuritis,
17
 which are 
protein aggregates containing (among other substances) alpha-synuclein.
18
 PD pathology 
starts with Lewy body inclusions and Lewy neurites within the projection neurons of the 
dorsal IX (glossopharyngeal) and X (vagal) motor nuclei, the medulla oblongata, and the 
anterior olfactory nucleus (stages 1 and 2). During stages 3-4 the severity of the lesions 
increases and neuropathology spreads to the midbrain (in particular the substantia nigra, 
pars compacta, and locus coeruleus) and to the temporal mesocortex and allocortex. 
Besides the progressive damage in subcortical and mesocortical structures at stage 5, the 
olfactory areas are severely affected, and at stage 6, involvement of nearly the entire 
neocortex can be seen, in association with clinical cognitive dysfunction.
16;19
  
During the first pathological stages, clinical motor symptoms are not apparent yet, but 
sensory dysfunction or autonomic failure can be present.
20-24
 Postmortem studies have 
reported alpha-synuclein pathology in the olfactory bulb of up to 20% of ‘healthy’ subjects 
over 55 years,
25;26
 suggesting that the presence of these changes may mark the preclinical 
phase of PD. By the time motor symptomatology arises, as many as 60% of the 
dopaminergic neurons projecting to the putamen already have been lost.
27;28
 
The most striking observation here is that the olfactory system may be among the 
induction sites of the neuropathological process in PD disease, and not the substantia 
nigra. Consequently, the olfactory system is an interesting research focus in PD, e.g. as a 
tool for future early diagnosis as well as to gain insight in the pathophysiology of PD. 
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Figure 1. Ascending stages of brain pathology in idiopathic Parkinson’s disease (PD).  
 
A. In stage 1, first lesions appear in the 
olfactory bulb, anterior olfactory nucleus 
(see arrow), and dorsal motor nucleus of the 
vagal nerve. From stage 2, lesions are 
present in the so-called gain setting nuclei: 
the locus coeruleus, gigantocellular reticular 
nucleus, and caudal raphe nuclei.  
B. In stage 3, pathological changes reach the 
amgygdala, the cholinergic nuclei of the 
basal forebrain, and the pars compacta of 
the substantia nigra. In stage 4, the 
anteromedial temporal mesocortex is the 
first cerebral cortical area to become 
involved. At this juncture, the 
presymptomatic phase probably yields to 
the symptomatic (i.e., clinically evident) 
phase of PD. 
C. Higher order cortical association areas 
become involved in stage 5, followed by 
first-order association areas and primary 
fields in stage 6.  
Increasing degrees of grey shading indicate 
growing severity of the lesions. 
 
(Reproduced with permission from Braak et 
al. J Neural Transm 2003;110:517-536.) 
  
 
 
 
 
 
 
 
THE OLFACTORY SYSTEM 
 
Human olfaction, although a unique sense, is still poorly understood. This could be due to 
the lack of a widely accepted odour classification or to inadequate instrumentation for 
measuring olfactory function, but also to the low value people give to smelling. 
Nevertheless, olfactory (dys)function plays an important role in safety and quality of life, 
adequate nutritional intake and social pleasures. 
Odour perception begins with stimulation of dendritic neurons in the olfactory mucosa of 
the nasal cavity. Odorant molecules bind to receptors on these neurons, which have axons 
passing through the cribriform plate of the ethmoid bone to synapse in the olfactory bulb. 
The olfactory bulb projects via the olfactory tract to five separate areas of the cerebral 
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hemisphere. The first three, the anterior olfactory nucleus, the olfactory tubercle and the 
amygdala, are part of the limbic system, and are thought to be involved in odour memory 
and the emotional processing of odours. The projection to the pyriform cortex (the 
primary olfactory cortex), may be important for olfactory perception and odour 
discrimination. Unlike other primary sensory cortical areas, the input to the pyriform 
cortex is not relayed through the thalamus. The last area to receive input from the 
olfactory bulb is the entorhinal cortex, which projects to the hippocampal formation, a 
structure important in memory, and to the orbitofrontal cortex, which might play a role in 
the conscious perception of smell and odour discrimination.
29;30
 
The identification of a large family of odorant receptor genes by Linda Buck and Richard 
Axel in 1991,
31
 for which they were awarded with the Nobel prize in Physiology or Medicine 
in 2004, led to a revival of scientific interest in what has often been referred to as the 
neglected sense. Since then, giant leaps have been made in the understanding of olfactory 
transduction mechanisms and the organization of the olfactory system. In parallel, 
assessment techniques of olfactory function in humans have rapidly become more 
sophisticated.  
 
Psychophysical testing of olfactory function 
In order to reliably assess olfactory function in clinical practice, many psychophysical tests 
have been developed that provide a quantitative measure of olfactory function. The 
University of Pennsylvania Smell Identification Test (UPSIT) and the “Sniffin’ Sticks” are the 
most widely used. The UPSIT is a 40-item, forced-choice odour identification test, 
originally developed for the US population.
32
 The “Sniffin’ Sticks” is a multimodal olfactory 
test battery that can be used to assess three different aspects of olfactory function: Odour 
identification, discrimination and detection,
33
 each consisting of 16 items.  
Odour detection threshold testing measures the lowest concentration of an odorant that 
can be perceived by a subject. It is generally determined by the administration of 
increasing dilutions of n-butanol or phenylethyl alcohol (PEA) in a single staircase design. 
Odour identification testing involves the perception and naming of an odour presented, 
most often in a forced-choice format. An odour discrimination task measures the ability to 
differentiate between a set of odorants, generally by selecting the odd odour out of a 
series of odorants, all of which are identical except for one, without the need to name or 
recognize the odour. Odour recognition memory can be tested by presenting subjects with 
a set of odours and then, after an interval, requesting the subject to pick the target 
odorant from a series of odours presented. So far, it remains unclear whether these 
aspects are truly separable or represent a common mechanism. In a few studies a 
principal component analysis has been performed, which yielded a primary component on 
which both odour identification and discrimination (and detection thresholds) loaded.
34;35
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When measuring olfactory function, there are a number of confounding factors and 
selection criteria that should be taken into account. Firstly, confounding of olfactory data 
by non-specific cognitive factors is a risk that can vary considerably. For instance, working 
memory and attention can be critical when assessing olfactory discrimination or odour 
recognition memory, whereas language capacity is involved during identification testing 
(for review see 
36
). Cognitive deficits should therefore be ruled out before testing, or taken 
into account when interpreting olfactory data. Furthermore, the type of odours employed 
should preferably activate only the first (olfactory) cranial nerve, and not also the fifth 
(trigeminal) nerve, as this could cloud the interpretation of acuity data. Reduced olfactory 
acuity may, at least theoretically, affect performance on other olfactory tasks and thus 
lead to an underestimation of the actual performance on the olfactory task in question. It 
has been argued that olfactory detection thresholds should therefore always be assessed 
in addition to the specific olfactory modality under consideration and used in appropriate 
statistical analyses to correct for impairments in odour detection.
37
 
A few environmental and demographic factors that can influence olfactory test scores are 
(a history of) smoking, medication, sex, age and exposure to toxic environmental agents. 
Decrements in smell are known to increase with age; especially after the 6
th
 decade there 
is an age-related decline in olfactory function that is superior to the effects of sex or 
smoking.
33;38-40
 Smoking is reported to have a negative effect on odour identification in a 
dose-related manner. However, return of function will occur when smoking is given up, 
corresponding to the amount of prior smoking and duration of cessation.
38
 Findings on the 
relationship between sex and olfactory function indicate that women in general have a 
better sense of smell then men.
38;39
  
 
Functional brain imaging of the olfactory system 
Functional imaging techniques could provide more objective methods to assess olfactory 
function. Olfactory information processing has been studied with electroencephalography 
(EEG), magnetoencephalography (MEG), positron emission tomography (PET) and 
functional magnetic resonance imaging (fMRI) techniques.  
Both fMRI and PET are imaging techniques that measure neuronal activity indirectly by 
means of changes in cerebral blood flow or metabolism, with a high spatial resolution. 
Olfactory brain regions identified by these techniques are highly correlated to known 
anatomical data, such as the pyriform cortex, orbitofrontal cortex, insular cortex, the 
amygdala and other parts of the limbic system that are involved in olfactory information 
processing.
41-49
 
EEG measures electrical potential differences across the scalp that reflect the underlying 
neuronal activity of the brain, in particular synaptic activity (excitatory and inhibitory 
postsynaptic potentials) of cortical pyramidal neurons. It is a non-invasive technique with 
a high temporal, but limited spatial resolution, and easy to employ in a clinical setting. 
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When the brain processes a stimulus, two types of changes in the EEG may occur: Evoked 
activities, which are exactly time-locked to the stimulus, and induced activities, which are 
changes in the EEG that are not phase-locked to the stimulus. The most basic approach to 
study the induced effects of olfactory stimulation was taken by Moncrieff in 1962.
50
 He 
presented healthy subjects with different odours while recording their EEG, and found 
that several odours reduced alpha activity, although probably not as a result of an 
olfactory-specific response but more likely due to arousal effects. Subsequent studies 
using EEG have found both increases and decreases of spectral power in almost all 
frequency bands upon olfactory stimulation.
51-59
 Much of the variation in these studies can 
probably be attributed to differences in EEG recording techniques and conditions, and in 
the type and quality of odours presented. Measurement of olfactory event-related 
potentials (OERPs) involves averaging of brain activity recorded from EEG electrodes 
following the presentation of odours using a so-called constant-flow olfactometer,
60
 
avoiding trigeminal nerve stimulation and assuring a steep stimulus onset that is not 
detectable for the subject. In 1966, Finkenzeller, and in 1967, Allison and Goff first 
described cerebral potentials, which they assumed to be of olfactory origin.
61;62
 
Measurement of OERPs has since become a useful method to quantify olfactory function 
in a manner relatively independent of subjective biases (for review see 
63
). When analyzing 
the averaged, stimulus-locked EEG signal, a number of waveforms can be identified (see 
Figure 2): The N1/P2 component of the event-related potential is generally used to assess 
sensory function,
63;64
 whereas the later P3 component is considered a cognitive 
component.
65
  
 
 
Figure 2. Typical example of an olfactory event-related potential, averaged over 160 trials in a single subject in 
response to H2S, recorded from midline position Cz. 
 
 
Arrow is stimulus onset; N1P2 amplitude is approximately 
20µV. 
 
 
 
 
 
 
 
 
The largest amplitudes after olfactory stimulation are found between 250-750 ms at 
positions Cz and Pz (parietocentral recording sites), and the trigeminal activation is mainly 
located at position Cz. Upon trigeminal stimulation, latencies are shorter, and amplitudes 
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larger than those evoked by pure odorants.
66
 Analyzing these two types of chemosensory 
responses separately is crucial, since they are recorded from similar areas on the skull and 
might therefore interfere with each other. Murphy et al.
67
 provided normative data for the 
OERP across the human life span: OERPs showed smaller N1/P2 and P3 amplitudes and 
longer latencies with increasing age. Furthermore, interindividual differences in OERP 
latencies should be taken into account.
63;68
 When evaluating the clinical significance of 
OERPs, the presence of an OERP indicates the presence of olfactory function, whereas 
absence of an OERP in subjects with intact olfactory function, as determined by 
psychophysical testing, has no diagnostic value.
69
  
MEG measures the magnetic field generated by electrical currents from active neurons in 
the brain, allowing for functional imaging of the brain’s electrophysiology at a millisecond 
temporal resolution. In contrast to EEG, it is a reference-free method and is not impaired 
by distortions created by the conductivity of the scalp.
70
 A recent MEG study using 
frequency analysis combined with a beamforming technique (a method to improve spatial 
resolution by reducing noise), reported olfactory event-related desynchronization in the 
beta and gamma band in the right precentral gyrus, frontal gyri, and the superior parietal 
lobe gyrus.
71
 Olfactory evoked magnetic fields have been found at latencies comparable to 
OERPs, bilaterally in the anterior-central parts of the insula, the parainsular cortex, the 
superior temporal sulcus,
72-75
 and near the orbitofrontal sulcus.
76
 These findings are to 
some extent supported by anatomical regions known to be involved in olfactory 
processing.
30;48;77
 
 
 
OLFACTORY DYSFUNCTION IN PARKINSON’S DISEASE 
 
Olfactory deficits in Parkinson’s disease were first empirically documented in 1975 by 
Ansari and Johnson,
78
 who found higher odour detection thresholds in 45% of PD patients. 
Over the ensuing years it has become clear that most PD patients have olfactory 
disturbances that are not restricted to a single functional modality but include 
impairments of odour detection, discrimination and identification.
79-85
 The reported 
prevalence of the odour identification deficit in PD patients ranges between 50-
90%.
80;85;86
 Nevertheless, only a third of PD patients have a subjective impairment of the 
sense of smell.
85
 The olfactory impairment is generally considered to be bilateral, and 
unrelated to disease stage and duration or the use of dopaminergic medication.
79;83-85;87
 
At present, it is quite firmly established that olfactory dysfunction is already present in 
early stages of the disease,
79;81
 and also occurs in first-degree relatives of PD patients, 
possibly as a first sign of incipient PD.
24;88
 The results of a prospective study in 
asymptomatic first-degree relatives of PD patients using a combination of smell testing 
and single-photon emission computed tomography (SPECT) scanning to assess 
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nigrostriatal dopaminergic function indicate that otherwise unexplained olfactory deficits 
in this population are associated with a 10% risk of developing PD within two years.
23;89
 
Further support for this finding comes from a German study in which 7% of a group of 
subjects with idiopathic hyposmia had newly developed clinical PD symptoms four years 
from baseline.
90
 These findings in selected populations were recently confirmed in the 
Honolulu Asia Aging Study, a large epidemiological cohort study involving 8006 men. In 
this population, deficits in olfactory function were associated with both an increased risk 
of future PD and an increased likelihood of incidental Lewy bodies at autopsy.
91
 
 
Olfactory (dys)function in other neurodegenerative disorders 
In contrast with the severe olfactory impairments in PD, olfactory function in most other 
degenerative movement disorders is either spared or only mildly affected. In progressive 
supranuclear palsy and corticobasal degeneration, for example, olfactory acuity and odour 
identification are intact,
86;92
 whereas multiple system atrophy patients show mild to 
moderate hyposmia.
93;94
 The observed differences in olfactory function between the 
various neurodegenerative movement disorders suggest that smell testing might be 
applied to discriminate between PD and other parkinsonian syndromes in routine clinical 
practice.  
Also in Alzheimer’s disease (AD), the presence of olfactory impairments is a well-
established feature, and in individuals with mild cognitive impairment, odour 
identification deficits have also been reported and constitute a risk factor for later 
conversion to AD.
95;96
 The olfactory deficits in AD appear to be similar in frequency and 
severity to those observed in PD.
97;98
 Nevertheless, there appear to be slight differences in 
the development of the olfactory impairments over time.
99
 These differences in olfactory 
function could be of assistance in differentiating between PD and AD in an early stage. 
 
 
PATHOPHYSIOLOGY OF OLFACTORY IMPAIRMENTS IN PARKINSON’S DISEASE 
 
The pathophysiology underlying the olfactory deficits in PD is far from being elucidated. 
According to the Braak staging system, the olfactory bulb, tract and anterior olfactory 
nucleus may be among the induction sites of PD pathology.
16;19
 In later pathological stages, 
the olfactory bulb and tract are among the brain regions where Lewy bodies and Lewy 
neurites are particularly abundant.
16
 In prior pathological studies, neuronal loss had been 
observed in the anterior olfactory nucleus of PD patients.
100
 Considering that loss of 
dopaminergic neurons in the substantia nigra is an important pathological feature of PD, 
the possibility of a relationship between the olfactory impairments and the dopaminergic 
deficit in PD may seem likely. However, there is little evidence to support this hypothesis. 
For instance, patients with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced 
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parkinsonism show dopamine deficiencies, however without a decreased sense of smell.
101
 
Furthermore, the use of dopaminergic medication does not appear to influence the 
olfactory deficit in PD.
79
 Most striking, however, is a recent study showing that the 
number of dopaminergic neurons in the olfactory bulb in PD is not reduced but, instead, 
doubled in comparison to age-matched controls.
102
 The authors suggest that this 
remarkable increase in the number of dopaminergic neurons may be a factor in the 
pathophysiology of the olfactory deficit in PD, because of the known inhibitory effect of 
activation of dopamine D2 receptors in the olfactory bulb on synaptic input to the bulb.
103
  
Clearly, the above-described pathological data point in different directions and leave many 
questions regarding the pathophysiology of olfactory impairments in PD unanswered. 
Ultimately, we need to know how the known pathological changes contribute to the 
clinical olfactory deficits observed in PD. Therefore, olfactory imaging studies, structural as 
well as functional, are necessary to provide additional information. 
Structural imaging studies have revealed a disruption of the olfactory tract,
104
 but no 
abnormalities of olfactory bulb volume in PD patients.
105
 A recent functional MRI study 
pointed to yet other brain areas that may be involved in PD-related olfactory dysfunction: 
After olfactory stimulation, neuronal activity in the amygdala and hippocampus was lower 
in PD patients when compared to control subjects.
106
 Also, impaired sniffing may 
contribute to the olfactory deficit in patients with PD, although actively increasing sniff 
vigour only slightly improved their odour identification scores.
107
 When applying 
electrophysiological techniques to measure olfactory function, OERP latencies, but not 
amplitudes, were found to be prolonged in PD patients when compared to controls, 
whereas the trigeminal system was not affected by the neuronal degeneration.
80;108
  
So far, MEG studies of olfactory information processing have not been performed in PD 
patients. However, a number of recent studies have used advanced time-series analysis 
techniques of resting-state MEG data to show changes in both local neural synchrony, as 
measured using calculations of spectral power, and functional connectivity between brain 
areas in PD.
109-111
 Furthermore, these advanced analysis techniques have proven their use 
in the analysis of resting-state data in a number of other neurological conditions.
112-115
 
Similar techniques can also be applied to study task-related MEG data,
115;116
 and might be 
promising to gain more insight in the neurophysiological parameters of olfactory 
information processing in both healthy subjects and PD patients. 
 
 
RESEARCH QUESTIONS AND THESIS OUTLINE  
 
In the previous sections, it was emphasized that olfactory dysfunction is a common 
symptom of PD, that may be among the earliest clinical manifestations of this disorder. 
However, still little is known about the (relative) involvement of the various specific 
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olfactory modalities, the optimal test to use for diagnostic purposes or the underlying 
neurophysiological basis of the olfactory dysfunction in PD. 
In this thesis the following research questions are addressed: 
• What is the prevalence and nature of impairments in the different specific olfactory 
modalities in PD and how do they relate to other (motor and non-motor) disease 
characteristics?  
• Which (combination of) olfactory test(s) is best in discriminating PD patients from 
control subjects? 
• Is it possible to explore the neurophysiological basis of olfactory (dys)function by 
means of MEG in healthy controls and PD patients? 
 
To reliably determine the prevalence of olfactory dysfunction in PD patients, normative 
olfactory values for a matched control population are necessary. Normative values for the 
“Sniffin’ Sticks” test battery, are available for the German population, based on over 3000 
subjects.
117
 However, two of the three elements in this test battery are culture-dependent. 
In section I, we provided normative values for the Dutch population over 45 years for the 
two culture-dependent components of the “Sniffin’ Sticks” test battery: Odour 
identification and odour discrimination. 
In section II, we describe the results of a number of studies aimed at elucidating the 
nature and prevalence of impairments in the various olfactory modalities, comparing PD 
patients with two different control populations: Healthy young subjects, and healthy age-
matched subjects. In addition, we studied the relationship between performance on 
odour identification and odour discrimination tasks, and other disease characteristics, 
including motor function, cognition, autonomic function, depressive symptoms, sleep, and 
psychiatric complications, in order to determine whether olfactory (dys)function might 
contribute to the phenotypic characterization of PD patients. The last chapter of this 
section focuses on determining what the best (combination of) olfactory test(s) is to 
distinguish between PD patients and control subjects. 
Section III describes the results of two neurophysiological studies. The initial aim was to 
explore the potential of recording olfactory event-related brain activity to serve both as a 
biological marker of impaired olfactory function in PD and as a means to study the 
pathophysiology of these olfactory deficits. In the first study, we determined the number 
of chemosensory stimuli needed to obtain an optimal signal-to-noise ratio by means of 
EEG. A subsequent pilot study applying these results to MEG showed that olfactory event-
related magnetic fields could not be obtained very consistently in all individuals, not even 
in healthy subjects (unpublished observations). Therefore, we chose to focus on time-
series analyses of MEG data instead, in particular on functional interactions between brain 
areas, as a means to gain more insight in the neurophysiological basis of olfactory 
information processing deficits in PD. We describe the results of the first MEG study to 
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report on the effects of olfactory stimulation on spectral power and functional 
connectivity in both healthy subjects and PD patients. 
Lastly, the general discussion combines the data presented in the various chapters of this 
thesis and provides a consideration of the potential implications as well as future research 
perspectives.  
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ABSTRACT 
 
Aim The aim of the study was to establish normative values for the two culture dependent 
components (odour identification and odour discrimination) of the “Sniffin’ Sticks” test 
battery in the Dutch population over 45 years of age, and to assess the influence of age 
and sex on olfactory function in this population. 
Methods This study was performed in 150 healthy Dutch subjects (87 male and 63 female, 
mean age 59.2 years, range 45-78 years). Olfactory performance was assessed using the 
odour identification and discrimination parts of the “Sniffin’ Sticks” test battery. 
Results In women, odour discrimination scores declined significantly with age, whereas 
there was no effect of age on odour discrimination performance in men. For odour 
identification, there were no effects of age or sex in this population. A moderate 
correlation was found between identification and discrimination test scores. 
Conclusion Provisional population-specific normative data for olfactory testing using the 
identification and discrimination parts of the “Sniffin’ Sticks” olfactory test battery have 
been established for the Dutch population over 45 years of age. The current data are 
applicable to the clinical evaluation of patients with olfactory disorders. 
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INTRODUCTION 
 
The prevalence of olfactory dysfunction in the general population depends on how it is 
defined. Subjective impairments of the sense of smell are present in 1.4% of US adults.
118
 
When using psychophysical tests of olfactory function, approximately 15% of the 
population can be classified as having mild to moderate hyposmia and around 5% as being 
anosmic.
119;120
 With increasing age, the prevalence of hyposmia increases.
117;121;122
 However, 
it is important to realize that there may be a difference between physiological age-related 
loss (“presbyosmia”) and excessive or unexplained loss of olfactory function in older age. 
A recent study 
123
 suggests that true presbyosmia is only a minor component of age-
related olfactory impairments. In this study, much of the commonly observed age-related 
decline in olfactory function appeared to be associated with other age-related factors such 
as use of medication.  
Olfactory dysfunction can also be an early sign of a neurodegenerative disorder, in 
particular Parkinson’s disease 
81;85
 or Alzheimer’s disease.
99
 In Parkinson’s disease, 
hyposmia may even be a prodromal sign, preceding the development of the characteristic 
motor features such as tremor and slowness of movement.
89;124
 Assessment of olfactory 
function in the elderly using validated tests is therefore bound to become an important 
element of early diagnostic strategies in neurodegenerative disorders.
125
 
In order to reliably assess olfactory function, many psychophysical tests have been 
developed that provide a quantitative measure of olfactory function (for review see 
126
). 
The University of Pennsylvania Smell Identification Test (UPSIT) and the “Sniffin’ Sticks” 
are the most widely used. The UPSIT is a 40-item, forced-choice odour identification test, 
developed for the US population.
32
 The “Sniffin’ Sticks” is an olfactory test battery that can 
be used to assess three different aspects of olfactory function: Odour identification, 
discrimination and detection.
33
 Normative values for the “Sniffin’ Sticks” have been 
established in various populations.
117;127;128
 While odour threshold values are not culture 
dependent,
129
 performance on odour identification (and discrimination) tests relies on 
prior exposure to and familiarity with the odours.
130
 This could severely limit the tests’ 
validity in other cultures or populations. For instance, recently published normative values 
for the “Sniffin’ Sticks” in a Greek population 
128
 were clearly different from those in a 
previously published German study.
117
 
The present study was initiated to establish normative values for the two culture 
dependent components (odour identification and odour discrimination) of the “Sniffin’ 
Sticks” in the Dutch population over 45 years of age, and to assess the influence of age 
and sex on olfactory function in this population. 
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METHODS 
 
Subjects 
This study was performed in 150 Dutch subjects (87 male and 63 female, mean age 59.2 
years, range 45-78 years), who did not have a history of major olfactory or neurological 
disorders. The age range was chosen to enable evaluation of olfactory function in (mostly) 
elderly patients with (suspected) neurodegenerative disorders. All participants were 
volunteers recruited among employees and partners of patients from the outpatient 
clinics of the Departments of Neurology of the VU University Medical Center (VUMC; n = 
70) and the Leiden University Medical Center (LUMC; n = 80). All subjects provided written 
informed consent. The study was approved by the Medical Ethics Committees of the 
VUMC and the LUMC. 
 
Olfactory function testing 
The “Sniffin’ Sticks” test battery (Burghart, Wedel, Germany) is an olfactory test battery 
comprising reusable felt-tip pens (‘sticks’) containing odorants dissolved in propylene 
glycol which the subject has to sniff. Olfactory tests were administered birhinally in a 
quiet, well-ventilated room to avoid any background smell interfering with the test 
odours. 
Odour identification was measured by presenting 16 odorants in suprathreshold intensity, 
in a multiple (4)-forced choice format with verbal descriptions. Each stick was held 
approximately 2 cm in front of the nostrils for 2-3 sec, with an interval of 20-30 sec 
between each stick. In the odour discrimination test, subjects were blindfolded and 
presented with 16 odour-triplets, with an interval of 30 sec between each triplet. Each 
triplet consisted of two identical and one aberrant odorant. Subjects were asked to select 
the odd odour out of the three odorants presented, without the need to recognize or 
name the odours.  
In both tests, olfactory scores were defined as the number of correct responses (0-16). The 
test odours and their response choices are listed in Table I a and I b. 
 
Data analysis 
To verify that there were no differences in olfactory test scores between the two sites of 
recruitment (VUMC, LUMC), data from the two centres were compared using the 
univariate general linear model UNIANOVA, with ‘recruitment centre’ as factor, and 
corrected for ‘age’ (covariate) and ‘sex’ (factor). 
To explore the influence of sex and age on olfactory function, olfactory test scores were 
submitted to linear regression analysis by means of a GLM UNIANOVA with ‘sex’ as factor, 
‘age’ as covariate and the interaction ‘age*sex’. Analyses were performed for odour 
identification and odour discrimination separately. 
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Subsequently, the 95% lower bound of the individual prediction interval of the linear 
regression lines for each of the olfactory tests plotted against age was used to determine 
cut-off values for men and women separately in six age-groups (45-49 years, 50-54 years, 
55-59 years, 60-64 years, 65-69 years, ≥ 70 years). When the regression lines for men and 
women coincided, the combined regression line was used to calculate cut-off values. The 
95% prediction interval used indicates that 95% of the population with a specific age will 
have a test score within the computed interval. 
Pearson correlation coefficients were computed to determine the correlation between 
identification and discrimination scores, both overall and for men and women separately. 
To determine which items were best identified, the percentage of subjects that had 
responded correctly was calculated for each item of the identification and discrimination 
tasks. 
Data were analyzed using SPSS 15.0 for Windows (Chicago, IL, USA). 
 
Table I a. Odour identification items. 
 
 
RESULTS 
 
Odour identification scores were not significantly different between centres (VUMC mean 
identification score = 12.5; LUMC = 12.6; F [1,146] = 0.24, p = 0.625). The same was true for 
the discrimination scores of subjects tested at the different centres (VUMC mean 
discrimination score = 11.2; LUMC = 11.7; F [1,146] = 1.37, p = 0.244). Furthermore, there 
was no significant age difference between men (mean age 59.3 years) and women (mean 
age 59.1 years; t = 0.23, p = 0.822). 
 
 Target Alternative response choices % correct responses 
Odour 1 Orange Blueberry, Strawberry, Pineapple 85.3 
Odour 2 Leather Smoke, Glue, Grass 88.7 
Odour 3 Cinnamon Honey, Vanilla, Chocolate 71.3 
Odour 4 Peppermint Chives, Fir, Onion 96.0 
Odour 5 Banana Coconut, Walnut, Cherry 94.7 
Odour 6 Lemon Peach, Apple, Grapefruit 58.0 
Odour 7 Liquorice Caramel, Chewing gum, Biscuit 75.3 
Odour 8 Turpentine Mustard, Rubber, Menthol 38.7 
Odour 9 Garlic Onion, Sauerkraut, Carrot 83.3 
Odour 10 Coffee Cigarette, Wine, Candle smoke 84.7 
Odour 11 Apple Melon, Peach, Orange 48.7 
Odour 12 Cloves Pepper, Cinnamon, Mustard 91.3 
Odour 13 Pineapple Pear, Plum, Peach 70.7 
Odour 14 Rose Chamomile, Raspberry, Cherry 81.3 
Odour 15 Aniseed Rum, Honey, Fir 88.7 
Odour 16 Fish Bread, Cheese, Ham 99.3 
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Table I b. Odour discrimination items. 
 
 
Odour identification 
The mean identification score (± SD) of men and women combined was 12.6 ± 2.3; for men 
only this was 12.5 ± 2.3, and for women 12.7 ± 2.2 (Table II). There was no significant 
interaction effect between age and sex (F [1,146] = 1.59, p = 0.209), nor was there a main 
effect of age (F [1,147] = 0.50, p = 0.480) or sex (F [1,147] = 0.29, p = 0.590). 
 
Table II. Descriptives and parameter estimates of the regression lines for identification and discrimination scores 
plotted against age (in years) of men and women. 
Identification Discrimination  
Male Female All Male Female All 
Mean 12.5 12.7 12.6 11.4 11.5 11.4 
SD 2.3 2.2 2.3 2.2 2.5 2.3 
Intercept 11.97 15.99 13.62 11.46 22.11 15.80 
b coefficient 0.008 -0.056 -0.018 -0.001 -0.179 -0.074 
R
2 
< 0.001 0.033 0.003 < 0.001 0.273 0.055 
p value ns ns ns ns < 0.001 0.004 
ns = non-significant. 
 
 
Regression analysis revealed no significant decline in identification scores with increasing 
age in men (regression coefficient b = 0.008, p = 0.798) or women (b = -0.056, p = 0.157) 
(Table II). Furthermore, the regression lines for men and women were not significantly 
different from each other (F [2,146] = 0.94, p = 0.392). No age effects were found when 
data of all subjects were pooled (b = -0.018, p = 0.473), therefore a horizontal line through 
the overall mean identification score was used to determine the 95% lower bound of the 
 Target Distracter % correct responses 
Odour 1 Octylacetate Cinnamonaldehyde 81.3 
Odour 2 n-Butanol 2-Phenylethanol 68.0 
Odour 3 Isoamylacetate Anethole 76.0 
Odour 4 Anethole Eugenol 78.7 
Odour 5 Geraniol Octylacetate 74.7 
Odour 6 2-Phenylethanol Isoamylacetate 87.3 
Odour 7 (+)-Limonene (+)-Fenchone 80.7 
Odour 8 (-)-Carvone (+)-Carvone 44.0 
Odour 9 (-)-Limonene Citronellal 62.7 
Odour 10 2-Phenylethanol (+)-Menthol 72.0 
Odour 11 (+)-Carvone Geraniol 70.0 
Odour 12 n-Butanol (-)-Limonene 85.3 
Odour 13 Citronellal Linalool 54.7 
Odour 14 Pyridine (-)-Limonene 68.7 
Odour 15 Eugenol Cinnamonaldehyde 70.7 
Odour 16 Eucalyptol α-Ionone 67.3 
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individual prediction interval in order to calculate cut-off values for hyposmia. The 95% 
cut-off value for hyposmia based upon all subjects was 8.81 (see Table III). Ten subjects 
(6.7%; three women, seven men) scored below the 95% lower bound of the individual 
prediction interval for identification scores (Figure 3). 
Items that were best identified by the Dutch subjects were ‘fish’ (99.3% correct) and 
‘peppermint’ (96.0% correct). ‘Turpentine’ was least often identified correctly (38.7% 
correct identification), followed by ‘apple’ (48.7% correct) (Table I a). 
 
Table III. Cut-off values for hyposmia based upon the 95% lower bound of the individual prediction interval of the 
linear regression lines for identification (ID) or discrimination (DIS) scores plotted against age, for both sexes. 
 Cut-off value 95% 
ID male 
Cut-off value 95% 
ID female 
Cut-off value 95% 
DIS male 
Cut-off value 95% 
DIS female 
45-49 years 8.81 8.81 7.76 9.99 
50-54 years 8.81 8.81 7.76 9.15 
55-59 years 8.81 8.81 7.76 8.28 
60-64 years 8.81 8.81 7.76 7.38 
65-59 years 8.81 8.81 7.76 6.46 
≥ 70 years 8.81 8.81 7.76 5.11 
 
 
Odour discrimination 
The mean odour discrimination score of men and women combined was 11.4 ± 2.3; for 
men only this was 11.4 ± 2.2, and for women 11.5 ± 2.5 (Table II). There was a significant 
interaction effect between age and sex (F [1,146] = 12.98, p < 0.001): A decrease in 
discrimination scores with increasing age was found for women (b = -0.179, p < 0.001), but 
not for men (b = -0.001, p = 0.962) (Table II). Furthermore, the regression lines for men 
and women were significantly different from each other (F [2,146] = 6.56, p = 0.002). For 
men, a horizontal line through their mean discrimination score was used to determine the 
95% lower bound of the individual prediction interval in order to calculate cut-off values 
for hyposmia. The 95% cut-off value for hyposmia for men was 7.76 (Table III). For women, 
the 95% lower bound of the individual prediction interval of the regression line was used 
to calculate the cut-off values for hyposmia (Table III).  
A total of six subjects (4.0%; four women, two men) scored below the 95% lower bound of 
the individual prediction interval of the regression lines for discrimination scores (Figure 
4). 
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Figure 3. Identification scores plotted against age.  Figure 4. Discrimination scores plotted against age.  
 
● Male subjects; ○ Female subjects; the solid lines 
are the combined regression line and 95% limits of 
the prediction interval for all subjects. 
 
 
● Male subjects; ○ Female subjects; the solid lines 
are the regression line and 95% limits of the 
prediction interval for male subjects; dotted lines 
are the regression line and 95% limits of the 
prediction interval for female subjects. 
 
 
Odour combinations that were best discriminated by the Dutch subjects were 2-phenyl 
ethanol with distracter isoamyl acetate (87.3% correct), and n-butanol with distracter (-)-
limonene (85.3% correct). The odour combination with target  (-)-carvone and distracter 
(+)-carvone was least often discriminated correctly (44.0% correct), followed by citronellal 
with linalool as distracter (54.7% correct) (Table I b). 
 
Correlation between identification and discrimination scores 
Identification and discrimination scores were only moderately correlated (Pearson 
correlation coefficient r = 0.30, p < 0.001). When analyzed separately for men and 
women, a moderate correlation was found in men (r = 0.35, p = 0.001) but not in women 
(r = 0.23, p = 0.071). At the individual level, two subjects (1.3%, one male: identification 
score = 8, discrimination score = 5; one female: identification score = 7, discrimination 
score = 8) had a deviant score on both tests. 
 
 
DISCUSSION 
 
The present study provides normative data for routine clinical use of the identification and 
discrimination parts of the “Sniffin’ Sticks” olfactory test battery in the Dutch population 
over 45 years of age. Effects of age and sex were observed for discrimination scores, but 
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not for identification scores. Furthermore, only in men a moderate correlation between 
identification and discrimination task performance was found. 
The normative data and cut-off values established for the Dutch population in the present 
study are comparable to the German normative data for subjects over 55 years,
117
 but 
lower than the values recently reported for the Greek population.
128
 Although 
Katotomichelakis et al. suggested that climatological differences would be the most likely 
explanation for the differences between the Greek and German populations, there are no 
clear data to support their hypothesis.
131
 Since performance on olfactory tasks is 
dependent on familiarity with the odours 
130
 and eating habits,
132
 the differences in odour 
discrimination and identification performance between the Greek population on the one 
hand and the German and Dutch populations on the other hand might alternatively be 
explained by a more important role of odours in the Greek cuisine. The odour 
discrimination and identification tasks of the “Sniffin’ Sticks” test battery mainly make use 
of odours related to food and spices, and could therefore give the Greek population an 
advantage over the Dutch and German populations.  
In the present study, there was no influence of sex on odour identification scores in 
healthy controls aged between 45-78 years. Although women have previously been shown 
to outperform men on tests of olfactory function,
121
 data from two recent studies using 
the “Sniffin’ Sticks” 
117;133
 indicate that the influence of sex on identification performance 
may not necessarily be a consistent finding. Hummel et al. found the sex difference to be 
age-related, and only present in subjects under 55 years of age.
117
 The present data 
confirm that there is no sex-effect on odour identification scores in older adult subjects, at 
least when using the “Sniffin’ Sticks”. 
In the present population of subjects over 45 years of age, we were unable to confirm the 
age-related decline in identification scores that has been reported previously.
117;121
 The 
current results are in agreement with the results of two recent studies in which there 
were no significant age-related differences between subgroups of older subjects.
133;134
 In 
the latter study, using “Sniffin’ Sticks”, an age-related difference in odour identification 
scores could only be demonstrated when comparing younger age groups (under 36 years) 
with older age groups (36 years and up).
133
 Apparently, the age-related decline in 
identification scores measured using the “Sniffin’ Sticks” per decade is small, and can 
therefore only be demonstrated in samples with a broad representation of all 
ages.
117;121;128;133;135
 Another factor that may explain the discrepancy with earlier studies, is 
the difference in sample size between the present study and some of the previous 
studies.
117;121
  
Odour discrimination performance in the present study was related to age in women, but 
not in men. In a very large sample, Hummel et al. found odour discrimination performance 
to decline more rapidly with increasing age than identification performance.
117
 In addition, 
women’s discrimination scores tended to decline more than those of men in the age 
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groups 36-55 years and > 55 years. In those over 55 years of age, there was no difference 
in mean odour discrimination score between men and women. The present data obtained 
in a smaller sample are largely in accordance with these findings.  
Previously, Doty et al. found a correlation between identification and discrimination test 
scores of 0.59,
34
 and proposed that both olfactory modalities load on a primary 
component. In the present study, only in men a moderate correlation (0.35) between 
identification and discrimination scores was found, suggesting that the odour 
discrimination task assesses a different aspect of olfactory function than the identification 
task. The differences with respect to the effects of age and sex on the two olfactory test 
scores in the current study seem to strengthen this notion. Several imaging studies 
provide additional anatomical evidence for this concept, demonstrating that olfactory 
functions are mediated by common as well as task-specific regions in the brain.
45
 
Specifically, a PET study showed distinct areas to be active during odour discrimination 
(hippocampus) and identification (Broca’s area and left inferior frontal lobe).
42
 Combining 
all of these data, we hypothesize that odour identification and odour discrimination tests 
involve at least partly differential components of olfactory information processing. 
Cognitive status is an important factor in olfactory function; odour identification may be 
considered a semantic memory task, whereas odour discrimination draws more on 
working memory (for review see 
36
). Variations in cognitive function are inevitable in the 
general population and may therefore influence olfactory function. The aim of the present 
study was to establish normative values applicable to the general population. Therefore 
we did not correct for variations in cognitive function, but did exclude individuals suffering 
from a neurological disorder. It is therefore unlikely that the presence of disease-related 
cognitive dysfunction could have negatively influenced olfactory test scores. 
Data obtained in a recent study 
123
 suggest that the actual physiological age-related 
decline in olfactory function (presbyosmia) is probably smaller and more gradual than 
previously assumed. The authors argue that the commonly observed age-related decline 
in olfactory function results to a large degree from age-related factors, such as use of 
medication or (a history of) nasal disease, that each independently affect olfactory 
function.
123
 Furthermore, smoking is generally reported to be adversely associated with 
olfactory function in a dose-related manner.
136;137
 Clearly, ‘pure’ normative values based 
upon selected healthy, non-smoking subjects are valuable in showing the true effect of 
aging on olfactory function. However, when olfactory testing is used in a clinical setting, 
e.g. to screen for neurodegenerative diseases, it is important to avoid unnecessarily high 
proportions of false positives (subjects with impaired olfactory ability from other causes). 
In this situation, normative values based upon a non-selected heterogeneous population 
as established in this study are more appropriate. 
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Conclusion 
In conclusion, provisional normative values for the identification and discrimination parts 
of the “Sniffin’ Sticks”, as well as cut-off scores for hyposmia, are now available for the 
Dutch population over 45 years of age. Although normative values for younger subjects 
are also recommended, the current results are applicable to the clinical evaluation of 
patients with olfactory disorders, including those with olfactory dysfunction after head 
trauma or (sino)nasal surgery. They can also be used to quantify olfactory function for 
medico-legal purposes. Future applications may include the incorporation of olfactory 
testing into screening strategies for incipient neurodegenerative disorders. 
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ABSTRACT  
 
Aim Previous data on the prevalence of olfactory dysfunction in Parkinson´s disease (PD) 
range from 45% to 90%. The present multicentre study aimed to provide data on the 
prevalence of smell loss in a large sample of PD patients from three independent 
populations.  
Methods Olfactory sensitivity was tested in 400 patients from Australia, Germany, and the 
Netherlands by means of a psychophysical olfactory test, the “Sniffin’ Sticks”, which is 
comprised of three subtests of olfactory function.  
Results Out of the total number of patients 45.0% presented as functionally anosmic, 
51.7% were hyposmic, whereas only 3.3% were normosmic. This indicates that 96.7% of PD 
patients present with significant olfactory loss when compared to young normosmic 
subjects. This figure falls to 74.5%, however, when adjusted to age-related norms.  
Conclusion Thus, olfactory dysfunction should be considered as a reliable marker of the 
disease. 
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INTRODUCTION 
 
There is convincing evidence from numerous studies using both psychophysical 
85;138
 and 
electrophysiological approaches 
108;139;140
 that olfaction is markedly reduced in Parkinson´s 
disease (PD). Data on the prevalence of olfactory dysfunction in PD however, range from 
45% and 49% in the pioneering studies of Ansari and Johnson,
78
 and Ward,
84
 respectively, 
up to 74% in the work of Hawkes et al.
80
, or as high as 90% in a study published by Doty et 
al.
85
 These differences may be due to the type of olfactory test used, sample size, 
normative data used, and age distribution which varied between these investigations. The 
aim of the present study was to more accurately estimate prevalence of olfactory loss in 
PD using a large sample of PD patients from three independent populations. Olfactory 
function should not only be investigated with an odour identification test, therefore other 
tests of olfactory function were used additionally, namely odour threshold measurements 
and the (non-verbal) subjects’ ability to discriminate odours at suprathreshold 
concentrations. 
 
 
METHODS  
 
Subjects 
A total of 400 patients with PD were included in the study (mean age, 64.3 years; range, 
33-85 years; 137 women and 263 men) for retrospective analysis. Disease duration ranged 
from 6 months to 30 years (mean 6.6 years). Patients presented with a mean “Unified 
Parkinson’s Disease Rating Scale III” (UPDRS III) 
141
 score of 22.7 (range, 5-63; mean Hoehn 
and Yahr (H&Y) stage, 2.25; range I-IV).  
This study population comprised patients from public and private movement disorders 
clinics in Brisbane, Australia (n = 164; mean age, 67.0 years; mean duration of the disease, 
7.1 years; mean UPDRS-III 25.2), the Department of Neurology at the University of Dresden 
Medical School, Germany (n = 161; mean age, 62.8 years; mean duration of the disease, 
6.4 years; mean UPDRS-III 28.7), and the Department of Neurology, VU University Medical 
Center, Amsterdam, The Netherlands (n = 75; mean age, 61.5 years; mean duration of the 
disease, 6.8 years; mean UPDRS-III 19.3). Consecutive patients were included in the study. 
Apart from a few newly diagnosed cases United Kingdom Parkinson's Disease Society Brain 
Bank Diagnostic Criteria for PD 
142
 were applied for all patients. Alternatively, DATScan or 
F-DOPA-PET imaging was performed. Previous studies 
143
 suggest that olfactory function 
may differ between subgroups of PD patients depending on their dominant movement 
symptoms. For this reason, where possible, we classified patients as either akinetic-rigid, 
tremor dominant or mixed depending on the presence of a dominating symptomatology. 
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Patients with a history of major sinonasal disease or known cognitive impairment were 
excluded from the study. Dementia screening was not performed. 
Participants underwent a standardized psychophysical olfactory test, the “Sniffin’ 
Sticks”.
33;144;145
 Odorants were presented in pen-like odour dispensing devices. For odour 
presentation the pen's cap was removed by the experimenter for approximately 3 sec; 
then the pen's tip was placed approximately 2 cm in front of both nostrils.  
 
Olfactory function testing 
Testing was performed bilaterally. It involved tests for odour threshold, discrimination, 
and identification (duration of testing was approximately 30 min). Odour thresholds for 
butanol or phenylethyl alcohol were assessed using a single-staircase, 3-alternative 
forced-choice procedure. Sixteen dilutions were prepared in a geometric series starting 
from pure 4% butanol, or phenylethyl alcohol (dilution ratio 1:2 in aqua conservans), 
respectively. This approach was used as previous research had shown that odour 
thresholds obtained with either odour are comparable.
146
 Three pens were presented in a 
randomized order, with two containing the solvent and the third the odorant at a certain 
dilution. The subject’s task was to identify the odour-containing pen. Reversal of the 
staircase was triggered when the odour was correctly identified in two successive trials for 
a total of 7 reversals. Threshold was defined as the mean of the last four staircase reversal 
points. Subjects’ scores ranged between 0 and 16. In the odour discrimination task, triplets 
of pens were presented in a randomized order, with two containing the same odorant and 
the third, a different odorant. Using a 3-alternative forced choice technique, subjects had 
to determine which of three odour-containing pens smelled differently. A total of 16 
triplets were tested. When measuring odour thresholds and odour discrimination, 
subjects were blindfolded to prevent visual identification of some of the odorant-
containing pens. Odour identification was assessed by means of 16 common odours. Using 
a multiple forced choice design, identification of individual odours was performed using a 
list of four descriptors. Again, the subjects’ scores ranged from 0 to 16 (for details see 
33;144;145
).  
Results of the three subtests were presented as a composite “TDI score” (range 0-48) 
which was the sum of the results obtained for threshold, discrimination, and identification 
measures.
40;147
 Using this measure, olfactory abilities can be classified in terms of 
functional anosmia (< 16), hyposmia, and normosmia.
40;123
 Apart from an absolute 
definition of the presence of hyposmia with a TDI < 30.5 (based upon healthy subjects 
aged between 18-35 years), in the present study definitions of hyposmia were also used in 
relation to the subjects´ age. For example, for male subjects aged over 55 years the 
definition of hyposmia applies to a TDI score ≤ 19.75. These definitions of hyposmia are 
based on the results of a previous multicenter study in over 3000 healthy subjects.
117
 In 
contrast, the range of TDI scores which characterize functional anosmia have been 
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established in patients with proven anosmia.
40
 Thus, the TDI score of 15.5 represents an 
age-independent cut-off score that separates functional anosmia from hyposmia. 
 
Data analysis 
Statistical analyses were performed by means of SPSS 14.0 (Chicago, IL, USA). Differences 
between groups (e.g., akinetic-rigid, tremor-dominant, or mixed) were assessed by means 
of ANOVAs (between subject factor ‘group’) with Bonferroni post-hoc testing. The level of 
significance was set at 0.05. The studies had been approved by the local ethics 
committees at the three sites and were performed according to the Guidelines for 
Biomedical Studies Involving Human Subjects (Helsinki Declaration).  
 
 
RESULTS 
 
Olfactory dysfunction in relation to age-independent definitions of hyposmia  
In this analysis we applied age-independent criteria for hyposmia, which have been 
derived from olfactory function in a group of 18-35 year old, healthy subjects, considered 
to be the standard population in terms of normal olfactory sensitivity.
117
 Out of the total 
number of 400 patients 180 (45%) presented as functionally anosmic, whereas only 13 
(3.3%) were normosmic as identified by means of the composite TDI score (mean n=400 17.1; 
range 2-38) (Figure 5).  
 
Figure 5. Olfactory loss in the different groups of Parkinson’s disease patients.  
Results are shown as a composite TDI score (sum of odour threshold, odour discrimination, and odour 
identification score) 
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Separate analysis of olfactory loss for the groups of patients showed that only 3.1% of the 
German PD patients, 2.4% of the Australian, and 5.3% of the Dutch patients presented 
with normosmia, i.e., overall, 96.7% of PD patients suffered from olfactory loss as 
described by the TDI score (Figure 6).  
 
Figure 6. Olfactory function of the total number of 400 Parkinson’s disease patients.  
Results are shown as a composite TDI score (sum of odour threshold, odour discrimination, and odour 
identification score) 
 
 
When the diagnosis was based on the results from individual olfactory tests a slightly 
different picture emerged. Specifically, 17 and 13% of all patients tested had normal odour 
threshold and odour discrimination scores, whereas 4.3% had normal odour identification 
scores (Table IV). When using the combined TDI score 3.3% of the patients were classified 
as normosmic. This clearly indicates that the diagnosis depends on the test used to 
establish this diagnosis, with odour identification tests providing the highest portion of 
olfactory loss. 
 
Table IV. Number/percentage of patients with normosmia and hyposmia/anosmia when assessed with different 
olfactory tests.  
olfactory test diagnosis  n % 
hyposmia / anosmia 387 96.7 TDI score 
normosmia 13 3.3 
hyposmia / anosmia 332 83.0 odour thresholds 
normosmia 68 17.0 
hyposmia / anosmia 349 87.3 odour discrimination 
normosmia 51 12.8 
hyposmia / anosmia 383 95.8 odour identification 
normosmia 17 4.3 
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Olfactory dysfunction in relation to age- and sex-dependent definitions of hyposmia 
When the diagnosis was based on normative data in relation to the subjects’ age and 
sex,
117
 we found that, for the TDI score, 25.5% of the investigated population were 
normosmic whereas 74.5% had hyposmia or were functionally anosmic.  
 
Sex-related differences in olfactory function  
Furthermore, when comparing olfactory sensitivity between male and female PD patients, 
women exhibited significantly higher TDI scores (t = 2.7, p = 0.008), and threshold scores 
(t = 3.1, p = 0.001), indicating better olfactory function. This difference was not seen for 
discrimination (t = 1.6, p = 0.11), and identification scores (t = 1.5, p = 0.14). Men and 
women did not, however, differ significantly in terms of age, duration of the disease, or 
UPDRS score.  
 
Differences between PD subtypes  
With regard to the TDI score there were no significant differences between patients with 
different disease subtypes (tremor dominant type [n = 49], akinetic-rigid type [n = 68] or 
mixed type [n = 114]; p = 0.24; Figure 7). This was also the case when individual tests of 
olfactory function were considered (odour thresholds, odour discrimination, and odour 
identification).  
 
Figure 7. Olfactory function separately for three subtypes of Parkinson’s disease.  
Results are shown separately for odour thresholds, odour discrimination, and odour identification (means, 
standard error of means).  
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Relationship between olfactory function and severity/duration of disease 
Correlational analyses between olfactory sensitivity in relation to the severity of PD were 
made across all patients and, separately, for hyposmic patients only. However, there were 
no significant correlations (Pearson) between the TDI score, duration of disease (r = -0.09, 
p = 0.20), the Hoehn and Yahr scale (r = -0.12, p = 0.18), and the UPDRS-III score (r = -0.09, 
p = 0.19), respectively. Duration of the disease correlated significantly with both UPDRS-III 
score (r = 0.23, p = 0.015) and Hoehn and Yahr score (r = 0.48, p = 0.001). 
 
 
DISCUSSION 
 
The main outcomes of the present study are A) that over 96% of PD patients present with 
olfactory dysfunction - compared to young and healthy subjects. B) More than 80% of PD 
patients with smell loss are functionally anosmic or severely hyposmic, respectively, 
regardless of the olfactory test being used for diagnosis. Additional findings were: C) With 
regard to olfactory function we did not observe major differences between subtypes of 
PD, namely tremor-dominant PD, akinetic-rigid PD, and equivalent-type PD. D) No 
correlation was found between olfactory loss and duration of disease, Hoehn and Yahr 
stage and disease severity as measured by means of the UPDRS III score.  
In three independent populations, the prevalence of olfactory dysfunction in people with 
PD is greater than previously reported with regard to norms obtained in healthy young 
subjects.
78;80;84;85
 There are several differences in methodologies that may contribute to 
differences in estimates of prevalence. The present study used a comprehensive 
psychophysical olfactory function test comprised of three subtests of olfactory function,
33
 
whereas previous work was mostly focused on odour identification tests. We demonstrate 
here that some tests, used alone, provide different estimates of the prevalence of 
olfactory dysfunction (Table IV). With regard to the identification of olfactory deficits it 
appears noteworthy that smell identification appears to be the most sensitive component 
of the TDI index. The TDI index identified only a further 4/400 patients compared to the 
results from odour identification alone. Thus, it appears that in this instance a test of 
odour identification alone might be simpler and equally informative compared to more 
extensive tests – this needs to be explored further.  
 By using age-independent criteria for hyposmia, which have been derived from olfactory 
function in a group of 18-35 year old subjects, a total olfactory loss of 96% in the study 
population was identified – compared to an established olfactory loss of at least 25% in 
the normal population over 52 years of age.
122
 When normative data in relation to the 
subjects’ age and sex were applied however, 74.5% of this study population was 
diagnosed with olfactory loss. Thus, olfactory loss needs to be qualified in terms of the 
olfactory test used and the normative data being applied 
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The present study used a population-based sampling design with large sample size, with 
olfactory function scores compared to normative values based on very large samples,
117
 
whereas other studies have used smaller patient groups matched with control groups 
78;85
 
even though case-control designs are less robust for estimating prevalence. In the present 
study great care was taken to establish a precise diagnosis according to the United 
Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson’s Disease 
whereas in other studies the criteria for inclusion are not always specified.  
The present data also confirmed numerous previous studies with regard to the missing 
correlation between olfactory loss and both duration of disease 
85;139;143
 and the clinical 
severity of PD as measured by means of the Hoehn and Yahr scale and the UPDRS-III 
(compare 
141
) - although some studies found a correlation between the severity of PD and 
certain measures of olfactory function, namely latencies of olfactory event-related 
potentials 
148
 or results from an odour discrimination task.
81
 Overall, this is in line with the 
idea that olfactory dysfunction is an early sign of PD 
149
 which can already be detected at 
the moment when motor symptoms appear. Recent investigations (e.g. 
89;90
) demonstrate 
that olfactory loss is a symptom that is present at the earliest stages of the disease, which 
is also compatible with predictions made on the basis of neuropathological 
investigations.
16
 With regard to pathophysiology of olfactory loss, Huisman et al.
102
 found 
an increase of (inhibitory) dopaminergic neurons in the olfactory bulb in PD patients. They 
interpreted their finding within the context of a possible compensatory mechanism in 
response to the loss of dopaminergic neurons in the basal ganglia.
150
 
With regard to olfactory function we did not find major differences between subtypes of 
PD, namely tremor-dominant PD, akinetic-rigid PD, and mixed-type PD. While this 
confirms previous observations in a small sample size of 37 patients 
93
 the present findings 
are in contrast to reports by Stern and colleagues 
143
 who reported significantly better 
odour identification scores in patients with tremor-predominant PD (n = 40) than in cases 
with postural instability-gait disorder-predominant PD (n = 23). However, because Stern et 
al. investigated a relatively small group of patients and their finding was not confirmed in 
the present study, it may be hypothesized that such differences in olfactory function 
between subgroups of PD are relatively subtle.  
 
Conclusion 
In conclusion, considering the current data on smell loss in over 95% of PD patients, 
olfactory dysfunction has to be seen as a significant marker of the disease which is even 
more frequent than the classical symptom tremor.
151
 Consequently, structured and 
validated tests of olfactory function should be a mandatory part in the diagnosis of PD. Of 
course, it does not make sense to tell individuals with olfactory loss that they are likely to 
end up with a diagnosis of PD, simply because there are so many reasons for olfactory 
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loss.
152
 However, it appears to be valid to question a diagnosis of PD in patients with a 
normal sense of smell.
153
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ABSTRACT 
 
Aim To compare the characteristics of odour discrimination and odour identification 
deficits in a large population of Parkinson’s disease (PD) patients, and to determine which 
of these olfactory tests best distinguishes between PD patients and controls. 
Methods Olfactory performance was assessed in 404 PD patients and 150 controls, using 
the odour identification and discrimination parts of the Sniffin’ Sticks battery. 
Results Mean identification and discrimination scores in PD patients were significantly 
lower than in controls. Linear regression analysis using a 95% confidence interval revealed 
that, relative to the performance of controls, 65.0% of PD patients had an impairment in 
odour identification, whereas 42.1% of patients were impaired on the odour 
discrimination task. ROC curves revealed a higher sensitivity and specificity for odour 
identification than for odour discrimination in separating patients from controls. In PD 
patients, odour discrimination performance decreased with increasing disease duration, 
whereas odour identification was not correlated with disease stage or duration. 
Conclusion In PD, odour identification is more frequently impaired than odour 
discrimination and allows a better discrimination between patients and controls. Although 
an odour identification deficit is generally believed to be independent of disease 
progression, the impairment in odour discrimination appears to increase with disease 
duration. 
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INTRODUCTION 
 
Olfactory deficits in Parkinson’s disease (PD) were first empirically documented in 1975 by 
Ansari and Johnson.
78
 Over the ensuing years it has become clear that most PD patients 
have olfactory disturbances that are not restricted to a single functional modality but 
include impairments of odour detection, discrimination and identification.
79-85
 At present, 
it is quite firmly established that olfactory dysfunction is one of the first and most 
prevalent clinical manifestations of this disorder. Clinical deficits in the sense of smell may 
even precede the development of overt motor symptoms.
23;89;90
 Pathological studies 
support these observations by demonstrating that the olfactory bulb, tract and anterior 
olfactory nucleus may be among the induction sites of PD pathology.
16;19
  
Most studies on olfactory dysfunction in PD have focused on odour identification 
performance using the University of Pennsylvania Smell Identification Test (UPSIT 
32
), or on 
composite scores based on multiple olfactory tests (e.g. the “Sniffin’ Sticks” test battery 
33
). The reported prevalence of the odour identification deficit in PD patients ranges 
between 50-90%,
80;85;86
 and appears to be unrelated to disease stage and duration or the 
use of dopaminergic medication.
79;83-85;87
  
Few studies have reported odour discrimination performance separately in PD. There are 
some indications to suggest that, contrary to odour identification, odour discrimination is 
related to clinical measures of disease progression. In a small sample of PD patients, we 
found that odour discrimination scores correlate with disease stage and severity.
81
 In 
addition, odour discrimination performance in PD patients improves after stereotactic 
neurosurgical treatment using deep brain stimulation,
154
 concurrent with clinical motor 
improvement. In spite of these interesting observations, little is known about the 
prevalence of odour discrimination deficits in PD. In a small sample of PD patients we 
studied previously, only 34% of PD patients scored below two standard deviations of the 
mean of control subjects.
81
 
The present study was initiated to directly compare odour discrimination and odour 
identification deficits, and their relationship with disease stage and duration, in a large 
population of PD patients, and to determine which of these olfactory tests best 
distinguishes between PD patients and control subjects. 
 
 
METHODS 
 
Subjects 
This study was performed in 404 PD patients (253 males; mean age 61.5 years, range 40-
90 years, Hoehn and Yahr (H&Y) stages I-V, disease duration 0-44 years), and 150 control 
subjects without a history of major olfactory or (other) neurological disorders (87 males; 
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mean age 59.2 years, range 45-78 years). PD patients were recruited from the outpatient 
clinics of the departments of Neurology of the VU University Medical Center (VUMC; n = 
72) and the Leiden University Medical Center (LUMC; n = 332). PD was diagnosed 
according to the United Kingdom Parkinson’s Disease Society Brain Bank criteria.
155
 
Patients were tested ‘ON’ medication, and rated for disease stage by means of the H&Y 
scale.
151
 All control subjects were volunteers recruited among hospital employees and 
partners of patients (VUMC (n = 70) and LUMC (n = 80)). All subjects provided written 
informed consent. The study was approved by the Medical Ethics Committees of the 
VUMC and the LUMC. 
 
Olfactory function testing 
The “Sniffin’ Sticks” test battery (Burghart, Wedel, Germany) is an olfactory test battery 
comprising reusable felt-tip pens (‘sticks’) containing odorants dissolved in propylene 
glycol which the subject has to sniff. Olfactory tests were administered birhinally in a 
quiet, well-ventilated room to avoid any background smell interfering with the test 
odours. 
Odour identification was measured by presenting 16 odorants in suprathreshold intensity 
in a multiple (4)-forced choice format with verbal descriptions. Each stick was held 
approximately 2 cm in front of the nostrils for 2-3 sec, with an interval of 20-30 sec 
between each stick. In the odour discrimination test, subjects were blindfolded and 
presented with 16 odour-triplets, with an interval of 30 sec between each triplet. Each 
triplet consisted of two identical and one aberrant odorant. Subjects were asked to select 
the odd odour out of the three odorants presented, without the need to recognize or 
name the odours.  
In both tests, olfactory scores were defined as the number of correct responses (0-16).  
 
Data analysis 
To determine the prevalence of odour identification and odour discrimination deficits in 
Parkinson patients, we compared olfactory test scores between patients and control 
subjects using the general linear model UNIANOVA in SPSS for both sexes separately, with 
factor ‘group’ (PD patients or control subjects), and adjusted for age. For each of the 
olfactory tests, and for men and women separately, we then modelled the 95% lower 
bound of the individual prediction interval of the linear regression lines for control 
subjects plotted against age and used those as a cut-off for hyposmia. When the 
regression lines for men and women coincided, the combined regression line was used as 
a cut-off for hyposmia.
156
 Both sexes were analyzed separately, since olfactory function is 
generally considered to be sex-dependent, also in PD.
157;158
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To establish criteria to best distinguish between PD patients and control subjects, we 
calculated ROC curves for each of the olfactory tests separately, and for both tests 
combined.  
To explore the influence of sex, age, disease duration (in years, based on first symptoms 
perceived by the patient) and disease stage (H&Y stage) on olfactory function in PD 
patients, olfactory test scores were submitted to a linear regression analysis by means of 
an UNIANOVA with factors ‘sex’, ‘age’, ‘disease duration’, ‘disease stage’ and relevant 
interactions. Non-significant interactions were excluded from the analyses. Analyses were 
performed for odour identification and odour discrimination separately.  
For each item in the identification and discrimination tasks, the percentage of subjects in 
each group (patients and control subjects) that had responded correctly was calculated. 
To determine which items best separated patients from control subjects, we subtracted 
the percentage of patients that responded correctly from the percentage of control 
subjects that responded correctly, for each item separately. 
Pearson correlation coefficients were computed to determine the correlation between 
identification and discrimination scores, both overall and for men and women separately. 
Data were analyzed using SPSS 15.0 for Windows (Chicago, IL, USA). 
 
 
RESULTS 
 
Odour identification 
A total of 400 PD patients (250 males) and 150 control subjects (87 males) completed the 
identification task. Both male and female PD patients had lower mean identification 
scores, compared to the control subjects, when adjusted for age (mean identification 
score PD males = 6.9; control males = 12.4; F [1,334] = 305.14, p < 0.001. Mean 
identification score PD females = 8.3; control females = 12.5; F [1,210] = 99.70, p < 0.001). 
260 PD patients (65.0%; 183 males) scored below the 95% lower bound of the individual 
prediction interval for identification scores of the control subjects (Figure 8). 
A cut-off value of 10.5 for the identification task best discriminated between PD patients 
and control subjects, with a sensitivity of 0.83 and a specificity of 0.82 (Table V, Figure 9).  
There were main effects of sex (women performed better than men; F [1,397] = 25.99, p < 
0.001), and age (F [1,370] = 61.75, b = -0.108, p < 0.001) on odour identification scores of 
PD patients. No relationship was found between identification performance and disease 
stage (H&Y stage; F [1,392] = 1.06, p = 0.303) or disease duration (F [1,392] = 0.07, p = 
0.785). 
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Figure 8. Identification scores of Parkinson’s disease (PD) patients plotted against age. 
 
 
 
Solid lines are the regression line and 95% limits of 
the prediction interval for healthy subjects; the 
dotted line is the regression line for PD patients. 
 
 
 
 
 
 
 
 
 
 
Table V. Receiver Operating Characteristics (ROC). 
Optimal cut-off values, associated sensitivity and specificity estimates, and area under the curve (AUC) for each 
olfactory test, determined from ROC curves (Figure 9).  
ID = identification task; DIS = discrimination task; ID plus DIS = identification task plus discrimination task 
 
 
 
Figure 9. Receiver Operating Characteristic (ROC) curves. 
 
 
 
Relating sensitivity and specificity for olfactory 
identification, discrimination, and the combination 
of identification and discrimination scores. 
Solid line represents the odour identification test; 
dotted line represents the odour discrimination 
test; striped line represents the combination of the 
odour identification and discrimination tests 
 
 
 
 
 
 Cut-off value Sensitivity Specificity AUC 
ID 10.5 0.83 0.82 0.91 
DIS 9.5 0.72 0.81 0.83 
ID plus DIS 20.5 0.84 0.85 0.91 
Sniffing out Parkinson’s disease 
53 
Odorants that were identified least often by the PD patients were ‘apple’ (15.3% correct 
identification), ‘cinnamon’ (28.3% correct) and ‘liquorice’ (34.0% correct) (Table VI). Items 
that best separated patients from control subjects were ‘aniseed’ (38.0% vs. 88.7% 
correctly identified), ‘cinnamon’ (28.3% vs. 71.3%), and ‘liquorice’ (34.0% vs. 75.3%). Items 
that least separated patients from control subjects were ‘turpentine’ (36.8% vs. 38.7% 
correctly identified), ‘garlic’ (64.3% vs. 83.3%), and ‘lemon’ (34.3% vs. 58.0%) (Table VI). 
 
Table VI. Identification items. 
 
 
Odour discrimination 
A total of 401 PD patients (251 males) and 150 control subjects (87 males) completed the 
discrimination task. Both male and female patients had lower mean discrimination scores, 
compared to the control subjects, when adjusted for age (mean discrimination score PD 
males = 7.8; control males = 11.3; F [1,335] = 155.05, p < 0.001. Mean discrimination score 
PD females = 8.8; control females = 11.4; F [1,210] = 45.29, p < 0.001).  
169 PD patients (42.1%; 118 males) scored below the 95% lower bound of the individual 
prediction interval for discrimination scores of the control subjects (Figure 10). 
A cut-off value of 9.5 for the discrimination task best differentiated between PD and 
control subjects, with a sensitivity of 0.72 and a specificity of 0.81 (Table V, Figure 9). 
Combining odour identification and odour discrimination did not provide a better 
differentiation between patients and control subjects than identification testing alone 
(Table V, Figure 9). 
 
 
Target Alternative response choices 
% correct 
responses 
PD patients 
% correct 
responses 
controls 
% controls - 
% PD 
patients 
Item 1 Orange Blueberry, Strawberry, Pineapple 54.5 85.3 30.8 
Item 2 Leather Smoke, Glue, Grass 55.8 88.7 32.9 
Item 3 Cinnamon Honey, Vanilla, Chocolate 28.3 71.3 43.1 
Item 4 Peppermint Chives, Fir, Onion 57.3 96.0 38.8 
Item 5 Banana Coconut, Walnut, Cherry 58.0 94.7 36.7 
Item 6 Lemon Peach, Apple, Grapefruit 34.3 58.0 23.8 
Item 7 Liquorice Caramel, Chewing gum, Biscuit 34.0 75.3 41.3 
Item 8 Turpentine Mustard, Rubber, Menthol 36.8 38.7 1.9 
Item 9 Garlic Onion, Sauerkraut, Carrot 64.3 83.3 19.1 
Item 10 Coffee Cigarette, Wine, Candle smoke 45.8 84.7 38.9 
Item 11 Apple Melon, Peach, Orange 15.3 48.7 33.4 
Item 12 Clove Pepper, Cinnamon, Mustard 60.3 91.3 31.1 
Item 13 Pineapple Pear, Plum, Peach 37.5 70.7 33.2 
Item 14 Rose Chamomile, Raspberry, Cherry 48.3 81.3 33.1 
Item 15 Aniseed Rum, Honey, Fir 38.0 88.7 50.7 
Item 16 Fish Bread, Cheese, Ham 69.0 99.3 30.3 
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Figure 10. Discrimination scores of Parkinson’s disease (PD) patients plotted against age. 
 
 
 
Solid lines represent the regression line and 95% 
limits of the prediction interval for healthy subjects; 
the dotted line represents the regression line for 
PD patients. 
 
 
 
 
 
 
 
 
 
In the group of PD patients, a significant interaction was found between sex and age: A 
decrease in discrimination performance with increasing age was found for women (F 
[1,396] = 3.39, b = -0.081, p < 0.001), and men (b = -0.032, p = 0.050). In addition, we 
found a main effect of disease duration on odour discrimination scores (F [1,396] = 13.90, 
b = -0.070, p < 0.001). No relationship was found between discrimination scores and 
disease stage (H&Y stage; F [1,392] = 1.05, p = 0.306). 
Odour combinations that were discriminated least often by the PD patients were target (-
)-carvone and distracter (+)-carvone (38.9% correct), (+)-carvone with distracter geraniol 
(41.9% correct), and (-)-limonene with distracter citronellal (44.4% correct) (Table VII). 
Odour combinations that best separated patients from control subjects were 
anethole/eugenol (47.4% vs. 78.7% correctly discriminated), 
octylacetate/cinnamonaldehyde (51.6% vs. 81.3%), (+)-limonene/(+)-fenchone (51.6% vs. 
80.7%). Odour combinations that least discriminated between patients and control 
subjects were (-)-carvone/(+)-carvone (38.9% vs. 44.0% correctly discriminated), followed 
by citronellal/linalool (48.9% vs. 54.7%), and eucalyptol/α-ionone (51.4% vs. 67.3%) (Table 
VII).  
 
Relationship between odour identification and discrimination test scores 
In PD patients, a moderate correlation was found between odour identification and 
discrimination scores (Pearson correlation coefficient r = 0.50, p <0 .001), also when 
analyzed separately for men (r = 0.43, p < 0.001) and women (r = 0.55, p < 0.001).  
296 PD patients (73.3%; 202 males) scored below the 95% lower bound of the individual 
prediction interval of the control subjects for either identification or discrimination scores. 
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Only 133 PD patients out of 397 PD patients (33.5%; 99 males) had a deviant score on both 
olfactory tests. 
 
Table VII. Discrimination items. 
 
 
 
DISCUSSION 
 
The present study confirms that olfactory dysfunction in PD includes impairments in both 
odour identification and discrimination performance. In the present population of PD 
patients, impaired odour identification performance was more prevalent than a deficit in 
odour discrimination. Moreover, odour identification testing differentiated better 
between patients and control subjects than odour discrimination. Odour discrimination 
performance worsened with increasing disease duration, whereas odour identification 
scores were not correlated with measures of disease progression.  
The prevalence of an olfactory deficit in PD patients on any of the two tasks in this study 
was 73%. A deficit on the odour identification task was present in 65% of PD patients. 
Although this figure is lower than that reported in a previous study by Doty, who found a 
prevalence of 90%,
85
 our data correspond with other studies reporting an odour 
identification deficit in 50-74% of PD patients.
80;86
 The present study is the first to directly 
compare odour identification and odour discrimination in a large population of PD 
patients. Our study shows a prevalence of impaired odour discrimination performance of 
42%, which is clearly lower than the prevalence of odour identification deficits in the same 
 
Target Distracter 
% correct 
responses 
PD patients 
% correct 
responses 
controls 
% controls - 
% PD 
patients 
Item 1 Octylacetate Cinnamonaldehyde 51.6 81.3 29.7 
Item 2 n-Butanol 2-Phenylethanol 45.1 68.0 22.9 
Item 3 Isoamylacetate Anethole 57.4 76.0 18.6 
Item 4 Anethole Eugenol 47.4 78.7 31.3 
Item 5 Geraniol Octylacetate 54.1 74.7 20.6 
Item 6 2-Phenylethanol Isoamylacetate 66.6 87.3 20.7 
Item 7 (+)-Limonene (+)-Fenchone 51.6 80.7 29.0 
Item 8 (-)-Carvone (+)-Carvone 38.9 44.0 5.1 
Item 9 (-)-Limonene Citronellal 44.4 62.7 18.3 
Item 10 2-Phenylethanol (+)-Menthol 54.1 72.0 17.9 
Item 11 (+)-Carvone Geraniol 41.9 70.0 28.1 
Item 12 n-Butanol (-)-Limonene 59.9 85.3 25.5 
Item 13 Citronellal Linalool 48.9 54.7 5.8 
Item 14 Pyridine (-)-Limonene 47.1 68.7 21.5 
Item 15 Eugenol Cinnamonaldehyde 50.9 70.7 19.8 
Item 16 Eucalyptol α-Ionone 51.4 67.3 16.0 
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population and confirms our previous observations using odour discrimination testing in a 
much smaller sample.
81
  
Using the 16-item odour identification part of the “Sniffin’ Sticks” test battery, we found a 
sensitivity of 0.83 and a specificity of 0.82 in discriminating between PD patients and 
control subjects at a cut-off value of 10.5. These sensitivity/specificity values are similar to 
the estimates in previous studies by Doty et al. using the 40-item UPSIT 
138
 and Daum et al. 
using the same 16-item identification subtest of the “Sniffin’ Sticks”.
159
 Combining odour 
discrimination and identification testing did not improve sensitivity or specificity over 
odour identification testing alone. It appears that odour identification can stand alone as a 
reliable and valid measure to discriminate between PD patients and control subjects. 
Lötsch et al. also recently suggested that testing of olfactory function in PD patients could 
be reduced to a single test,
35
 in their case odour detection thresholds. In the present 
study, we did not measure odour detection thresholds, and therefore cannot exclude that 
this modality differentiates better between PD patients and control subjects.  
In the present study, we found a moderate correlation between odour identification and 
discrimination scores in PD patients. Interestingly, this correlation was higher in PD 
patients than in control subjects. This phenomenon may be related to a lower overall 
variance in olfactory test scores in control subjects, leading to a lower correlation between 
the individual tasks than in PD patients. Alternatively, the higher correlation between 
odour identification and discrimination scores in PD patients may reflect a common 
underlying olfactory deficit, such as an increased odour detection threshold (see also 
37
). 
The latter explanation finds support in studies by Doty et al. and Lötsch et al. who found a 
primary component on which both odour identification and discrimination (and detection 
thresholds) loaded.
34;35
 Even though odour identification and odour discrimination may 
share a certain aspect of olfactory function, this does not imply that odour identification 
and discrimination are fully equivalent olfactory modalities. Several imaging studies 
provide additional anatomical evidence for this notion, demonstrating that olfactory 
functions are mediated by common as well as task-specific regions in the brain.
42;45
  
The present study confirms previous findings that the impairment of odour identification 
in PD is independent of disease stage or severity.
85
 For odour discrimination performance, 
however, we found an inverse correlation with disease duration. This result partly relates 
to the observations in a smaller sample of patients, that disease stage and severity 
accounted for part of the variance in discrimination scores of PD patients.
81
 Longitudinal 
follow-up of a small group of five de novo PD patients indicated that olfactory function 
(based on composite scores of multiple olfactory tests) decreased in relation to the 
duration of disease, at least during the first phases of PD.
160
 Further support for a possible 
relationship between olfactory dysfunction and clinical disease variables comes from 
electrophysiological 
108
 and neuropathological studies.
16;100
 Clearly, this relation needs to 
be addressed more thoroughly in future, preferably in longitudinal studies.  
Sniffing out Parkinson’s disease 
57 
A selective hyposmia for identifying specific odorants in PD has been suggested by some 
authors. The very first study, using the UPSIT, reported this phenomenon for the odours 
‘pizza’ and ‘wintergreen’.
161
 Since then, several studies have suggested a ‘selective 
hyposmia’ in PD for a variety of other odorants, including liquorice, pineapple, aniseed, 
banana, dill pickle, gasoline, smoke, cinnamon and mint.
159;162-164
 In the present study, 
odorants that best separated patients from control subjects, based on identification 
scores, were aniseed, cinnamon and liquorice. Considering the sheer number of different 
odorants over the various studies, none of which has consistently been implicated in the 
alleged ‘selective hyposmia’ in PD, we believe that there is no convincing evidence for this 
concept.  
Odours that have related molecular structures might have overlapping chemical and 
psychophysical properties. It is likely that such odours will be recognized by very similar 
sets of odorant receptors, which will make them more difficult to differentiate from one 
another than odorants with highly divergent structures.
165;166
 In this study, the odour 
combination that was least often discriminated correctly was indeed a combination of 
stereo isomers, (-)-carvone and (+)-carvone, that have identical molecular structures. 
However, since this was the most difficult combination in the discrimination test for both 
patients and control subjects, there does not seem to be a selective deficit in 
distinguishing between structurally strongly related odorants in PD. 
 
Conclusion 
Olfactory dysfunction is a consistent feature of PD and includes impairments in odour 
identification and odour discrimination. Odour identification is more frequently impaired 
in PD patients than odour discrimination and allows a better discrimination between PD 
patients and control subjects. The present findings further indicate that, contrary to the 
odour identification deficit, which is independent of disease progression, the impairment 
in odour discrimination increases with disease duration. 
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ABSTRACT 
 
Aim To evaluate the relation between olfactory impairment (OI) and other impairment 
domains in Parkinson’s disease (PD) and the characteristics of OI in patients with certain 
genotypic characteristics. 
Methods In 295 non-demented PD patients and 150 controls with a similar overall age and 
sex distribution, olfactory function was evaluated with the identification (ID) and 
discrimination (DIS) tests of the “Sniffin’ Sticks”. In patients, demographic and clinical 
characteristics were evaluated, and genetic analyses were carried out.  
Results Of all patients, 61% had an impaired ID and 43% had an impaired DIS. Age and sex 
contributed significantly to the explained variance in the ID score regression model (total 
explained variance 22%), whereas age, sex, and disease duration contributed significantly 
to the explained variance in the DIS score regression model (total explained variance 15%). 
Parkin and DJ-1 mutation carriers (homozygous or heterozygous compound, n = 6) had 
normal ID scores. Carriers of apolipoprotein E (APOE) ε2- or APOEε4 allele(s) had no 
significantly different olfactory scores compared to non-carriers. The distribution of the 
alleles of the alpha-synuclein (SNCA)-REP1 polymorphism in groups with a normal or 
impaired ID or DIS was comparable. 
Conclusion OI in PD is not related to other impairment domains. This may indicate that 
olfaction is an independent feature of the disease. Parkin and DJ-1 mutation carriers had 
normal ID scores but the number of patients with mutations is too small to draw 
conclusions. The APOE genotype (APOEε2 or APOEε4 alleles) and SNCA-REP1 
polymorphism do not seem to influence olfaction in PD. 
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INTRODUCTION 
 
Olfactory impairment (OI) is one of the many non-motor features of Parkinson’s disease 
(PD), which may also include cognitive impairment, autonomic dysfunction, depression, 
nighttime sleep problems, daytime sleepiness, and psychiatric complications.
15
 In PD, OI is 
very common and may consist of impairments in the detection, identification (ID), or 
discrimination (DIS) of odours.
80;81
 OI may occur early in the disease course 
81
 and even 
antedate the onset of motor symptoms in PD,
90
 which is in line with pathological findings 
in PD showing that neurodegenerative changes may start in the lower brainstem and 
olfactory bulb, and extend gradually onto the rostral brainstem and cerebral cortex.
16
 
The relation between OI and cognitive impairment in PD patients has been assessed, but 
no associations were found.
84;167
 As far as we know, no other non-motor domains have 
been evaluated with respect to their relation with OI, although relations between OI and 
other premotor manifestations in PD,
22
 such as depression and autonomic symptoms, 
could be expected. Furthermore, only two genotype-phenotype studies evaluated 
olfaction in PD patients with mutations and found that ID scores of patients carrying 
Parkin and LRRK2 mutations and controls were comparable.
168;169
 Therefore, the aims of 
this study were to assess the relations between OI and other impairment domains in PD 
and to evaluate characteristics of OI in patients with certain genotypic characteristics. 
 
 
METHODS 
 
Design 
The study is part of the “PROfiling Parkinson’s disease” (PROPARK) study, a longitudinal 
cohort study of patients with PD (n = 420), who are profiled on phenotype, genotype, 
disability, and global outcomes of health, using valid and reliable assessment instruments 
for PD. Patients from this longitudinal cohort with their annual appointment between 
November 2005 and August 2006 (n = 337) were tested with regard to olfactory function. 
 
Subjects 
All patients fulfilled the United Kingdom Parkinson’s Disease Society Brain Bank criteria for 
idiopathic PD.
155
 Recruitment of patients in the PROPARK study was based on age at onset 
and disease duration, which are important determinants of disease course in PD.
170
 The 
recruitment procedure has been described elsewhere.
171
 For this particular study, patients 
with Mini Mental State Examination (MMSE) scores < 24 were excluded. No other 
selection criteria were applied. Most patients were assessed at the Leiden University 
Medical Center (LUMC). To avoid bias towards recruiting less severely affected patients, 
patients who were unable to come to the hospital were assessed at home. Controls (n = 
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150) were volunteers recruited among employees and partners of patients from the 
outpatient clinics of the Departments of Neurology of the LUMC (n = 80) and the VU 
University Medical Center (VUMC; n = 70). Controls had no history of major olfactory or 
neurological disorders and were selected to match the overall age and sex distribution of 
the patients. Characteristics of the controls have been published elsewhere.
156
 This study 
was approved by the medical ethical committees of the LUMC and VUMC and all 
participants gave informed consent. 
 
Olfactory function testing 
For the “Sniffin’ Sticks” ID test,
33
 16 odorants in suprathreshold intensity were presented, 
in a multiple-forced choice format with four descriptions (written and verbal). Each stick 
was held approximately 2 cm in front of the nostrils for 2-3 sec, with an interval of 20-30 
sec between each stick.  
For the “Sniffin’ Sticks” DIS test,
33
 subjects were blindfolded and presented with 16 odour-
triplets, with an interval of 30 sec between each triplet. Each triplet consisted of two 
identical and one deviant odorant. Subjects were asked to select the odd odour out of 
three odorants presented, without the need to recognize or name the odours. 
The tests were administered birhinally in a well-ventilated room to avoid any background 
smell interfering with the test odours. In both tests, olfactory scores were defined as the 
number of correct responses (0-16). Both olfactory tests have been proven to be reliable 
and valid in controls.
33
 To determine if patients had an impaired ID or DIS, “Sniffin’ Sticks” 
cut-off points of ID and DIS for age and sex groups which were based on control values, 
were used as described previously.
156
 
 
SCOPA/PROPARK 
Within PROPARK, all patients received a standardized assessment, including evaluation of 
demographic and clinical characteristics, family history of PD, and medication use. 
Measurement instruments for the different clinical domains of PD were derived from a 
prior project (SCales for Outcomes in Parkinson's disease: SCOPA).
172
 
For the current study, data obtained for disease severity (Hoehn & Yahr (H&Y)),
151
 motor 
function (SPES/SCOPA-motor, range 0-42),
173
 cognition (SCOPA-COG, range 0-43),
174
 
autonomic function (SCOPA-AUT, range 0-69),
175
 depressive symptoms (Beck Depression 
Inventory (BDI), range 0-63),
176
 nighttime sleep (SCOPA-SLEEP NS, range 0-15) and daytime 
sleepiness (SCOPA-SLEEP DS, range 0-18),
177
 and psychiatric complications (first six items of 
the SCOPA-PC, range 0-18) 
178
 were used. Except for the SCOPA-COG, higher scores 
indicate more severe impairment. Motor phenotype (tremor-dominant, postural 
instability gait difficulty (PIGD), or indeterminate) was determined for every patient with a 
method that has been described earlier.
179
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All instruments were either self-administered (SCOPA-AUT, BDI, SCOPA-SLEEP) or 
administered by trained research associates (H&Y, SPES/SCOPA-motor, SCOPA-COG, and 
SCOPA-PC). For reasons of comparability, all patients who used levodopa or a dopamine-
agonist and experienced motor fluctuations, were assessed during ‘ON’-state. For each 
patient, a total levodopa equivalent (LDE) for the dose of levodopa and dopamine agonists 
was calculated.
180
 
 
Genetic testing 
Peripheral blood was collected and genomic DNA was isolated according to standard 
procedures.  
 
Mutation screening 
DNA from patients was screened for the most frequent LRRK2 mutations which occur at 
the exons 19, 31, 35, 38, 41 and 48, whereas only DNA from patients with an age at onset < 
50 years was screened for Parkin, DJ-1 and PINK1 mutations by direct sequencing of all 
exons. Additionally, DNA from patients with an age at onset < 50 years was screened for 
the A30P missense mutation in the alpha-synuclein (SNCA) gene and analyzed for genomic 
rearrangements (including deletions and duplications) for all exons of SNCA, Parkin, DJ-1, 
and PINK1 genes except for exons 2 and 4 of the DJ-1 gene with the multiplex ligation-
dependent probe amplification method. 
 
APOE genotyping 
For APOE allelic discrimination, two non-synonymous coding single nucleotide 
polymorphisms (SNPs), rs429358 (R130C) and rs7412 (R176C), were genotyped. A validated 
TaqMan assay was used for detection of these SNPs, catalog numbers C_3084793_20 and 
C_904973_10 (Applied Biosystems, Foster City, CA). For double heterozygotes a direct 
PCR-based restricted fragment length polymorphism method was used. In brief, this 
method consisted of PCR amplification of a APOE fragment (244b) containing the gene 
region encoding the amino acids 130 and 176 (primers AAACGCGGGCACGGCTGTCCAAG 
and AAAAAAAAAGCCCCGGCCTGGTACACTG) followed by cleavage with Hhal Fastdigest 
Enzyme (Fermentas) and electrophoresis in a 15% non-denaturing polyacrylamide gel.
181
 
 
SNCA genotyping 
PCR was performed with 20 ng of DNA and the following conditions: An initial 
denaturation of 95°C for 12 min, followed by 30 cycles of denaturation at 94°C for 30 sec, 
annealing at 55°C for 30 sec and extension at 72°C for 30 sec. The final extension was at 
72°C for 45 min. 
The sequence of PCR primers are: Fluorescent-labelled Forward, 5'-
CCTGGCATATTTGATTGCAA-3', and Reverse, 5'-GACTGGCCCAAGATTAACCA-3'. Two µl of 
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50X diluted PCR product was mixed with 10 µl of the following mixture, which was 
prepared with 10 µl of 500 Liz size standard (ABI) in 1000 µl of formamide (ABI). The 
mixture consisting of diluted PCR product and size standard-formamide was denaturated 
at 95°C for 5 min and cooled on ice for 10 min. Fluorescent labelled PCR fragments were 
resolved by the capillary electrophoresis on an ABI 3730 and allelic sizes assessed using 
GeneMapper® software version 4.0 provided by ABI. 
 
Statistical Analysis 
If 25% or more of the data from a questionnaire or scale was missing, data from this scale 
for this patient was excluded from statistical analyses. Differences between groups were 
analyzed with Chi-square tests (Χ
2
), student’s T-tests for independent samples, or analysis 
of covariance. Pearson’s correlation coefficient or Spearman’s rho were used to assess 
relations between ID or DIS scores and other demographic and clinical variables. Multiple 
forward linear regression analyses were used to explore the contribution of different 
variables to the ID and DIS score. A p-value < 0.05 was considered significant. All analyses 
were performed with SPSS 14.0 Software (Chicago, IL, USA). 
 
 
RESULTS 
 
Of the 337 patients, four patients had too many missing values on both the ID and DIS test 
and were therefore excluded from the study. Furthermore, 35 patients had MMSE scores 
< 24 and three patients had a missing MMSE score, and were also excluded. In total, 295 
patients (65% men) with a mean (SD) age of 60.2 (10.6) years participated in the study 
(Table VIII). Two patients had too many missing values on the ID test and were therefore 
excluded from analyses for that particular test.  
 
Olfaction in patients 
The patients had a mean (SD) ID score of 7.6 (3.0), and a mean (SD) DIS score of 8.3 (2.6). 
Women had higher scores than men on both tests (ID mean scores: 8.7 versus 7.1 (mean 
difference 1.6, 95% CI 0.9 to 2.3); DIS mean scores: 9.2 versus 7.9 (mean difference 1.3, 
95% CI 0.6 to 1.9)). Current smokers (n = 19) were younger than non-smokers (n = 260) 
(mean difference -8.5, 95% CI -13.4 to -3.6). After correction for age, olfactory scores of 
smokers and non-smokers were comparable (ID: F = 0.88, p = 0.350; DIS: F = 2.81, p = 
0.095). 
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Table VIII. Characteristics of patients with Parkinson’s disease. 
Characteristics Patients 
No. of patients 295 
Sex (M/F) 192/103 
Age, in years; mean (SD) 60.2 (10.6) 
Disease duration, in years; mean (SD) 11.8 (6.3) 
Age at onset, in years; mean (SD) 48.4 (11.2) 
Hoehn and Yahr stage (%; 1/2/3/4/5/missing) 4/42/37/14/2/1 
Motor phenotype (%)  
     Tremor-dominant 37 
     PIGD 50 
     Indeterminate 12 
     Missing 1 
Total LDE, mg/day; mean (SD) 683.5 (513.5) 
Levodopa therapy, no. of patients 214 
Dopamine-agonist therapy, no. of patients 211 
PIGD: postural instability gait difficulty; LDE: levodopa dosage equivalent 
 
 
Patients had lower scores on both tests compared to controls (ID: mean difference -4.9, 
95% CI -5.4 to -4.4; DIS: mean difference -3.1, 95% CI -3.6 to -2.6). Lower scores for 
patients in comparison with controls were also found when analyzing scores of women 
and men separately (women ID: mean difference -4.0, 95% CI -4.8 to -3.2; women DIS: 
mean difference -2.4, 95% CI -3.2 to -1.5; men ID: mean difference -5.4, 95% CI -6.0 to -
4.8; men DIS: mean difference -3.5, 95% CI -4.1 to -2.9). 
Overall, 293 patients had valid scores on both olfactory tests, of which 27% had no OI (n = 
78, 42% men), 43% had impaired ID or impaired DIS (n = 126, 70% men), and 30% had 
both impaired ID and DIS (n = 89, 78% men). 
 
Subgroup evaluations  
Of 293 patients with valid scores on the ID test, 178 patients (61%) had an impaired ID. 
These patients were significantly more often men, older, had a significantly older age at 
onset, more severe PD as measured by H&Y, more motor, cognitive, and psychiatric 
problems, and experienced significantly more daytime sleepiness, compared to patients 
with normal ID (Table IX). 
Of 295 patients with valid scores on the DIS test, 128 patients (43%) had an impaired DIS. 
Patients with an impaired DIS were more often men (Χ
2
:8.3, p = 0.004), were younger 
(mean difference -6.9, 95% CI -9.2 to -4.7), and had a younger age at onset (mean 
difference -7.7, 95% CI -10.1 to -5.3) compared to patients with a normal DIS. 
Patients with a tremor-dominant phenotype (n = 110) were younger than patients with a 
PIGD phenotype (n = 148) (mean difference -5.2, 95% CI -7.7 to -2.6), but had comparable 
olfactory scores after correcting for age influences (ID: F = 0.21, p = 0.646; DIS: F = 0.12, p 
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= 0.726), or when analyzing women and men separately (women ID: F = 2.29, p = 0.134; 
women DIS: F = 0.13, p = 0.722; men ID: F = 0.85, p = 0.357; men DIS: F = 0.13, p = 0.908). 
 
Table IX. Characteristics of patients with Parkinson’s disease with impaired and normal ID. 
Characteristics Impaired ID Normal ID 95% CI p-value 
No. of patients 178 115 - - 
Sex (M/F) 133/45 57/58 - < 0.001
2
 
Age, in years; mean (SD) 62.6 (10.1) 56.3 (10.1) 4.0 to 8.7
1
 - 
Disease duration, in years; mean 
(SD) 
12.0 (6.1) 11.2 (6.1) -0.7 to 2.2
1
 - 
Age at onset, in years; mean (SD) 50.7 (11.1) 45.0 (10.5) 3.1 to 8.2
1
 - 
Hoehn and Yahr stage (%; 
1/2/3/4/5/missing) * 
2/38/41/16/2/2 7/50/30/11/1/1 - 0.03
2
 
Total LDE, mg/day; mean (SD) 713.4 (474.3) 637.9 (570.9) -46.8 to 197.7
1
 - 
SPES/SCOPA-motor score; mean 
(SD) 
15.2 (5.5) 13.1 (5.3) 0.7 to 3.3
1
 - 
SCOPA-COG score; mean (SD) 27.0 (5.9) 29.6 (5.3) -4.0 to -1.3
1
 - 
SCOPA-AUT score; mean (SD) 18.5 (8.2) 16.9 (8.2) -0.3 to 3.6
1
 - 
SCOPA-SLEEP NS score; mean (SD) 4.7 (3.6) 4.6 (3.3) -0.7 to 2.2
1
 - 
SCOPA-SLEEP DS; mean (SD) 5.4 (4.0) 4.3 (3.7) 0.2 to 2.0
1
 - 
SCOPA-PC score; mean (SD) 2.4 (1.9) 1.8 (1.6) 0.2 to 1.0
1
 - 
BDI score; mean (SD) 9.5 (6.2) 10.0 (6.6) -2.0 to 1.0
1
 - 
ID = identification; LDE = levodopa dosage equivalent; NS = nighttime sleep; DS = daytime sleepiness; SCOPA-PC = 
SCOPA-Psychiatric Complications; BDI = Beck Depression Inventory 
*
 sum of percentages does not equal 100 due to rounding off 
1
 student’s T-tests for independent samples; Χ
2
: Chi-square test 
 
 
Determinants of ID and DIS scores 
There were no significant moderate or strong correlations (r > 0.4) found between ID and 
DIS scores and other demographic or clinical variables. The multiple regression analysis 
revealed that age (15%) and sex (7%) accounted for the 22% explained variance of the ID 
score (total regression model; p < 0.001) where lower age and female sex were associated 
with higher ID scores. Age (6%), sex (5%), and disease duration (4%) together explained 
15% of the variance of the DIS score (total regression model; p < 0.001) where lower age, 
female sex and shorter disease duration were associated with higher DIS scores (Table X). 
 
Olfaction in relation to genotypic characteristics 
DNA from 268 patients was screened for LRRK2 mutations and genotyped for APOE 
polymorphisms, whereas the SNCA-REP1 polymorphism was genotyped in 247 patients. 
DNA of 159 patients with an age at onset ≤ 50 years was screened for the SNCA A30P 
mutation and mutations in Parkin, PINK1, and DJ-1. 
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Table X. Determinants of ID and DIS scores in patients with Parkinson’s disease.  
 Variable
1,2
 R square Standardized β 
Age 0.15 -0.378 
Sex 0.07 -0.263 
ID score 
Total 0.22 - 
Age 0.06 -0.203 
Sex 0.05 -0.243 
Disease duration 0.04 -0.180 
DIS score 
Total 0.15 - 
ID = identification; DIS = discrimination 
1
 Multiple forward linear regression analysis was used with the variables: 
Age, sex, disease duration, total LDE, H&Y stage, cognitive functioning, autonomic functioning, depressive 
symptoms, nighttime sleep, daytime sleepiness, psychiatric complications 
2
 Variables are ordered in the table as they appeared in the model 
  
 
Mutation carriers 
One patient had a mutation in heterozygous state in the LRKK2 gene. In total, six patients 
had homozygous or compound heterozygous mutations in Parkin (n = 5) or DJ-1 (n = 1). No 
patients had an A30P mutation in the SNCA gene or compound heterozygous or 
homozygous mutations in the PINK1 gene. The LRRK2 mutation carrier had impaired ID but 
normal DIS. The Parkin mutation carriers had either normal olfactory scores (n = 2) or 
normal ID but impaired DIS (n = 3). The DJ-1 mutation carrier had normal ID but impaired 
DIS (Table XI). 
 
Table XI. Olfaction scores of mutation carriers. 
Patient no. Genotype  ID DIS 
1 Parkin homozygous Normal Normal 
2 Parkin homozygous Normal Normal 
3 Parkin homozygous Normal Impaired 
4 Parkin homozygous Normal Impaired 
5 Parkin compound heterozygous Normal Impaired 
6 DJ-1 homozygous Normal Impaired 
7 LRRK2 heterozygous Impaired Normal 
ID = identification; DIS = discrimination 
 
 
Influence of APOE genotype on olfaction 
Of 268 patients in which APOE genotype was determined, 76 patients carried one (n = 71) 
or two (n = 5) APOEε4 allele(s). No age (mean difference -2.6, 95% CI -5.3 to 0.1) or sex 
(Χ
2
:1.4, p = 0.243) differences existed between APOEε4 allele-positive or APOEε4 allele-
negative patients. Olfactory scores were comparable between APOEε4 allele-positive and 
APOEε4 allele-negative PD patients (ID: mean difference 0.7, 95% CI -0.1 to 1.5; DIS: mean 
difference 0.3, 95% CI -0.4 to 1.0). Furthermore, 42 patients carried an APOEε2 allele. No 
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differences in age (mean difference 0.5, 95% CI -2.9 to 3.9) or sex (Χ
2
:1.6, p = 0.205) were 
found between APOEε2 allele-positive or APOEε2 allele-negative patients. Olfactory scores 
were comparable between APOEε2 allele-positive and APOEε2 allele-negative PD patients 
(ID: mean difference 0.0, 95% CI -1.0 to 1.0; DIS: mean difference -0.5, 95% CI -1.4 to 0.3). 
 
Influence of SNCA-REP1 polymorphism on olfaction 
The SNCA-REP1 genotype was determined in the DNA of 247 patients. Four alleles (266, 
268, 270 and 272) of this polymorphism were observed in our population. Only one copy 
of the 272-allele was present in our population and was therefore excluded from the 
analyses. The allele distribution in the groups with an impaired or normal ID (Χ
2
:1.0, p = 
0.617) or in the groups with an impaired or normal DIS (Χ
2
:3.6, p = 0.167) were 
comparable. 
 
 
DISCUSSION 
 
The aims of this study were to assess the relations between OI and other impairment 
domains in PD and to evaluate characteristics of OI in patients with certain genotypic 
characteristics. In this study, olfactory scores were lower in men and older patients, and 
not influenced by smoking status, which is in line with other studies.
138;143;159;163
 Contrary to 
the results of a previous study, olfactory scores did not differ between patients with a 
tremor-dominant or PIGD phenotype.
143
 In our sample of non-demented PD patients, OI 
occurred in a large proportion of patients with PD, with ID being more frequently impaired 
(61%) than DIS (43%), which was also found in a previous study with a largely overlapping 
population.
182
 Most other studies, however, reported higher percentages of impaired 
patients.
80;163
 Differences between our results and results of others could be due to the 
use of different olfactory tests or differences in sample characteristics.  
In our study a relatively high percentage of patients has normal olfaction. Concerning 
neuropathology in PD, evidence has been presented for a sequential involvement of 
different regions of the central nervous system.
183
 Braak stage 1 reflects involvement of 
the olfactory bulb, the anterior olfactory nucleus, and the dorsal motor nucleus of the 
vagal nerve.
183
 A longitudinal study in patients with PD showed that in some patients 
olfactory function improved over time.
184
 Furthermore, a significant improvement of DIS 
was noted in patients with PD treated with subthalamic deep brain stimulation.
154
 These 
findings suggest that OI cannot be accounted for by cell loss only and may indicate a role 
of other mechanisms like complex adjustments in neuronal activities and network 
interactions.
185
 In view of the large percentage of patients with normal olfaction, our 
findings apparently indicate a differential vulnerability of the olfactory circuitry to the 
different disease mechanisms that may operate in PD. 
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An important finding of this study is the absence of relations between olfaction and other 
specific PD features. The lack of relation between OI and disease severity has also been 
described by others,
93
 whereas relations with other non-motor symptoms, except for 
cognition,
84;167
 have not been evaluated before. Here we show that OI has no relation with 
any of the other impairment domains of PD. Apparently, OI, like tremor 
186
 behaves as an 
independent feature of the disease. The lack of relations found between OI and other 
early non-motor symptoms of PD could be due to the long mean disease duration of our 
cohort (12 years). To reliably evaluate the relation between OI and other early non-motor 
symptoms, an incident patient cohort would be more appropriate. 
Our study shows that homozygous or compound heterozygous Parkin and DJ-1 mutation 
carriers had normal ID, whereas the heterozygous LRRK2 mutation carrier had impaired 
ID. Three out of five mutation carriers had an impaired DIS. There were no homozygous or 
compound heterozygous PINK1 mutation carriers or SNCA mutation carriers in our cohort. 
Hitherto, the only studies evaluating olfaction in mutation carriers have been evaluating ID 
in homozygous and heterozygous (single and compound) Parkin mutation carriers and in 
LRRK2 mutation carriers.
168;169
 These studies also reported normal ID in these 
patients,
168;169
 in accordance with our findings in Parkin mutation carriers. Although our 
findings on ID in Parkin mutation carriers corroborate those of others, our results make it 
impossible to draw conclusions because of the few mutation carriers. 
The APOEε2 allele and APOEε4 allele are both described as risk factors for PD.
187;188
 The 
APOEε4 allele also is a well-known risk factor for Alzheimer’s disease,
189
 a disease that is 
also associated with OI.
190
 Non-demented persons with at least one APOEε4 allele have 
been shown to have a significantly poorer ID than those without an ε4 allele,
190
 which 
could indicate that the presence of an APOEε4 allele by itself is associated with OI. The 
results of our study show that in PD neither the ε4 nor the ε2 allele seems to contribute to 
OI. Finally, there was no significant effect from the different alleles of the SNCA-REP1 
polymorphism on olfaction. 
 
Conclusion 
This study shows that OI in PD is unrelated to other impairment domains of the disease. 
Considering genotypic characteristics, Parkin and DJ-1 mutation carriers had normal ID 
scores whereas the APOE genotype (APOEε2 or APOEε4 alleles) and SNCA-REP1 
polymorphism do not seem to influence olfaction in PD. 
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Chapter 5 
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independently impaired in Parkinson’s 
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ABSTRACT 
 
Aim The results of previous studies in small groups of Parkinson’s disease (PD) patients are 
inconclusive with regard to the presence of an odour recognition memory impairment in 
PD. The aim of the present study was to investigate odour recognition memory in PD in a 
larger group of patients. 
Methods Odour recognition memory and detection thresholds were assessed using 
components of the “Sniffin’ Sticks” test battery in 55 non-demented PD patients (Hoehn 
and Yahr stages I-III) and 50 control subjects of comparable age and sex. 
Results PD patients performed slightly but significantly worse than control subjects on the 
odour recognition memory task. After correction for odour detection scores, however, the 
difference in odour recognition memory performance between PD patients and controls 
was no longer statistically significant.  
Conclusion These data indicate that odour recognition memory is not independently 
impaired in PD patients. 
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INTRODUCTION 
 
Olfactory deficits in Parkinson’s disease (PD) were first empirically documented in 1975 by 
Ansari and Johnson.78 Over the ensuing years  it has become clear that most PD patients 
have  olfactory  disturbances  that  are  not  restricted  to  a  single  functional measure  but 
include  impairments of odour detection, discrimination and  identification (for review see 
191). Clinical deficits  in  the  sense of  smell may  even precede  the development of overt 
motor symptoms.89;90  
Few studies have addressed odour recognition memory performance  in PD patients. The 
results of these studies are  inconclusive. A review paper based upon three small studies 
concluded  that  odour  recognition  memory  is  impaired  in  PD  patients,98  whereas  a 
separate study suggested that odour recognition memory may be intact in PD.192  
Reduced olfactory acuity may, at least theoretically, affect performance on other olfactory 
tasks and thus lead to an underestimation of the actual performance on the olfactory task 
in  question.  It  has  been  argued  that  olfactory  detection  thresholds  should  therefore 
always be assessed in addition to the specific olfactory measure under consideration and 
used in appropriate statistical analyses to correct for impairments in odour detection.37 
The  aim of  the present  study was  to  investigate odour  recognition memory  in  a  larger 
group of PD patients. 
 
 
METHODS  
 
Subjects 
This  study was  performed  in  55  control  subjects  and  63  PD  patients.  Eight  subjects  (4 
control subjects and 4 PD patients) had a score below 25 on the MMSE or a score below 
27  on  the  CAMCOG  on  the  day  of  olfactory  testing,  and  were  therefore  excluded.  In 
addition,  five  subjects  (1  control  subject  and  4  PD  patients)  did  not  complete  both 
olfactory  tasks  and  were  excluded.  55  non‐demented  PD  patients  (31  males  and  24 
females;  mean  age  62.0  years,  range  50‐73  years,  Hoehn  and  Yahr  (H&Y)  stages  I‐III, 
disease duration 0‐19 years), and 50 control subjects (27 males and 23 females; mean age 
59.5 years, range 49‐78 years) remained in the study. All PD patients were recruited from 
the outpatient clinic  for movement disorders of the department of Neurology of the VU 
University Medical Center  (VUMC) or  via  advertisements on Parkinson’s disease‐related 
websites  on  the  internet.  Parkinson’s  disease  was  diagnosed  according  to  the  United 
Kingdom Parkinson’s Disease Society Brain Bank criteria. Four patients were drug‐naive. Of 
the remaining PD patients, three patients were treated with levodopa monotherapy, five 
patients  were  on  dopamine‐agonist  monotherapy,  18  patients  were  treated  with  a 
combination of both levodopa and a dopamine agonist, and 25 patients used levodopa, a 
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dopamine agonist, as well as other medication, including monoamine oxidase B (MAO-B) 
inhibitors, catechol-O-methyltransferase (COMT) inhibitors, parasympathicolytica and 
beta-blockers. Medicated patients were tested in the ‘ON’ state, and all patients were 
rated for disease stage by means of the modified H&Y scale,
193
 and for motor symptom 
severity by the Unified Parkinson’s Disease Rating Scale III (UPDRS-III). All control subjects 
were volunteers recruited among hospital employees and partners of patients and 
reported normal subjective olfactory function and had no history of major olfactory or 
(other) neurological disorders. All subjects provided written informed consent. The study 
was approved by the Medical Ethics Committee of the VUMC. 
 
Olfactory function testing 
Odour recognition memory and odour detection threshold were assessed using 
components of the “Sniffin’ Sticks” test battery (Burghart, Wedel, Germany).
33
  
For the odour recognition memory task, we used the odorants of the extended 
identification part of the “Sniffin’ Sticks”.
194
 Subjects were presented with 8 target 
odorants, with an interval of approximately 10 sec between odorants, and were asked to 
memorize them. No verbal descriptions were provided. After a short break (1-5 min), in 
which instructions on the task were given, 16 odours (8 target odours, 8 distracters; Table 
XII) were presented and the subject was asked whether the odour had been smelled 
before. A fixed presentation order of the target and distracter odours was randomly 
selected at the onset of the study and used in for all participants. Odour recognition 
memory scores were calculated as “proportion correct” measure: correctly recognized 
target odours (0-8) plus correctly recognized distracter odours (0-8), divided by the total 
number of targets and distracters (16).  
 
Table XII. Target and distracter odours used in the odour recognition memory task. 
Target odours Distracter odours 
Lilac Pear 
Grass Coke 
Peach Grapefruit 
Raspberry Ginger 
Mushroom Coconut 
Onion Melon 
Honey Smoked meat 
Lavender Chocolate 
 
 
Odour detection threshold was assessed using a single-staircase, three-alternative forced-
choice procedure, with a 1:2 dilution series of sixteen stages. Subjects had to identify the 
odour-containing pen when presented with three pens, two containing the solvent and 
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one the odorant (score 0-16). Subjects who were unable to correctly identify even the 
highest concentration of the odour-containing pens received a score of 0. 
Subjects were blindfolded during the two tests to prevent visual identification of the 
sticks. Olfactory tests were administered birhinally in a quiet, well-ventilated room to 
avoid any background smell interfering with the test odours. 
 
Data analysis 
Since olfactory function is generally considered to be age- and sex-dependent 
121;157
 we 
used these terms as covariates in our analyses.  
Odour recognition memory scores (‘proportion correct’) were analyzed by means of an 
analysis of variance (ANOVA), with ‘group’ as factor, and ‘age’, ‘sex’, and ‘detection score’ 
as covariates, using SPSS 15.0 for Windows (Chicago, IL, USA). 
To explore sex differences in odour recognition memory performance, data were analyzed 
by means of an ANOVA, with ‘sex’ as factor, and ‘group’, ‘age’, and ‘detection score’ as 
covariates.  
To investigate a possible relation between odour recognition memory performance and 
disease duration or severity, data of the PD patients were analyzed by means of an 
ANOVA with ‘disease duration’ (in years, based on first symptoms perceived by the 
patient), ‘disease stage’ (modified H&Y scale), ‘motor symptom severity’ (as measured by 
the UPDRS-III), ‘sex’, and ‘age’, as determinants. 
 
 
RESULTS 
 
The mean number of correctly recognized target odours (± SEM) was 6.3 ± 0.19 for control 
subjects, and 5.2 ± 0.23 for PD patients. The mean number of correct rejections (± SEM) 
was 4.4 ± 0.25 for control subjects, and 3.6 ± 0.22 for PD patients. Total odour recognition 
memory score (‘proportion correct’; ± SEM) was 0.67 ± 0.019 for control subjects, and 
0.55 ± 0.018 for PD patients (Figure 11A). Mean odour detection threshold score (± SEM) 
was 7.9 ± 0.41 for control subjects, and 2.4 ± 0.36 for PD patients.  
Odour recognition memory scores were significantly lower in PD patients than in control 
subjects (F [1,101] = 15.59, p < 0.001), when corrected only for age and sex. When odour 
recognition memory scores were also adjusted for odour detection threshold scores, there 
was no significant difference between PD patients and control subjects (F [1,100] = 0.87, p 
= 0.352; Figure 11B). 
There was no main effect of sex with respect to odour recognition memory scores (F 
[1,100] = 0.65, p = 0.423), when corrected for age and odour detection threshold scores. 
No relationship was found between disease duration (F [1,49] = 2.63, p = 0.111), disease 
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stage  (F [1,49] = 1.08, p = 0.304) or motor symptom severity  (F [1,49] = 0.89, p = 0.350) 
and odour recognition performance, when corrected for age and sex. 
 
Figure 11. Odour recognition memory scores. 
A. Mean odour recognition memory scores (‘proportion correct’) and standard errors of the mean, for control 
subjects and Parkinson’s disease patients. 
* indicates p‐value < .05, based upon an ANOVA with ‘group’ as factor. 
B. Mean odour recognition memory scores (‘proportion correct’) and standard errors of the mean, for control 
subjects and Parkinson’s disease patients, after statistical correction for age, sex and odour detection threshold 
scores. 
 
 
DISCUSSION 
 
The results of the present study demonstrate that PD patients had slightly but significantly 
lower  odour  recognition  memory  scores  than  control  subjects.  However,  when  odour 
recognition  memory  scores  were  corrected  for  odour  detection  threshold  scores,  the 
difference between PD patients and control subjects lost statistical significance.  
Few  studies  have  previously  addressed  odour  recognition  memory  performance  in  PD 
patients, and the results of these studies are inconclusive. In a meta‐analysis Mesholam et 
al. concluded that odour recognition memory was impaired in PD.98 However, the analysis 
was  based  on  only  three  small  studies,  including  a  study  by  Kesslak  et  al.  that  lacked 
statistical significance due to the low number of subjects (n = 4) 195 and a study by Zucco et 
al.  in which no difference had been  found between PD patients and control  subjects  in 
odour  recognition  memory  performance.196  In  the  third  study,  an  odour  recognition 
paradigm was used that actually did not involve a memory component.197 In contrast, the 
results of  a  separate  study  in PD patients  suggested  that odour  recognition memory  is 
intact.192  Although  our  results without  correction  for  odour  detection  threshold would 
seem  to support  the conclusion by Mesholam et al.  that  there  is a slight  impairment of 
odour recognition memory  in PD, the present data  indicate that this slight  impairment  is 
not independent of the deficit in odour detection.  
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 To correct for the influence of olfactory acuity on odour recognition memory 
performance - a methodological issue that was previously raised 
37
 - we used a statistical 
correction for odour detection thresholds. Using this approach, we found no significant 
difference between PD patients and control subjects on the odour recognition memory 
task. Presumably, the PD patients were not able to perceive the target odours sufficiently 
well to memorize and recognize them afterwards. This finding suggests that an 
impairment in olfactory acuity may also underlie reduced performance on other olfactory 
tasks in PD, which would be in line with the suggestion by Doty et al. that most olfactory 
tests measure a common source of variance.
34
 However, this does not seem to apply to all 
olfactory measures, since in at least one recent study odour identification and 
discrimination deficits were independent from the increase in odour detection threshold.
81
  
The current findings suggest that the olfactory impairments in PD, which appear to involve 
several specific olfactory functions, do not include odour recognition memory.  
In Alzheimer’s disease (AD), previous studies have reported odour recognition memory to 
be impaired,
98;192
 even when corrected for odour detection thresholds.
198-200
 Therefore, 
testing of odour recognition memory may prove useful in the differential diagnosis 
between PD patients and AD patients, in particular in the context of early diagnostic 
procedures. Future studies directly comparing groups of PD and AD patients are necessary 
to confirm this. 
 
Conclusion 
In conclusion, the present data indicate that odour recognition memory is not 
independently impaired in PD patients. 
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ABSTRACT 
 
Aim To determine whether extended olfactory testing within a single olfactory task and/or 
across olfactory tasks increases diagnostic accuracy of olfactory testing in Parkinson’s 
disease (PD). 
Methods Olfactory function was assessed using an extended version of the “Sniffin’ 
Sticks”, comprising 32-item odour identification and discrimination tasks, and a detection 
threshold task in 52 PD patients and 50 controls, all aged between 49 and 78 years. ROC 
curves based on sensitivity and specificity estimates were used to compare the diagnostic 
accuracy of extended and combined olfactory testing.  
Results There was no significant difference in diagnostic accuracy between the 16-item 
and the 32-item versions of the odour identification or discrimination test. The single 
olfactory test that was best in discriminating between PD patients and controls was a 16-
item odour identification test. A combination of the 16-item identification test and the 
detection threshold task had a significantly higher area under the curve than the 16-item 
odour identification test alone. 
Conclusion Extended testing across, and not within, olfactory tasks increases diagnostic 
accuracy of olfactory testing in PD. A combination of an odour detection threshold task 
and a 16-item odour identification test had the highest sensitivity and specificity in 
distinguishing between PD patients and controls.  
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INTRODUCTION 
 
Olfactory dysfunction is a frequent symptom in Parkinson’s disease (PD). Even in early 
stage, untreated PD patients, deficits in olfactory function have been demonstrated,
79;81;160
 
which is supported by recent neuropathological studies demonstrating that the olfactory 
bulb and anterior olfactory nucleus may be among the induction sites of PD pathology.
19
 In 
later pathological stages, the olfactory bulb and tract are among the brain regions where 
Lewy bodies and Lewy neurites are particularly abundant.
16
 Impairments in the sense of 
smell may even precede the development of overt motor symptoms,
23;89;90
 and 
prospective studies in first degree relatives of PD patients,
89
 subjects with idiopathic 
hyposmia,
90
 and in a large cohort of Asian men 
91
 have shown that olfactory loss is 
associated with an increased risk of developing PD. Olfactory testing could therefore be 
valuable in establishing an early diagnosis of PD when other clinical (motor) symptoms are 
not apparent yet, presumably before significant loss of dopaminergic neurons has already 
occurred.  
Since the first study on olfactory deficits in PD, reporting an increase in odour detection 
thresholds,
78
 it has become clear that most PD patients have olfactory disturbances that 
are not restricted to a single functional measure but also include impairments of odour 
discrimination and identification.
80-85
 So far the only olfactory measure that does not 
appear to be independently impaired is odour recognition memory (unpublished 
observations). 
In order to reliably assess olfactory function in clinical practice, many psychophysical tests 
have been developed that provide a quantitative measure of olfactory function, such as 
the University of Pennsylvania Smell Identification Test (UPSIT) and the “Sniffin’ Sticks”. 
The UPSIT is a 40-item, forced-choice odour identification test, developed for the US 
population.
32
 The “Sniffin’ Sticks” is an olfactory test battery that can be used to assess 
three different aspects of olfactory function: Odour identification, discrimination and 
detection,
33
 each consisting of 16 items. Odour detection threshold testing measures the 
lowest concentration of an odorant that can be perceived by a subject. Odour 
identification testing involves the perception and naming of an odour presented. An odour 
discrimination task measures the ability to differentiate between a set of odorants. The 
main differences between these the UPSIT and the “Sniffin’Sticks” are the number of 
items (within a single task) and the functions tested. We have previously observed in a 
large population of PD patients that an odour identification test is better at distinguishing 
PD patients from control subjects than an odour discrimination test and that adding a 
discrimination test to an identification test does not improve diagnostic accuracy.
182
 
Although this would suggest that combining multiple olfactory tests is not useful, this type 
of analysis was not performed for other combinations, in particular those including odour 
detection. Nor do we know whether the diagnostic accuracy of olfactory testing in PD 
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might be increased by extending the number of items within a test of a single olfactory 
measure.  
The present study was set out to determine whether extended olfactory testing within a 
single test and/or a combination of tests involving different olfactory functions can 
increase diagnostic accuracy of olfactory testing in PD patients. 
 
 
METHODS 
 
Subjects 
This study was performed in 52 non-demented PD patients (29 males and 23 females; 
mean age 61.8 years, range 50-73 years, Hoehn and Yahr (H&Y) stages I-III, disease 
duration 0-19 years), and 50 control subjects (27 males and 23 females; mean age 59.5 
years, range 49-78 years). All PD patients were recruited from the outpatient clinic of the 
department of Neurology of the VU University Medical Center (VUMC) or via 
advertisements on PD-related websites on the internet. PD was diagnosed according to 
the United Kingdom Parkinson’s Disease Society Brain Bank criteria.
155
 Four patients were 
drug-naive. Of the remaining PD patients, two patients were treated with levodopa 
monotherapy, five patients were on dopamine-agonist monotherapy, 18 patients were 
treated with a combination of both levodopa and a dopamine agonist, and 23 patients 
used levodopa, a dopamine agonist, as well as other medication, including monoamine 
oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, 
anticholinergics and/or beta-blockers. For an overview of subjects characteristics, see 
table XIII. Medicated patients were tested in the ‘ON’ state, and all patients were rated for 
disease stage by means of the modified H&Y scale.
193
 All control subjects were volunteers 
recruited among hospital employees and partners of patients and reported normal 
subjective olfactory function. All subjects reported no history of major chronic olfactory or 
(other) neurological disorders. All subjects provided written informed consent. The study 
was approved by the Medical Ethics Committee of the VUMC. 
 
Table XIII. Subject characteristics. 
 PD patients control subjects 
Age, in years; mean ( SD) 61.8 (7.0) 59.5 (7.6) 
Sex (M/F) 29/23 27/23 
Disease duration, in years; mean  (SD) 6.7 (4.3) - 
H&Y stage (1/1.5/2/2.5/3) 2/2/19/25/4 - 
PD medication (levodopa/dopamine agonist/other PD 
medication) * 
30/39/23 - 
PD = Parkinson’s disease; H&Y = Hoehn and Yahr 
* Sum does not equal total number of PD patients due to subjects using a combination of medication 
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Olfactory function testing 
An extended version of the Sniffin’ Sticks test battery (Burghart, Wedel, Germany), which 
employs reusable felt-tip pens (“sticks”) containing odorants dissolved in propylene glycol, 
was used.
33
  
First, odour detection thresholds were assessed using a single-staircase, three-alternative 
forced-choice procedure, with a 1:2 dilution series of sixteen stages. Subjects were 
blindfolded and had to identify the odour-containing pen when presented with three 
pens, two containing the solvent and one the odorant (score 0-16). Subsequently, 
odorants 17-32 of the odour identification test were presented in suprathreshold intensity 
in a 4-alternative forced-choice format with verbal descriptors. Each stick was held 
approximately 2 cm in front of the nostrils for 2-3 sec, with an interval of 20-30 sec 
between each stick. Next, in the odour discrimination task, subjects were blindfolded 
again and presented with 32 odour-triplets, with an interval of 30 sec between each 
triplet. Each triplet consisted of two identical and one aberrant odorant. Subjects were 
asked to select the odd odour out of the three odorants presented, without the need to 
recognize or name the odours. Lastly, subjects were presented with odorants 1-16 of the 
odour identification test. 
The order of olfactory testing was the same for all participants, with short breaks in 
between. Olfactory tests were administered birhinally in a quiet, well-ventilated room to 
avoid any background smell interfering with the test odours. 
 
Data analysis 
Olfactory scores were defined as the total number of correct answers. For the odour 
identification and discrimination tasks, test scores were calculated for the first 16-items in 
the task (the standard versions of the tasks) and for the total of 32-items (the extended 
versions of the tasks).  
To determine whether the olfactory measures were independently impaired in PD 
patients when compared to control subjects, we used an analysis of variance (ANOVA) 
with ‘group’ as factor, and ‘age’, ‘sex’, and ‘detection score’ as covariates. 
To establish whether extended olfactory testing within a single test is useful for 
discriminating between PD patients and control subjects, we plotted receiver operating 
characteristic (ROC) curves based on sensitivity and specificity estimates, and calculated 
the area under the curve (AUC) for the 16- and 32-item versions of the odour identification 
and discrimination tasks separately. To compare the diagnostic accuracy of the olfactory 
tests, we used a nonparametric analysis of the areas under the correlated ROC curves.
201
  
To determine whether combining tests across different olfactory measures would further 
improve the diagnostic value compared to the best single olfactory test, we first converted 
olfactory test scores to standardized z-scores. Subsequently, we used the best single 
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olfactory test, added the other olfactory tests, and performed similar analyses as 
mentioned above for the single extended tasks. 
ANOVAs were analyzed using SPSS 15.0 for Windows (Chicago, IL, USA); ROC curves were 
analyzed using Stata 10.0 (StataCorp LP, College Station, TX, USA). 
 
 
RESULTS 
 
Olfactory test scores 
PD patients scored significantly worse than control subjects on each of the olfactory tests, 
also when corrected for age, sex and odour detection thresholds (see Table XIV). 
 
Table XIV. Mean olfactory test scores for PD patients and control subjects, and areas under the curve (AUC) for 
the individual tests. 
 PD patients Control subjects p-value AUC 
ID-16 7.0 12.3 < 0.001 0.91 
ID-32 13.9 22.4 < 0.001 0.91 
DIS-16 8.0 11.2 0.013 0.83 
DIS-32 15.5 22.4 0.001 0.87 
THR 2.5 7.9 < 0.001 0.90 
PD = Parkinson’s disease; ID-16 = 16-item identification test; ID-32 = 32-item identification test; DIS-16 = 16-item 
discrimination test; DIS-32 = 32-item discrimination test; THR = detection threshold test. 
p-values correspond to an ANOVA with ‘group’ as factor, and ‘age’, ‘sex’, and ‘detection score’ as covariates.  
 
 
Extended testing within a single olfactory test 
ROC curves were plotted and corresponding AUCs were calculated for each olfactory test 
separately (see Table XIV). The 32-item odour identification test (AUC = 0.91, sensitivity 
0.87, specificity 0.80) was not better at discriminating between PD patients and control 
subjects than the 16-item identification test (AUC = 0.91, sensitivity 0.83, specificity 0.90; 
p = 0.63; Figure 12A). The extended 32-item odour discrimination test (AUC = 0.87, 
sensitivity 0.90, specificity 0.76) was not better at discriminating between PD patients and 
control subjects than the 16-item discrimination test (AUC = 0.83, sensitivity 0.69, 
specificity 0.82; p = 0.09; Figure 12B). 
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Figure 12. Receiver Operating Characteristic (ROC) curves relating sensitivity and specificity estimates for the 16-
item and 32-item versions of the odour identification and discrimination tests. 
 
A. Odour identification test: Solid line represents 
the 16-item identification test; dotted line 
represents the 32-item identification test. 
B. Odour discrimination test: Solid line represents 
the 16-item discrimination test; dotted line 
represents the 32-item discrimination test. 
 
 
Extended testing across different olfactory measures 
ROC curves were plotted and corresponding AUCs were calculated for combinations of 
olfactory tasks (using converted standardized z-scores) comprising the best single 
olfactory test (16-item odour identification test; see above) with the addition of one or 
more of the other olfactory tests (see Table XV). A combination of the 16-item odour 
identification test and the 16-item discrimination test (AUC = 0.91, sensitivity 0.81, 
specificity 0.90) did not significantly increase the AUC when compared to the 
identification test by itself (p = 0.80; Figure 13A). A combination of the 16-item odour 
identification test and the detection threshold test significantly improved the AUC 
compared to the single odour identification test (AUC = 0.95, sensitivity 0.90, specificity 
0.92; p = 0.04; Figure 13B). Adding both the 16-item odour discrimination task and the 
odour detection threshold task to the odour identification test did not improve the AUC 
further (AUC = 0.94, sensitivity 0.81, specificity 0.96; p = 0.16 for comparison with 
identification testing only; Figure 13C).  
 
Table XV. Optimal cut-off z-scores, associated sensitivity and specificity estimates, and area under the curve 
(AUC) for combined tests, determined from ROC curves (Figure 13).   
 Cut-off z-score Sensitivity Specificity AUC 
ID-16 + DIS-16 -0.148 0.81 0.90 0.91 
ID-16 + THR * -0.215 0.90 0.92 0.95 
ID-16 + DIS-16 + THR -0.736 0.81 0.96 0.94 
ID-16 = 16-item identification test; DIS-16 = 16-item discrimination test; THR = detection threshold test. 
* indicates that the AUC is significantly different from the AUC of the 16-item identification test alone (p-value < 
.05). 
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Figure 13. Receiver Operating Characteristic (ROC) curves relating sensitivity and specificity estimates for the 
combinations of olfactory tests. 
 
 
 
 
 
A. Solid line represents the 16-item identification test; 
dotted line represents the 16-item identification test 
combined with the 16-item discrimination test. 
B. Solid line represents the 16-item identification test; 
dotted line represents the 16-item identification test 
combined with the detection threshold test 
C. Solid line represents the 16-item identification test; 
dotted line represents the 16-item identification test 
combined with the 16-item discrimination test and the 
detection threshold test. 
 
 
 
 
 
DISCUSSION 
 
The present study shows that extended testing within a single olfactory test (odour 
identification or discrimination) does not improve the diagnostic accuracy of olfactory 
testing in PD. A combination of an odour detection task and a 16-item odour identification 
task best discriminated between PD patients and control subjects. 
Extended, 32-item, odour identification testing was not better at distinguishing between 
PD patients and control subjects than a 16-item identification task. Similarly, there was no 
significant improvement in diagnostic accuracy when comparing the 32-item with the 16-
item version of the odour discrimination task, even though there was a trend towards an 
increase of the AUC. Apparently, 16-items are sufficient to detect olfactory deficits within 
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a single test, and increasing the number of items in the olfactory tests does not increase 
test accuracy of the Sniffin’Sticks. These findings do not necessarily imply that the 
diagnostic potential of the identification part of the “Sniffin’ Sticks” is superior to the 40-
item UPSIT. In order to reliably assess this, a direct comparison between the two tests is 
necessary, preferably in both healthy controls and PD patients. Additionally, since the 
UPSIT and “Sniffin’ Sticks” do not consist of identical odorants, item analyses for the odour 
identification tests could result in a set of odours that increases the diagnostic accuracy of 
this test further.  
In line with our previous observations in a larger group of PD patients, the present data 
confirm that adding an odour discrimination task to a combination of olfactory tests that 
includes an odour identification task does not further improve the diagnostic value of the 
olfactory test (battery).
182
 By contrast, combining tests of odour identification and odour 
detection does improve the diagnostic accuracy of olfactory testing. Thus, the present 
findings support the notion that the olfactory impairment in PD is not based on a single 
common underlying deficit, such as an increased odour detection threshold,
34;37
 but 
reflects a disturbance of multiple olfactory functions. This is further confirmed by our 
observation that odour identification and discrimination are impaired independent of 
increased odour detection thresholds in PD patients. 
In this study, the best combination of olfactory tests to distinguish between PD patients 
and control subjects was a combination of the odour detection task and the 16-item odour 
identification task of the “Sniffin’ Sticks” test battery. Not surprisingly, these two tasks had 
the highest AUC based on the individual ROC curves and, in addition, displayed the largest 
relative difference in test scores between PD patients and control subjects. These results 
partly correspond to recent findings by Lötsch et al., asserting that combined testing of 
several components of olfaction provides the most significant approach to the diagnosis of 
smell loss.
35
 In their study, involving primarily healthy subjects with or without olfactory 
loss, these authors found odour detection thresholds to be the most important function to 
assess when screening for olfactory loss. The present findings, however, indicate that this 
is different when trying to distinguish between patients with Parkinson’s disease and 
controls: The 16-item odour identification task is the best individual task to discriminate 
between PD patients and control subjects, which tallies with previous findings using the 
“Sniffin’ Sticks”.
159
  
In contrast with the severe olfactory impairments in PD, olfactory function in most other 
degenerative (movement) disorders is either spared or only mildly affected.
86;98;202;203
 
Future studies will have to determine which combination of olfactory tests is most useful 
in the differential diagnosis between PD and other parkinsonian syndromes, such as 
multiple system atrophy and progressive supranuclear palsy, or Alzheimer’s disease. 
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Conclusion 
A combination of tests assessing different olfactory functions improves the diagnostic 
value of olfactory testing in PD to a greater extent than increasing the number of trials 
within a test of a single olfactory function. The best combination of olfactory tests to 
distinguish PD patients from control subjects is a combination of an odour detection task 
and a 16-item identification test. 
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ABSTRACT 
 
Aim We investigated the influence of the number of stimuli on signal-to-noise (S/N) ratio 
of CSERP.  
Methods CSERP from 20 normosmic subjects were obtained in response to stimulation 
with two olfactory (H2S and PEA) and a trigeminal (CO2) stimulant. For each of these 
odours, 160 stimuli were delivered into the right nostril (duration 200 ms, mean ISI 30 sec) 
using a constant-flow, air-dilution olfactometer. For each EEG recording site (Fz, Cz, Pz, C3, 
C4), peak-to-peak amplitude N1P2 and noise amplitude levels were determined. 
Subsequently, S/N ratios were calculated.  
Results The S/N ratios for olfactory ERP generally improved for H2S and PEA. For responses 
to PEA, S/N ratios increased significantly up to 80 averages (S/N ratio = 5.6). The number 
of stimuli for an optimal S/N ratio for trigeminal ERP was slightly lower, i.e. 60 averages 
(S/N ratio = 7.9).  
Conclusion S/N N1P2 ratios in olfactory and trigeminal ERP significantly improve with an 
increasing number of responses averaged under these experimental conditions. This is 
mainly due to a reduction of noise level. Applying more stimuli has little additional effect 
on S/N ratio due to a concomitant decrease in signal amplitude. 
Significance An optimal S/N ratio is essential when recording CSERP in neurodegenerative 
disorders, where responses may be of low amplitude, and for medico-legal purposes. 
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INTRODUCTION 
 
In 1966, Finkenzeller, and in 1967, Allison and Goff first described cerebral potentials, 
which they assumed to be of olfactory origin. Measurement of chemosensory event-
related potentials (CSERP) has since become a useful method to quantify olfactory 
function in a manner relatively independent of subjective biases (for review see 
63
). 
Despite this long-standing use, methods for appropriate stimulation are still under debate, 
as olfactory ERP (OERP) components are affected by the same factors that influence ERP in 
other modalities, such as variations in interstimulus interval (ISI), stimulus duration, 
stimulus concentration, and type of stimulus.
67;204-207
  
Since ERP reflect cognitive processing, attention has a major influence on their 
appearance.
208
 Most subjects have difficulty maintaining vigilance and attention during 
long test sessions. Experiments should therefore not be excessively lengthy. Other than by 
choosing short ISIs, this can be achieved by minimizing the number of stimuli. However, 
little is known about the influence of the number of stimuli on CSERP latency, amplitude, 
and signal-to-noise ratio. According to previous research,
204;209
 the absolute minimum 
number of averages per ERP is 8 records. Although this number of stimuli may produce 
meaningful results, there tends to be a high noise level. So far, this issue has not been 
investigated systematically.  
The aim of the present study was to determine the number of stimuli that is required to 
obtain an optimal signal-to-noise ratio in recording of the general amplitude of the CSERP.  
 
 
METHODS 
 
Subjects 
Twenty subjects (11 male, 9 female, aged between 15-35 years, mean age 23.9 years), 
recruited from the University of Dresden Medical School, were included in this study. Only 
subjects with normal olfactory function, as determined by administration of the odour 
identification part of the “Sniffin’ Sticks” test battery,
33;40
 were included. Subjects provided 
written informed consent. The study was approved by the Ethics Committee of the 
University of Dresden Medical School. 
 
Test procedures 
In a training session before the actual experiment, subjects were instructed to perform a 
special breathing technique (velopharyngeal closure) that avoids respiratory airflow in the 
nasal cavity during ERP recording 
64
 and were acquainted with the experimental condition. 
Subjects were installed comfortably in an air-conditioned room. They received white noise 
(approximately 50 Hz) through headphones to mask switching clicks of the stimulation 
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device. During the actual EEG experiment, subjects performed a tracking task on a 
computer screen in order to maintain vigilance and to reduce unwanted eye 
movements.
63
 They were instructed to hold a white dot inside a larger, moving square 
using a joystick. Following each stimulus presentation, a visual analogue scale was 
presented on screen which subjects used to rate the intensity of the presented stimulus 
by moving a marker on the scale. The left hand end of the scale was defined as “no 
sensation” (0 estimation units [EU]), the right hand end as “maximum intense sensation” 
(100 EU). 
 
Chemosensory event-related potentials (CSERP) 
Chemosensory ERP were obtained in response to stimulation by two pure olfactory (H2S, 
6.8 ppm, and phenylethyl alcohol [PEA], 20% v/v) and one trigeminal (CO2, 44% v/v) 
stimulant in suprathreshold concentrations. As only one odorant was used per session, the 
order of sessions was randomized across subjects to minimize possible sequence effects. 
During a single session, 160 stimuli of a stimulant were delivered into the right nostril 
(stimulus duration 200 ms, mean interstimulus interval 30 sec, range 25-35 sec) using an 
air-dilution olfactometer (OM6b, Burghart, Wedel, Germany). This olfactometer allows for 
application of rectangular-shaped chemical stimuli. Mechanical stimulation is avoided by 
embedding these stimuli in a constant flow of odourless, humidified air of controlled 
temperature (8 l/min, 36°C, 80% relative humidity). In addition to the training session, 
three sessions (one for each stimulant) were completed, each lasting approximately 90 
min, with a short break after each 30 min of recording. 
EEG was recorded from 5 positions of the international 10/20 system (Fz, Cz, Pz, C3, C4; 
see insert in Figure 14), referenced to linked earlobes A1 and A2 (bandpass filter 0.2-30 Hz; 
8-channel EEG amplifier, SIR, Röttenbach, Germany). Possible eye blinks were registered 
from the Fp2 site. A 1500 ms post-stimulus period was recorded, as well as a 500 ms pre-
stimulus period.  
 
Data analysis 
The raw data were divided into blocks of 20 consecutive stimuli. After removing trials 
containing artefacts (such as eyeblinks or motor artefacts), responses were averaged 
separately for each odorant. Peaks N1 and P2 were then marked for each recording site as 
defined by Kobal (see insert in Figure 14).
64
 As peak latencies exhibit relatively large 
interindividual variability, the temporal search windows for components were set at 200-
700 ms for N1, and 300-800 ms for P2.
209
 Subsequently, peak-to-peak amplitudes N1P2 
were determined. Noise levels were calculated as the average of two heuristically selected 
maxima and minima of spontaneous EEG during the 500 ms pre-stimulus interval. Dividing 
the N1P2 amplitude by the average noise level yielded the signal-to-noise (S/N) ratio.  
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ERP results were submitted to analyses of variance for repeated measures (rm-ANOVA) 
performed separately for amplitude N1P2 (A-N1P2), noise in the pre-trigger period, the 
signal-to-noise ratio for amplitude N1P2 (S/N N1P2), and for intensity ratings. Within-
subject factors ‘sequence’ (averages for records 1-20, 1-40, 1-60, …, 1-160) and, in case of 
the ERP ‘position’ (recording sites Fz, Cz, Pz, C3, and C4) were used. ‘Sex’ was used as a 
between-subject factor. In order to have a more conservative measure of effects, degrees 
of freedom were corrected according to Greenhouse-Geisser. Only significant main effects 
will be reported plus significant interactions. Reporting significant effects of the factor 
‘recording site’ was deemed not informative as, for example, the amplitude of ERP at the 
different sites is typically different;
63
 however, interactions between this and other factors 
will be discussed, as this indicates different behaviour of the recordings over the various 
recording sites. Eta
2 
(η
2
)-values are presented for significant results of the ANOVAs as a 
measure of statistical power. Bonferroni tests were applied for post-hoc testing. The level 
of significance was set at 0.05. All analyses were performed using SPSS software (version 
12.0; Chicago, IL, USA).  
  
 
RESULTS  
 
Chemosensory event-related potentials 
Descriptive statistics for results obtained at position Cz are shown in Table XVI (see also 
Figure 14). 
 
Trigeminal stimulation with CO2 
For A-N1P2 a significant effect of the factor ‘sequence’ was found (F [7,98] = 16.3, p < 
0.001; η
2 
= 0.54) suggesting that the amplitude decreased with the number of averages. 
Similar observations were made for the general noise level (F [7,98] = 33.6, p < 0.001; η
2 
= 
0.71). Specifically, noise levels for averages over trials 1-20 and 1-40 were significantly 
higher compared to all other averages, except for the comparison between noise levels for 
averages over trials 1-40 and 1-60. In addition, noise level for the average over trials 1-60 
was significantly higher than noise levels for averages over trials 1-100, 1-120, and 1-160. 
Furthermore, a higher noise level was found for the average over trials 1-80 compared to 
the noise level for the average over trials 1-120.   
S/N N1P2 increased with the number of averages (F [7,98] = 8.47, p < 0.001; η
2 
= 0.38). 
Post-hoc Bonferroni testing indicated that S/N N1P2 for the average over trials 1-20 was 
significantly smaller than that for all other averages, and S/N N1P2 for the average over 
trials 1-40 was still significantly smaller than that for the average over trials 1-120. All other 
pairs of S/N N1P2 were not significantly different from each other indicating that there 
was no further improvement of the S/N ratio from 60 trials onward (S/N ratio = 7.9). With 
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regard to the factor ‘sex’ generally higher S/N N1P2 was found in women compared to 
men (women: mean = 9.55, SEM = 0.78; men: mean = 7.11, SEM = 0.53; F [1,14] = 6.68, p = 
0.022; η
2 
= 0.32). 
 
Table XVI. Descriptive statistics (means, standard errors of means [SEM]) of investigated parameters (A-N1P2 [in 
µV]; general noise level [in µV]; signal-to-noise ratio S/N N1P2; intensity ratings [in estimation units]), separately 
for responses to CO2, H2S and PEA obtained at recording site Cz.  
Averages A-N1P2 Noise level S/N N1P2 Intensity 
 Mean SEM Mean SEM Mean SEM Mean SEM 
Trigeminal stimulation (CO2) - n > 18 
1-20 21.39 2.75 4.66 0.52 4.98 0.58 34.3 3.5 
1-40 19.05 1.93 3.11 0.24 6.47 0.63 32.9 3.6 
1-60 17.58 1.86 2.45 0.19 7.88 0.99 32.3 3.5 
1-80 16.24 1.90 2.19 0.18 7.87 0.88 31.9 3.4 
1-100 15.05 1.74 1.90 0.14 8.47 0.98 31.3 3.3 
1-120 14.34 1.72 1.74 0.13 8.68 0.89 31.2 3.2 
1-140 13.58 1.65 1.64 0.10 7.86 0.74 31.1 3.2 
1-160 13.49 1.66 1.56 0.11 8.73 0.89 30.8 3.1 
Olfactory stimulation (H2S) - n > 17 
1-20 12.95 1.00 4.11 0.31 3.30 0.26 18.6 2.9 
1-40 10.42 1.01 2.65 0.17 4.06 0.38 16.8 3.0 
1-60 10.22 1.08 2.22 0.17 4.94 0.52 16.5 3.0 
1-80 10.47 1.22 2.01 0.13 5.29 0.55 15.9 2.9 
1-100 9.75 1.21 1.78 0.11 5.57 0.67 15.1 2.9 
1-120 9.37 1.16 1.77 0.12 5.73 0.86 14.9 2.9 
1-140 8.77 1.16 1.68 0.12 5.62 0.88 14.6 2.9 
1-160 8.52 1.07 1.57 0.12 5.77 0.77 14.3 2.8 
Olfactory stimulation (PEA) - n > 18 
1-20 11.72 1.02 3.57 0.30 3.76 0.45 18.0 3.3 
1-40 10.00 0.72 2.64 0.22 4.42 0.49 16.2 3.0 
1-60 8.67 0.71 2.04 0.13 4.55 0.48 15.8 2.9 
1-80 8.09 0.71 1.65 0.14 5.60 0.67 15.4 2.9 
1-100 7.57 0.74 1.35 0.08 6.02 0.70 15.1 2.9 
1-120 7.37 0.72 1.35 0.13 5.99 0.67 14.9 2.9 
1-140 7.00 0.67 1.35 0.11 5.90 0.83 13.2 2.5 
1-160 6.87 0.68 1.34 0.12 5.97 0.88 13.0 2.5 
 
Sniffing out Parkinson’s disease 
97 
Figure 14. Mean amplitudes N1P2 (left), general noise level (middle), and S/N ratio for amplitude N1P2 (right) with 
increasing number of stimuli at midline recording position Cz, in response to PEA (n > 18), H2S (n > 17), and CO2 (n 
> 18).  
 
Please note the different scaling of the Y-axes. For standard errors of means see Table XVI. The olfactory event-
related potential in the insert is an average over 160 trials in a single subject in response to H2S. 
 
 
Olfactory stimulation with PEA 
A-N1P2 decreased in relation to the number of trials (F [7,105] = 23.2, p < 0.001; η
2 
= 0.61), 
as did the noise level (F [7,105] = 56.4, p < 0.001; η
2 
= 0.79). Interestingly, for A-N1P2 the 
change varied as a function of the recording position (F [28,420] = 3.43, p = 0.005; η
2 
= 
0.19). It was most pronounced for recording sites Pz and Cz, and least pronounced at 
recording site Fz.  
Noise levels were significantly different between averages over trials 1-20, 1-40, 1-60, and 
1-80 and all other averages.   
S/N N1P2 increased with the number of trials (F [7,105] = 10.7, p < 0.001; η
2 
= 0.42). 
Averages over trials 1-20 differed significantly from averages over trials 1-100, 1-120, 1-140, 
and 1-160, and averages over trials 1-60 were significantly different from those over trials 
1-120. All other pairs of S/N N1P2 were not significantly different from each other. Thus, 
averaging more than 80 trials did not show further improvement of S/N N1P2 (S/N ratio = 
5.6). 
In addition, there was an interaction between factors ‘sequence’ and ‘sex’ (F [7,105] = 
3.49, p = 0.026; η
2 
= 0.19) indicating that the increase in S/N N1P2 was less pronounced in 
women compared to men, when up to 80 stimuli were used for averaging. The opposite 
occurred when more stimuli were utilized for averaging.  
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Olfactory stimulation with H2S 
A-N1P2 in response to olfactory stimulation with H2S decreased with increasing number of 
trials (F [7,77] =14.4, p < 0.001; η
2 
= 0.57). In addition, the general noise level decreased 
with averaging more stimuli (F [7,77] = 36.8, p < 0.001; η
2 
= 0.77). Post-hoc Bonferroni 
tests indicated that noise levels for averages over trials 1-20 and 1-40 were significantly 
different from noise levels for all other averages, except for the comparison between 
noise levels for the averages over trials 1-40 and 1-60. In addition, noise level for the 
average over trials 1-60 stimuli was significantly higher than that for the average over 
trials 1-100. 
A significant effect of averaging was found for S/N N1P2 (F [7,77] = 4.28, p < 0.016; η
2 
= 
0.28). However, post-hoc Bonferroni tests did not yield significant differences between 
S/N N1P2 when averaging 1-20, 1-40 or up to 160 trials. 
  
Psychophysical data 
The overall perceived intensity for CO2 was rated higher than that of H2S and PEA. When 
CO2 was used, there was a trend towards a decrease in intensity ratings with an increase 
in the number of trials (F [7,133] = 3.42, p = 0.061; η
2 
= 0.15) (Figure 15). This effect was 
significant for the olfactory stimuli PEA (F [7,126] = 5.38, p = 0.023; η
2 
= 0.23) and H2S (F 
[7,126] = 4.12, p = 0.046; η
2 
= 0.19). When performing Bonferroni post-hoc testing, a 
significant difference between the various trials was present only for H2S in the 
comparison of averages over trials 1-20 with that over trials 1-100.  
 
Figure 15. Mean intensity ratings with increasing number of stimuli, for PEA (n > 18), H2S (n > 18), and CO2 (n = 
20).  
 
 
For standard errors of means see Table XVI. 
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DISCUSSION 
 
The present study revealed that the S/N ratio of olfactory ERP significantly improves with 
an increasing number of stimuli. For PEA the optimal number of stimuli was found to be 
approximately 80. For H2S, a significant effect of averaging was found, indicating an 
increase of S/N ratio for repeated averaging. However, no significant differences were 
found after post-hoc testing, probably because Bonferroni correction is too conservative 
an adjustment for this analysis. The optimal number of stimuli for the trigeminal ERP is 
slightly lower, i.e. 60 stimuli. These results are mainly due to a reduction of the noise level 
with increasing numbers of responses averaged and a concomitant decrease of signal 
amplitudes that is initially less pronounced. Further increases in the number of stimuli 
have little additional effect due to a subsequent parallel decline in both signal amplitudes 
and noise level, resulting in a plateau for S/N ratios. Since the different peaks of the ERP 
may represent different psychological processes, and thus show different physical 
features under different conditions, these findings hold true only for S/N N1P2 ratios in 
experiments under similar circumstances. For instance, the amplitude of the late positivity 
in CSERP studies increases with higher concentration,
210
 longer duration,
206
 prolonged 
ISI,
207
 or when the stimulus is attended.
208
 
In the present study, all identical stimuli were given within a single session, in order to 
maximize the number of consecutive stimuli of one odorant without exhausting the 
subject by a lengthy experiment. In future studies, multiple odorants can be applied in a 
randomized design within a single session – using the optimal number of stimuli 
determined in the present study – without the experiment becoming excessively lengthy. 
This may further reduce habituation and produce even better signal-to-noise ratios.  
S/N ratio was generally larger in women compared to men. This relates to previous 
research indicating that women have larger ERP amplitudes in response to chemosensory 
stimuli than men.
211;212
 In addition, men had a larger benefit from averaging over an 
increasing number of trials compared to women in terms of the S/N ratio which may be an 
expression of the idea that the S/N ratio reached an optimum in women while there was 
still room for improvement in the S/N ratio of men. Although not investigated in the 
present study, other factors like smoking 
213
 or hormonal status 
214
 can also be expected to 
affect the S/N ratio. 
The present results compare only partly to previous work with regard to the improvement 
of the S/N ratio of ERP. The S/N ratio of ERP has been assumed to increase according to 
the formula N/√(N) – N being the number of trials averaged – which implies a steady 
increase of the S/N ratio.
215
 The present results, however, clearly indicated that a plateau 
is reached after averaging 60-80 stimuli. It has been argued that this discrepancy between 
theoretical and measured behaviour of the S/N ratio may be due to the increased 
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occurrence of artefacts or decrease in vigilance with accompanying slowing of the EEG 
that occur when the experiment prolongs.
216
 
The observed decrease in signal amplitude with increased number of stimuli might be 
caused by adaptation or habituation to the stimulant – which is indicated by the decrease 
of the averaged intensity ratings, at least for olfactory stimuli. Considering the observation 
by Kobal,
64
 using electro-olfactograms (EOG) from the nasal mucosa, that peripheral 
olfactory chemical receptors show hardly any adaptation at all, the reduction in responses 
must hence originate in central neuronal structures (habituation) (see also 
217
). 
Alternatively, the decrease in signal amplitude may be brought about by jitter of individual 
ERP – meaning the temporal variation of peak amplitudes when recording repeated 
responses to an identical stimulus. This question was addressed through ancillary analyses 
where responses were analyzed for consecutive blocks of 20 stimuli each, i.e., the 
response to stimuli 1-20, 21-40, 41-60, and 61-80. Results from rm-ANOVAs conducted 
separately for the three stimulants and peaks N1 and P2 (and factor ‘recording site) 
suggested that latencies did not change significantly in response to repeated stimulation 
(p > 0.10), which confirms and extends previous experiments on trigeminal ERP by 
Hummel et al.
218
 From this result, it can be concluded that ERP peak latencies are relatively 
stable when up to 80 stimuli are presented, indicating that it is unlikely that jitter of ERP 
responses is responsible for amplitude decreases with increasing numbers of stimuli. 
Rather, the result supports the hypothesis that the signal rises more clearly from the noise 
with the process of repeated stimulation.  
The pronounced decrease of response amplitudes has no behavioural equivalent, i.e., it is 
not evident from the psychophysical ratings that are reduced only mildly. This discrepancy 
between ERP data and psychophysical ratings might reflect differential mechanisms of 
habituation. CSERP amplitudes, as a measure of the objective physiological response of 
the olfactory or trigeminal system to a stimulus, may decrease rapidly as a result of 
habituation to the repetitive character of stimulation. Yet, intensity ratings, as a subjective 
measure of the effect of a stimulus on the organism as a whole, may be more resistant to 
habituation as a result of the influence of higher order cognitive and affective processes. 
In other words, this would suggest that, following repeated exposure to the same 
stimulus, a smaller number of neurons producing a smaller ERP amplitude are necessary 
to produce the same percept at the level of intensity; the observed discrepancy could be 
explained by a learning effect, such that cortical circuits are used more efficiently.  
 
Conclusion 
The results of the present study highlight the importance of using a sufficient number of 
stimuli when recording CSERP, which can be of particular value in patients with 
(neurological) disorders associated with olfactory impairments, such as Parkinson’s 
disease, where responses might be reduced in amplitude. Moreover, these results will also 
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have an effect on the practical conduct of medico-legal investigations in patients with 
olfactory loss where measures of utmost reliability are required. Application of the 
present results is also highly valuable in experimental investigations aimed at localization 
of sources of olfactory ERP components, e.g. in magnetoencephalographic studies, where 
a high S/N ratio is of crucial significance. 
Neurophysiological studies of olfactory function 
102 
Sniffing out Parkinson’s disease 
103 
 
Chapter 8 
 
 
Advanced time-series analysis of MEG data 
as a method to explore olfactory function in 
healthy controls and Parkinson’s disease 
patients 
 
 
 
S Boesveldt 
1 
CJ Stam 
2
 
DL Knol 
3 
JPA Verbunt 
4 
HW Berendse 
1
 
 
 
1 
Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands 
2 
Department of Clinical Neurophysiology, VU University Medical Center, Amsterdam, the 
Netherlands 
3 
Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, 
Amsterdam, the Netherlands 
4 
Department of Physics and Medical Technology, VU University Medical Center, 
Amsterdam, the Netherlands 
 
Submitted 
 
Neurophysiological studies of olfactory function 
104 
ABSTRACT 
 
Aim To determine whether time-series analysis of magnetoencephalography (MEG) data is 
a suitable method to study brain activity related to olfactory information processing, and 
to detect differences in odour-induced brain activity between Parkinson’s disease (PD) 
patients and controls.  
Methods Whole head 151-channel MEG recordings were obtained in 21 controls and 20 PD 
patients during a 10-min olfactory stimulus paradigm, consisting of 10 alternating rest-
stimulus cycles (30 sec each), using phenylethyl alcohol administered by means of a 
Burghart olfactometer. Relative spectral power and synchronization likelihood (SL; an 
unbiased measure of functional connectivity) were calculated for delta, theta, alpha1, 
alpha2, beta and gamma frequency bands.  
Results In controls, olfactory stimulation produced an increase in theta power and a 
decrease in beta power. In PD patients there was a decrease in alpha1 power. No 
significant interaction between group and condition was found for spectral power. SL 
analysis revealed a significantly different response to olfactory stimulation in PD patients 
then in controls. In controls, the odour stimulus induced a decrease in local beta band SL. 
The response in PD patients involved a decrease in intrahemispheric alpha2 band SL. 
Conclusion This is the first study to show that time-series analysis of MEG data, including 
spectral power and SL, can be used to detect odour-induced changes in brain activity. In 
addition, differences in odour-induced brain activity were found between PD patients and 
controls using analysis of SL, but not of spectral power. These differences may reflect 
olfactory dysfunction and abnormal olfactory information processing in PD patients. 
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INTRODUCTION 
 
Olfactory dysfunction is a frequent symptom in Parkinson’s disease (PD),
78;85
 that may 
even precede the development of overt motor symptoms.
23;89-91
 Pathological studies 
support these observations by demonstrating that the olfactory bulb and tract may be 
among the induction sites of PD pathology and show an abundance of Lewy bodies and 
Lewy neurites in later pathological stages.
16;19
 The pathophysiology underlying the 
olfactory deficits in PD is far from being elucidated. In pathological studies, neuronal loss 
has been observed in the olfactory bulb and tracts of PD patients,
100
 whereas others have 
reported a doubling of the number of dopaminergic neurons in the olfactory bulb.
102
 
Structural imaging studies have revealed disruption of the olfactory tract,
104
 but no 
abnormalities of olfactory bulb volume.
105
 A recent functional MRI study pointed to yet 
other brain areas that may be involved in PD-related olfactory dysfunction: After olfactory 
stimulation, neuronal activity in the amygdala and hippocampus was lower in PD patients 
when compared to control subjects.
106
  
Another way to study olfactory information processing is by using electrophysiological 
techniques. When the brain processes a stimulus, two types of changes may occur in the 
electroencephalogram (EEG) or magnetoencephalogram (MEG): Evoked activities, which 
are exactly time-locked to the stimulus, and induced activities, which are changes in the 
EEG that are not phase-locked to the stimulus. The most basic approach to study the 
effects of olfactory stimulation was taken by Moncrieff.
50
 He presented healthy subjects 
with different odours while recording their EEG, and found that several odours reduced 
alpha activity. Subsequent studies using EEG have found both increases and decreases of 
spectral power in almost all frequency bands upon olfactory stimulation.
51;53-59
 Much of 
the variation in these studies can probably be attributed to differences in EEG recording 
techniques and conditions, and in the type and quality of odours presented. Olfactory 
evoked magnetic fields have been found bilaterally in the anterior-central parts of the 
insula, the parainsular cortex, the superior temporal sulcus,
72;75
 and near the orbitofrontal 
sulcus.
76
 A recent MEG study using frequency analysis combined with a beamforming 
technique, reported olfactory event-related desynchronization in the beta and gamma 
band, in the right precentral gyrus, frontal gyri, and the superior parietal lobe gyrus.
71
 
In PD patients, electrophysiological studies have shown that olfactory event-related 
potentials have prolonged latencies when compared to controls, whereas amplitudes are 
similar.
80;108
 MEG studies of olfactory information processing have so far not been 
performed in PD patients. However, advanced time-series analysis techniques of resting-
state MEG data have been used in a number of recent studies in PD patients to show 
changes in both frequency distribution and functional connectivity between brain 
areas.
109-111
 Furthermore, these same analysis techniques have proven their use in studying 
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resting-state data in a number of other neurological conditions,
112-115
 but can also be 
applied to task-related MEG data.
115;116
 
The aim of the present study was to determine whether time-series analysis of MEG data, 
including spectral power (as a measure of local synchronization) and synchronization 
likelihood (as a measure of functional connectivity), can be used to study olfactory 
information processing in healthy subjects, and also to detect differences in task-related 
brain activity during olfactory stimulation between PD patients and healthy controls.  
 
 
METHODS 
 
Subjects 
23 healthy control subjects and 21 PD patients participated in this study. Due to 
considerable dental artefacts in the MEG recordings of two subjects, and technical 
problems during the MEG recording of one subject, the final study population consisted of 
21 control subjects (9 male; mean age 56.3 years, range 49-73 years) and 20 PD patients 
(12 male; mean age 61.5 years, range 50-73 years; Hoehn and Yahr stage I-III). All PD 
patients were recruited from the outpatient clinic of the department of Neurology of the 
VU University Medical Center (VUMC) or via advertisements on PD-related websites on 
the internet. Parkinson’s disease was diagnosed according to the United Kingdom 
Parkinson’s Disease Society Brain Bank criteria.
155
 Three patients were drug-naive. Of the 
remaining PD patients, two patients were treated with levodopa monotherapy, three 
patients were on dopamine-agonist monotherapy, five patients were treated with a 
combination of both levodopa and a dopamine agonist, and seven patients used levodopa, 
a dopamine agonist as well as other medication, including monoamine oxidase B (MAO-B) 
inhibitors, catechol-O-methyltransferase (COMT) inhibitors, anticholinergics, and/or beta-
blockers. Medicated patients were tested ‘ON’ medication, and all patients were rated for 
disease stage by means of the modified Hoehn and Yahr scale.
193
 Control subjects were 
volunteers recruited among hospital employees and partners of patients, and reported 
normal subjective olfactory function and no history of major olfactory or neurological 
disorders. All subjects underwent olfactory testing by means of the “Sniffin’ Sticks” test 
battery.
33
 Both an odour detection threshold score, and a composite TDI (threshold, 
discrimination, identification) score were used to assess olfactory function; higher test 
scores indicate better olfactory function.  
The study was approved by the Medical Ethics Committee of the VUMC, and all subjects 
gave written informed consent. 
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MEG data acquisition 
MEG data were acquired using a 151-channel whole-head axial gradiometer MEG system 
(CTF Systems Inc., Port Coquitlam, BC, Canada). Average distance between sensors in this 
system is 3.1 cm. Patients were seated in a magnetically shielded room (Vacuum-schmelze 
GmbH, Hanau, Germany). The recording pass-band was 0–200 Hz with a sample rate of 
625 Hz. A third-order software gradient was applied. At the beginning and at the end of 
the measurement, head position relative to the coordinate system of the helmet was 
recorded by leading small alternating currents through three position coils situated at the 
left and right pre-auricular points and the nasion on the subject’s head.  
MEG recordings were made during a 10-min olfactory stimulus paradigm, consisting of 10 
alternating rest-stimulus cycles (30 sec each). Phenylethyl alcohol (PEA) was presented in 
a suprathreshold concentration (40% v/v) unilaterally into the right nostril using an air-
dilution olfactometer (OM6b, Burghart, Wedel, Germany) asynchronous to breathing, for 1 
sec every 4 sec during the 30 sec ‘stimulus’ period; during the 30 sec ‘rest’ period, 
subjects received odourless air (Figure 16). Mechanical stimulation was avoided by 
embedding the olfactory stimuli in a constant flow of odourless, humidified air of 
controlled temperature (8 l/min, 36°C, 80% relative humidity). All subjects were asked to 
breathe through their mouth to avoid respiratory airflow in the nasal cavity, to keep their 
eyes open and to avoid eye blinking or other ocular movement as much as possible. In 
addition, they received white noise (approximately 50 dBA) through headphones to mask 
switching clicks of the olfactory stimulation device.  
 
Figure 16. A schematic representation of the olfactory stimulus protocol.  
 
 
Phenylethyl alcohol (PEA, 40% v/v) was delivered for 1 sec every 4 sec during a 30 sec period in the ‘stimulus’ 
condition. During the 30 sec ‘rest’ period, subjects received odourless air. A total of 10 alternating rest-stimulus 
cycles were presented. Four sec of odourless air preceded the first stimulus condition; MEG recordings acquired 
during these four sec were not used in the analyses. 
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MEG data analysis  
For each cycle, a rest and a stimulus epoch of approximately 6.56 sec (sample rate 625 Hz; 
4096 samples per epoch) free of significant artefacts as detected by visual inspection, 
were selected. For further off-line processing and data analysis, epochs were converted to 
ASCII-files and imported into the DIGEEGXP 2.0 software package (CJ Stam, Amsterdam, 
the Netherlands). Subsequently, the MEG data were digitally filtered off-line with a band-
pass of 1–48 Hz.  
Relative spectral power was calculated in the following frequency bands: 1–4 Hz (delta), 4–
8 Hz (theta), 8–10 Hz (alpha1), 10–13 Hz (alpha2), 13–30 Hz (beta) and 30–48 Hz (gamma). 
The MEG channels were grouped into regions of interest (ROIs), roughly corresponding to 
the major cortical areas (frontal, central, temporal, parietal and occipital) on the left and 
right side of the brain. The nine midline channels were left out of this clustering, leaving a 
total of 141 channels divided over 10 ROIs (Figure 17A and B). Furthermore, seven channels 
(one above the left frontal, the left occipital, the right central, the right frontal and the 
right parietal region, and two above the right temporal region) were excluded in all 
patients because of technical problems during the recordings in some of the patients. 
Power values for these channels were left out of the averaging, ensuring that the mean 
relative power in a ROI containing bad channels was not distorted. Fast Fourier 
Transformation was separately applied for every subject on all epochs in the previously 
mentioned frequency bands. Mean relative power averaged over all included channels 
was used in the primary statistical analysis (‘overall spectral power’).  
Functional connectivity between all pair-wise combinations of MEG channels was 
computed with synchronization likelihood (SL).
219
 SL is a general measure of the 
correlation or synchronization between two time series that is sensitive to linear as well as 
non-linear interdependencies. In case of total synchrony the value of synchronization 
likelihood is 1, while for completely independent systems it equals 0. Parameter settings 
used for SL computation were explicitly based on the frequency content of the data (for 
lags and embedding dimensions used, see 
220
).  
SL was computed for the same epochs as aforementioned, in the same frequency bands. 
Digital, zero-phase lag filtering was done off-line. MEG channels were grouped into (left 
and right) central, frontal, occipital, parietal and temporal regions, ROIs (Figure 17A). 
Midline sensors and the aforementioned channels containing artefacts were excluded 
from averaging. Ten local SL measures were computed per epoch by averaging the SL 
values of all possible sensor pairs within each ROI (Figure 17B). Five interhemispheric SL 
measures were computed per epoch by averaging the SL values of all possible sensor 
combinations between two homologous ROIs involved in the specific measure (Figure 
17C). Eight intrahemispheric SL measures were computed per epoch by averaging the SL 
values of all possible sensor combinations between the two ROIs involved in the specific 
measure (Figure 17D). Within ROI (local) SL, between ROI intrahemispheric SL and between 
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ROI interhemispheric SL represent overall weighted averages (based on the number of 
possible sensor combinations) of the aforementioned specific SL measures.  
 
Figure 17. Sensor clustering and selection of relative spectral power and synchronization likelihood (SL) measures.  
 
 
A. Clustering of MEG sensors above major cortical areas; midline sensors were excluded from spectral power and 
SL analysis 
B. Schematic representation of regions of interest (ROIs) used to calculate spectral power and short-distance 
local SL  
C. Long-distance interhemispheric connections used to calculate SL 
D. Long-distance intrahemispheric connections used to calculate SL 
Arrows indicate SL connections used. 
L = left, R = right, F = frontal, C = central, P = parietal, O = occipital, T = temporal. 
 
 
Statistical analysis 
For each frequency band separately, we used a multilevel general linear model with a 
compound symmetric covariance structure, with ‘epoch’ as level-1 units, and subjects as 
level-2 units to determine changes in overall relative power and overall SL measures (local, 
inter- and intrahemispheric SL) in response to the olfactory stimulus in both groups (PD 
patients and control subjects). ‘Condition’ (rest versus stimulus) was used as fixed factor. 
Parameters were estimated by the method of restricted maximum likelihood. 
To determine whether PD patients responded differently to an olfactory stimulus 
compared to control subjects, we performed similar analyses, with ‘condition’, ‘group’ (PD 
patients and control subjects) and the interaction ‘condition*group’ as fixed factors.  
When overall relative power, local, interhemispheric or intrahemispheric SL showed 
statistically significant effects within a frequency band for ‘condition’ or the interaction 
‘condition*group’, we performed an exploratory post-hoc analysis for each ROI or short- 
or long-distance connection (Figure 17B-D) within the frequency band of interest to obtain 
an indication of the regional distribution of the effect.  
To determine if there were differences in olfactory test scores between PD patients and 
control subjects, we used the univariate general linear model UNIANOVA, with ‘group’ (PD 
patients and control subjects) as factor, and corrected for ‘age’ (covariate) and ‘sex’ 
(factor). 
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We studied the relationship between spectral power, SL and olfactory function by first 
subtracting overall relative power, local, interhemispheric and intrahemispheric SL in the 
rest condition from the same measures in the stimulus condition for all epochs and, 
subsequently, averaging these values for each subject. Pearson correlation coefficients 
were then computed to determine the correlation between the changes in relative 
spectral power or SL measures and odour detection threshold scores or composite TDI 
scores, measured with the “Sniffin’ Sticks” test battery, for each group separately. 
Data were analyzed using SPSS 15.0 for Windows (Chicago, IL, USA). 
 
 
RESULTS 
 
Relative spectral power 
Control subjects and PD patients showed a similar pattern of changes in overall spectral 
power for the stimulus compared to the rest condition (Figure 18): A power increase in the 
lower frequency bands (delta and theta), a power decrease in alpha1 and alpha2 bands 
and a power increase in the gamma band. In the beta band, control subjects showed a 
power decrease, whereas PD patients showed an increase. The overall similarity in the 
patterns of changes in spectral power is reflected in the absence of a significant 
interaction effect for overall spectral power between group (PD and control subjects) and 
condition (rest and stimulus) in any of the frequency bands (Figure 18).  
 
Figure 18. Percentage of change in relative spectral power (stimulus compared to rest condition), for each 
frequency band. 
 
 
Grey bars represent control subjects, white bars represent Parkinson’s disease patients. 
* indicates p-value < 0.05, when comparing all rest and stimulus epochs in a multi-level statistical model 
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Statistical analysis revealed a significant increase in overall spectral power for the stimulus 
compared to the rest condition for control subjects in the theta frequency band (F [1,383] 
= 5.93, p = 0.015). Post-hoc analyses indicated that this increase in power was mainly over 
bilateral central and temporal regions (Table XVII a). Also in control subjects, a significant 
decrease in overall spectral power for the stimulus compared to the rest condition was 
found in the beta frequency band (F [1,383] = 5.98, p = 0.015). Post-hoc analyses indicated 
that this decrease in power mainly involved bilateral central regions, and the right 
temporal region (Table XVII b). 
In PD patients, a significant decrease in overall spectral power for the stimulus compared 
to the rest condition was found in the alpha1 frequency band (F [1,366] = 5.59, p = 0.019). 
Post-hoc analyses indicated that this decrease in power mainly involved bilateral central 
and parietal regions and the left temporal region (Table XVII c). 
 
Table XVII a. Relative spectral power in the theta band for control subjects.  
Relative power 
theta (4-8 Hz) 
rest odour p-value 
overall 0.1689 0.1735 0.015 
LC 0.1505 0.1556 0.045 
LF 0.1982 0.2017 0.233 
LO 0.1535 0.1557 0.390 
LP 0.1394 0.1437 0.160 
LT 0.1781 0.1836 0.045 
RC 0.1461 0.1534 0.006 
RF 0.2010 0.2060 0.104 
RO 0.1559 0.1571 0.684 
RP 0.1371 0.1418 0.120 
RT 0.1809 0.1860 0.045 
 
 
Table XVII b. Relative spectral power in the beta band for control subjects.  
Relative power 
beta (13-30 Hz) 
rest odour p-value 
overall 0.3193 0.3119 0.015 
LC 0.3817 0.3701 0.006 
LF 0.2983 0.2911 0.092 
LO 0.2999 0.2978 0.560 
LP 0.3717 0.3664 0.287 
LT 0.2664 0.2609 0.148 
RC 0.3967 0.3859 0.015 
RF 0.2978 0.2902 0.058 
RO 0.3009 0.2948 0.075 
RP 0.3832 0.3754 0.104 
RT 0.2733 0.2662 0.043 
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Table XVII c. Relative spectral power in the alpha1 band for PD patients. 
Relative power 
alpha1 (8-10 Hz) 
rest odour p-value 
overall 0.1174 0.1107 0.019 
LC 0.1012 0.0941 0.019 
LF 0.0903 0.0874 0.399 
LO 0.1698 0.1600 0.051 
LP 0.1353 0.1229 0.002 
LT 0.1404 0.1312 0.022 
RC 0.0851 0.0799 0.034 
RF 0.0751 0.0732 0.403 
RO 0.1610 0.1532 0.134 
RP 0.1257 0.1143 0.011 
RT 0.1262 0.1217 0.241 
All p-values are determined by a multi-level model, comparing all rest and stimulus epochs of control subjects. 
Analysis of regional changes was performed to explore the distribution of the odour-induced changes within a 
frequency band.  
A and B. After Holm-Bonferroni correction for multiple comparisons, regional p-values lost significance. 
C. After Holm-Bonferroni correction for multiple comparisons, only the LP regional p-value remained significant. 
L = left, R = right, C = central, F = frontal, O = occipital, P = parietal, T = temporal. 
 
 
Synchronization likelihood 
Local SL 
Control subjects and PD patients showed a similar pattern in local SL for the stimulus 
compared to the rest condition (Figure 19A): An increase in the delta band, and a decrease 
in the alpha1, alpha2, beta and gamma bands in functional connectivity were found for 
both control subjects and PD patients. In the theta band, control subjects showed an 
increase in local SL, whereas PD patients showed a decrease. 
Statistical analysis revealed only a significant decrease in local SL for the stimulus 
compared to the rest condition for control subjects in the beta frequency band (F [1,411] = 
4.59, p = 0.033). Post-hoc analyses indicated that this decrease in functional connectivity 
mainly involved connections within the left central and frontal regions (Table XVIII a).  
In PD patients there were no significant differences in local SL for the stimulus compared 
to the rest condition in any of the frequency bands (Figure 19A). 
There was no significant interaction effect for local SL between group (PD and control 
subjects) and condition (rest and stimulus) in any of the frequency bands (Figure 19A).  
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Figure 19A. Percentage of change in local synchronization likelihood (stimulus compared to rest condition), for 
each frequency band. 
 
 
 
 
 
Grey bars represent control 
subjects, white bars represent 
Parkinson’s disease patients. 
* indicates p-value < 0.05, when 
comparing all rest and stimulus 
epochs in a multi-level statistical 
model 
 
 
 
 
 
 
 
Interhemispheric SL 
Control subjects and PD patients showed a similar pattern in interhemispheric SL for the 
stimulus compared to the rest condition (Figure 19B): An increase in the lower frequency 
bands (delta and theta), and decreases in the alpha1, alpha2, beta and gamma bands were 
found in both control subjects and PD patients.  
 
Figure 19B. Percentage of change in interhemispheric synchronization likelihood (stimulus compared to rest 
condition), for each frequency band. 
 
 
 
 
Grey bars represent control 
subjects, white bars represent 
Parkinson’s disease patients. 
* indicates p-value < 0.05, when 
comparing all rest and stimulus 
epochs in a multi-level statistical 
model. 
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Statistical analysis revealed only a significant increase in interhemispheric SL for the 
stimulus compared to the rest condition for control subjects in the delta frequency band 
(F [1,383] = 4.84, p = 0.028). Post-hoc analyses indicated that this decrease in functional 
connectivity mainly involved connections between the temporal regions of both 
hemispheres (Table XVIII a).  
In PD patients, here were no significant differences in interhemispheric SL for the stimulus 
compared to the rest condition in any of the frequency bands (Figure 19B). 
There was no significant interaction effect for local SL between group (PD and control 
subjects) and condition (rest and stimulus) in any of the frequency bands (Figure 19B). 
 
Intrahemispheric SL 
Control subjects showed an increase in alpha2 intrahemispheric SL and a decrease in the 
beta band, whereas PD patients showed the opposite pattern. Both control subjects and 
PD patients showed an increase in intrahemispheric SL in the delta band, and a decrease 
in the alpha1 band. There were no changes in theta or gamma band intrahemispheric SL 
(Figure 19C).  
 
Figure 19C. Percentage of change in intrahemispheric synchronization likelihood (stimulus compared to rest 
condition), for each frequency band. 
 
 
 
 
 
 
Grey bars represent control 
subjects, white bars 
represent Parkinson’s disease 
patients. 
* indicates p-value < 0.05, 
when comparing all rest and 
stimulus epochs in a multi-
level statistical model;  
# indicates p-value < 0.05 for 
the group*condition 
interaction in a multi-level 
statistical model 
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Statistical analysis revealed no significant differences in intrahemispheric SL for control 
subjects in any of the frequency bands. In PD patients, only the decrease in 
intrahemispheric alpha2 SL for the stimulus compared to the rest condition was 
statistically significant (F [1,375] = 9.64, p = 0.002). Post-hoc analyses indicated that this 
decrease in functional connectivity mainly involved fronto-parietal and fronto-temporal 
connections in the right hemisphere (Table XVIII c).  
Furthermore, in the alpha2 band, a significant interaction effect for intrahemispheric SL 
between group (PD and control subjects) and condition (rest and stimulus) was found (F 
[1,749] = 4.25, p = 0.039; Figure 19C). Post-hoc analyses indicated that this interaction 
effect mainly involved fronto-parietal connections in the right hemisphere (Table XVIII c).  
 
Table XVIII a. Local synchronization likelihood in the beta band for control subjects.  
SL local 
beta (13-30 Hz) 
rest odour p-value 
local 0.1149 0.1142 0.033 
LC 0.1188 0.1172 0.009 
LF 0.1125 0.1110 0.032 
LO 0.1252 0.1253 0.879 
LP 0.2017 0.1997 0.103 
LT 0.0887 0.0886 0.777 
RC 0.1073 0.1071 0.753 
RF 0.1076 0.1071 0.397 
RO 0.1403 0.1394 0.091 
RP 0.1583 0.1575 0.376 
RT 0.0765 0.0764 0.669 
 
 
Table XVIII b. Interhemispheric synchronization likelihood in the delta band for control subjects. 
SL inter 
delta (1-4 Hz) 
rest odour p-value 
inter 0.0785 0.0822 0.028 
inter C 0.0662 0.0655 0.710 
inter F 0.0773 0.0804 0.266 
inter O 0.0715 0.0737 0.336 
inter P 0.0618 0.0633 0.583 
inter T 0.0987 0.1078 0.012 
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Table XVIII c. Intrahemispheric synchronization likelihood in the alpha2 band for PD patients and control subjects. 
PD patients Control subjects 
Group * 
condition 
interaction 
SL intra 
alpha2 (10-13 
Hz) 
rest odour p-value rest odour p-value 
intra 0.0252 0.0245 0.002 0.0247 0.0249 0.009 
left FT 0.0269 0.0261 0.091 0.0270 0.0268 0.397 
left FP 0.0208 0.0203 0.272 0.0204 0.0213 0.054 
left PO 0.0318 0.0305 0.059 0.0296 0.0292 0.297 
left TO 0.0254 0.0253 0.831 0.0253 0.0261 0.126 
right FT 0.0261 0.0251 0.012 0.0255 0.0255 0.107 
right FP 0.0188 0.0179 0.016 0.0184 0.0186 0.038 
right PO 0.0312 0.0308 0.617 0.0276 0.0274 0.833 
right TO 0.0227 0.0222 0.176 0.0229 0.0232 0.138 
All p-values are determined by a multi-level model, comparing all rest and stimulus epochs of control subjects or 
Parkinson’s disease (PD) patients. All p-values for group*condition interactions are determined by a multi-level 
statistical model, comparing the difference between all rest and stimulus epochs of control subjects with the 
difference between all rest and stimulus epochs of PD patients. Analysis of regional changes was performed to 
explore the distribution of the odour-induced changes within a frequency band. After Holm-Bonferroni 
correction for multiple comparisons, regional p-values lost significance. 
L = left, R = right, C = central, F = frontal, O = occipital, P = parietal, T = temporal. 
FT = fronto-temporal, FP = fronto-parietal, PO = parietal-occipital, TO = temporal-occipital. 
 
 
Correlations with olfactory function 
PD patients had lower mean olfactory test scores (based on odour detection threshold 
scores and composite TDI scores on the “Sniffin’ Sticks” test battery) compared to control 
subjects, when corrected for age and sex (mean detection score control subjects = 8.0, PD 
patients = 2.3, F [1,37] = 44.7, p < 0.001; mean TDI score control subjects = 31.0, PD 
patients = 17.9, F [1,37] = 70.5, p < 0.001). 
In control subjects, correlations were found between overall relative power and local SL in 
the alpha1 band and TDI scores (r = 0.50, p = 0.020, and r = 0.44, p = 0.049 respectively), 
and between intrahemispheric SL in the alpha1 band and odour detection threshold scores 
(r = 0.47, p = 0.031). In PD patients, no correlations were found between olfactory test 
scores and overall relative power or local, interhemispheric or intrahemispheric SL. 
 
 
DISCUSSION 
 
This is the first report using time-series analysis of MEG data to study odour-induced 
changes in spectral power and functional connectivity in controls and PD patients. The 
pattern of these changes in controls and PD patients was similar for spectral power, but 
differed for functional connectivity in the alpha2 band.  
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The present study showed a significant increase in overall theta band power and a 
decrease in overall beta band power for control subjects. Although different conclusions 
have been generated as to which frequency bands are involved in olfactory information 
processing due to variations in data analysis methods and stimulation paradigms for odour 
responses, our present data confirm previous findings in the theta and beta band in 
healthy subjects.
55;71;221
 A study by Klemm et al. showed widespread increases in the theta 
band in response to a variety of odours, especially over the left anterior group of EEG 
electrodes and the right hemisphere.
55
 Increases in evoked theta have been reported in 
response to various other sensory stimuli, such as visual and auditory stimulation.
222;223
 
The odour-induced changes in theta rhythm we observed are therefore probably 
associated with non-specific sensory processing.  
Our findings for spectral power in the beta band are concurrent with a recent MEG study 
using intravenous application of odorous stimuli, reporting event-related 
desynchronization in the beta (and gamma) band, mainly in the right precentral gyrus, and 
superior and middle frontal gyri.
71
 In addition, a study by Kemp et al. partly supports our 
findings, stating that elderly subjects with intact olfactory function displayed a decrease in 
beta band power in the odour condition, which was not specific to particular brain regions 
but rather an overall effect.
221
  
A decrease in relative spectral power in the alpha1 band was seen in both controls and PD 
patients, although this reached significance only in the PD patients. All subjects were told 
beforehand that odorous stimuli would be delivered; however, PD patients may not have 
been able to perceive any odour during the whole of the experiment, due to their 
olfactory dysfunction. This might have resulted in an increased state of vigilance or 
attention (“searching the odour”), compared to control subjects, and therefore in a 
significant decrease in (centro-parietal) spectral power in the alpha1 band.
224;225
 Another 
explanation for the findings in the alpha1 band might be derived from a series of studies 
by Lorig et al. who demonstrated a decrease in central alpha band power after low-
concentration odorous stimulation in healthy subjects.
226;227
 Possibly, suprathreshold 
odour exposure in PD patients who suffer from olfactory deficits is similar to low-level 
odour exposure in healthy subjects and thus induces a decrease in alpha power. 
The absence of a significant difference in odorant-induced changes in spectral power 
between PD patients and control subjects in this study corresponds to the results of a 
previous study by Gori et al. that failed to find any alterations in the EEG of PD patients 
after olfactory stimuli compared to control subjects.
228
 Spectral analysis apparently is not 
a suitable method to study differences in olfactory information processing between PD 
patients and controls.  
 
Synchronization likelihood is a measure of the integration of neuronal activity between 
brain regions (‘functional connectivity’), which is essential to normal brain function in a 
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resting-state condition, but also plays a key role in cognitive functioning. A number of 
recent studies have shown changes in functional connectivity between brain areas in the 
resting-state condition in various neurological disorders compared to healthy controls.
112-
115
 Moreover, analysis of functional connectivity has also proven a useful tool to study task-
related brain activity, for instance in a working memory paradigm.
115;229
 The present study 
showed that the analysis of functional connectivity is also a suitable method to study 
olfactory information processing, and moreover, to detect odour-induced differences in 
ongoing brain activity between healthy control subjects and PD patients. Olfactory 
stimulation induced a decrease in local SL in the beta frequency band in the control 
subjects and an increase in interhemispheric SL in the delta frequency band compared to 
the rest condition. Considering the decrease in the beta band in both overall relative 
power and local SL, this frequency band might be particularly sensitive to olfactory stimuli.  
Furthermore, an increase in functional connectivity between both hemispheres in the 
delta band was found in control subjects. A previous EEG study on odour-induced changes 
in functional connectivity revealed a decrease in coherence in the delta band in the frontal 
region.
52
 However, findings on functional connectivity in the delta frequency band should 
be interpreted with caution, as slow-wave artefacts as a result of breathing or ocular 
movement that might have passed the visual inspection unnoticed.  
The most interesting observation was an odour-induced decrease in intrahemispheric SL in 
the alpha2 band in PD patients, which was significantly different from the response to 
olfactory stimulation in control subjects. Apparently, in addition to the changes in 
functional connectivity in the resting state,
111
 PD patients also have a defective functional 
coupling within hemispheres in a stimulus condition.  
 
Correlations between olfactory function and changes in spectral power or functional 
connectivity were found in the alpha1 band, only for control subjects. The lack of a similar 
relationship between the scores on a psychophysical test and measures of local synchrony 
or functional connectivity in PD patients may be due to the differences in odour delivery 
between the psychophysical tests and the olfactory stimulation paradigm during the MEG 
registrations. The olfactory stimulus-paradigm used during MEG recordings is a ‘passive’ 
method of odour delivery, whereas psychophysical testing demands a more ‘active’ 
approach in order to perceive the odour. Since PD patients are reported to have difficulty 
sniffing,
107
 the reduced sniff vigour in PD patients might (partly) explain the lack of a 
correlation in the present study between the neurophysiological parameters, as measured 
by MEG, and the psychophysical test scores.  
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Conclusion 
In conclusion, the present study showed that time-series analysis of MEG data is a suitable 
method to detect odour-induced changes in brain activity. Furthermore, we demonstrated 
that there are differences in odour-induced functional connectivity, but not spectral 
power, between PD patients and control subjects. 
General discussion 
120 
Sniffing out Parkinson’s disease 
121 
 
General discussion 
 
General discussion 
122 
 
At present it is quite firmly established that olfactory dysfunction is one of the first clinical 
manifestations of Parkinson‘s disease (PD).
79;81
 Bearing in mind the recently introduced 
Braak staging system (see Figure 1) in which the olfactory system is one of the induction 
sites of the neuropathological process in PD,
16
 and considering that the onset of 
dopaminergic neuronal loss probably antedates the clinical diagnosis by about 3-7 
years,
230
 olfactory testing could be highly valuable in establishing an early diagnosis of PD 
when other clinical (motor) symptoms are not apparent yet. Also in the early clinical 
motor stages of PD, olfactory testing may contribute to the accuracy of the clinical 
diagnosis. In specific clinical situations, olfactory testing may help to differentiate between 
PD and other neurodegenerative disorders. Yet, still little is known about the involvement 
of the various specific olfactory modalities and their relationship to motor and other non-
motor disease characteristics. 
Furthermore, the pathophysiology of olfactory deficits in PD is far from being fully 
elucidated. Ultimately, we need to know how the known pathological changes contribute 
to the clinical olfactory deficits observed in PD. Therefore, olfactory imaging studies, 
structural as well as functional, are necessary to provide additional information. 
From this perspective, the following research questions were addressed in this thesis: 
• What is the prevalence and nature of impairments in the different specific olfactory 
modalities in PD and how do they relate to other (motor and non-motor) disease 
characteristics?  
• Which (combination of) olfactory test(s) is best at discriminating PD patients from 
control subjects? 
• Is it possible to explore the neurophysiological basis of olfactory (dys)function by 
means of MEG in healthy controls and PD patients? 
 
 
PREVALENCE AND NATURE OF OLFACTORY DEFICITS IN PD 
 
In order to assess the prevalence of olfactory deficits in PD in three different modalities 
(odour identification, discrimination and detection threshold), we formed a large sample 
of PD patients from three populations in Australia, Germany, and the Netherlands. In this 
study (chapter 2), age-independent criteria for hyposmia were first applied. These criteria 
had been derived previously from a group of 18-35 year old healthy subjects, considered 
to be the standard population in terms of normal olfactory sensitivity.
117
 Using these age-
independent criteria, only 3.3% out of a total of 400 PD patients were normosmic.  
However, since olfactory function is age-related,
121
 to reliably determine the prevalence of 
olfactory dysfunction in PD patients, normative values for a matched control population 
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are necessary. In addition to age, cultural influences also affect a subjects’ performance on 
olfactory tests. While odour threshold values are not culture dependent,
129
 performance 
on odour identification (and discrimination) tests relies on prior exposure to, and 
familiarity with the odours used.
130
 Normative values for these tests may therefore be 
influenced by the cultural background of the reference population. In chapter 1, we 
provided age-specific normative values for the Dutch population (over 45 years of age) for 
the two culture-dependent components of the “Sniffin’ Sticks” test battery: Odour 
identification and odour discrimination, and found them to be comparable to the German 
normative data for subjects over 55 years.
117
 However, the values for the Ducth population 
were lower than the values recently reported for the Greek population,
128
 which might be 
explained by cultural differences, such as a more important role of odours in the Greek 
cuisine. 
Subsequently, in chapter 3 we compared these normative values to a large population of 
Dutch PD patients from two university medical centres. The prevalence of an olfactory 
deficit in PD patients on either the odour identification or discrimination task in this study 
was 73%. Clearly, these figures are lower than those in chapter 2, obtained using age-
independent normative values derived from healthy young subjects. This is not very 
surprising, since olfactory function declines with age, even in healthy subjects.
121
 Also in 
chapter 2, when comparing the combined TDI scores of the (partly overlapping) 
multinational PD patients to (German) normative data in relation to the subjects’ age,
117
 
the percentage of PD patients with an olfactory deficit was only 74.5%. Using a different 
olfactory test, the 40-item UPSIT (University of Pennsylvania Smell Identification Test), 
Doty et al. reported a much higher prevalence (90%) of olfactory dysfunction in PD.
85
 This 
difference may be related to the method of individually matching PD patients with control 
subjects used by Doty et al. rather than to the olfactory test used, since Hawkes et al. 
reported olfactory dysfunction in 74% of PD patients, using the same 40-item UPSIT.
80
 
Apparently, taking all data in consideration, a significant minority of PD patients does not 
suffer from olfactory dysfunction.  
It has been suggested that PD patients with intact olfactory function may have been 
misdiagnosed and in reality suffer from a different neurodegenerative disorder that is not 
accompanied by olfactory dysfunction.
231
 Therefore, in this thesis, great care was taken to 
establish a precise diagnosis according to the United Kingdom Parkinson’s Disease Society 
Brain Bank criteria.
155
 Furthermore, although the Braak staging system suggests that 
olfactory bulb pathology is essential for a pathological diagnosis of PD,
16
 this does not 
necessarily imply that olfactory dysfunction should be present in all PD patients. Intact 
olfactory function in many PD patients, as demonstrated in the studies presented in this 
thesis, could indicate that olfactory deficits in PD may require additional pathology in 
other brain areas. Moreover, the validity of the Braak staging system and the proposed 
topographical spreading of Lewy pathology has been questioned recently.
232-235
 The results 
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of a post-mortem study demonstrated that the dorsal motor nucleus of the vagal nerve is 
not the induction site in all PD brains.
234
 The same could also hold true for the olfactory 
bulb. Along this line of reasoning, there may be a subgroup of PD patients without Lewy 
pathology in the olfactory bulb and, hence, without clinical olfactory deficits. Studies 
relating pathological data to clinical olfactory data of PD patients are necessary to address 
this issue.  
 
When focussing on the (age-independent) results from the individual olfactory tests in 
chapter 2, 85% and 87% of PD patients had deviant odour detection threshold or odour 
discrimination scores, respectively, whereas 96% scored outside the normosmic range for 
odour identification. Age-dependent results from chapter 3 showed an impairment in 
odour identification for 65% of PD patients relative to the performance of controls, 
whereas 42% of patients were impaired on the odour discrimination task. These different 
percentages of impairment for the specific modalities indicate that the sensitivity of 
olfactory testing for a diagnosis of PD depends on the test used to establish this diagnosis.  
Reduced olfactory acuity may affect performance on other olfactory tasks and thus lead to 
an overestimation of the actual deficit on the olfactory task in question. It has been 
argued that olfactory detection thresholds should therefore always be assessed in 
addition to the specific olfactory modality under consideration and used in appropriate 
statistical analyses to correct for impairments in odour detection.
37
 In chapter 6 we 
showed that odour identification and odour discrimination are impaired independent of 
increased odour detection thresholds in PD patients. By contrast, the results described in 
chapter 5 indicate that PD patients have a slight impairment of odour recognition memory 
that appears to be fully accounted for by an increased odour detection threshold. These 
findings argue against the notion that all olfactory impairments in PD would be based on a 
single common underlying deficit, such as an increased odour detection threshold.
34;37
 The 
pyshophysical data presented in this thesis suggest that olfactory dysfunction in PD entails 
a disturbance of multiple, but not all, olfactory modalities. 
 
 
RELATIONSHIP BETWEEN OLFACTORY (DYS)FUNCTION AND OTHER DISEASE 
CHARACTERISTICS 
 
The results presented in this thesis reveal that there is a relatively large percentage of 
normosmic PD patients when using age-specific normative values. Therefore, olfactory 
function might contribute to the phenotypic characterization of PD patients. 
Consequently, we wanted to determine the relationship between the different olfactory 
modalities and other domains in PD, including general disease characteristics, and specific 
motor and non-motor features. 
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Odour identification performance in PD was found to be related to age and sex, but 
independent of disease duration or stage (chapters 3 and 4), which is in accordance with 
previous reports 
85
 and supported by the pathological staging system by Braak et al. that 
shows that the olfactory bulb is involved in the earliest pathological stages.
16
  
The novel finding that odour discrimination performance decreases with disease duration 
in PD (chapters 3 and 4), partly relates to previous observations in a smaller sample of 
patients, in which disease stage and severity accounted for part of the variance in 
discrimination scores of PD patients.
81
 In addition, others have shown that odour 
discrimination performance in PD patients improves after stereotactic neurosurgical 
treatment using deep brain stimulation,
154
 concurrent with clinical motor improvement.  
The differential characteristics of the odour identification and discrimination deficits in PD 
suggest that these olfactory modalities involve at least partly distinct components of the 
olfactory information processing system. Several imaging studies (in healthy controls) 
support this notion by demonstrating that olfactory functions are mediated by common, 
as well as task-specific regions in the brain.
42;44;45
 Additionally, different cognitive 
components are involved in these two olfactory modalities: Working memory is critical 
when assessing odour discrimination, whereas language capacity or semantic memory is 
involved in identification (for review see 
36
).  
Our findings suggest that part of the PD patients may suffer from an odour identification 
deficit in the early phases of the disease, and develop an impairment in odour 
discrimination later on. This would also provide a further argument in favour of the notion 
that the olfactory deficits in PD may not solely depend on pathology in the olfactory bulb. 
Additional support for the latter notion comes from a recent fMRI study, pointing to other 
brain areas that may also be involved in PD-related olfactory dysfunction: the amygdala 
and the hippocampus.
106
  
In the olfactory bulb, specific ensembles of activated glomeruli are activated by each 
odorant.
166
 If Lewy pathology in the bulb somehow leads to a ‘shift’ in these 
representations, this could result in an alteration in recognition and thus in an incorrect 
identification of odorants. In odour discrimination testing, there is no need to recognize a 
specific odorant as such. Therefore, in PD, odour discrimination performance may be 
more resistant to olfactory bulb pathology than odour identification performance. Odour 
discrimination deficits may arise either with progressive degenerative changes in the 
olfactory bulb or, alternatively, when other brain structures become affected by the 
disease process. An independent progression over time of the different olfactory deficits 
in PD is compatible with a differential vulnerability to disease pathology. This could be 
investigated further, preferably by means of functional neuroimaging techniques and by 
studies relating pathological data to clinical olfactory data.  
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The presence of differential patterns of olfactory impairment might be related to other 
aspects of phenotypical heterogeneity among PD patients. This issue was addressed in 
chapter 4. Although odour discrimination deficits turned out to be related to disease 
duration, there were no other significant correlations between olfactory function and 
motor or (other) non-motor symptoms in PD, such as cognitive status, psychiatric 
complications, sleep or autonomic function. Moreover, as described in both chapter 2 and 
4 there were no significant differences with regard to olfactory test scores (as measured 
by TDI or separate olfactory modalities) between patients with different motor 
phenotypes (tremor-dominant, akinetic-rigid, postural instability gait difficulty or mixed). 
Consistent with previous reports,
79
 we did not find a relationship between the use of 
dopaminergic medication and olfactory performance on the identification or 
discrimination task (chapter 4). In combination with the pathological observation that the 
number of dopaminergic neurons in the olfactory bulb is doubled in PD,
102
 this strengthens 
the notion that the olfactory deficit in PD is independent of the dopaminergic deficit that 
is associated with the characteristic motor symptoms. 
 
In the study described in chapter 4 we did not test odour detection thresholds and 
therefore could not analyze the relationship between odour detection thresholds and 
other PD characteristics. Since a detection threshold test is often considered as a more 
peripheral measure of olfactory function, it may be hypothesized that such deficits are 
present in the early stages of the disease already and do not progress. However, since the 
experimental design of an odour detection threshold test resembles that of an odour 
discrimination test 
33
 and may therefore involve working memory, this should be explored 
carefully. 
 
 
DIAGNOSTIC VALUE OF OLFACTORY TESTING IN PD 
 
In considering the use of olfactory testing as a diagnostic procedure in patients suspected 
of suffering from PD, or as a component of screening strategies for the detection of PD in 
the premotor phase, the question arises which individual test or combination of tests 
would be best to use. As part of this thesis we aimed to determine which (combination of) 
olfactory test(s) is best at discriminating PD patients from control subjects. From the 
results described in chapters 2 and 3 we learned that odour identification is more 
frequently impaired in PD than odour discrimination and odour detection, and that an 
odour identification test allows a better discrimination between patients and controls. As 
described in chapter 5, odour recognition memory did not appear to be independently 
impaired in PD. Consequently, odour recognition memory testing is not useful as a 
diagnostic tool to differentiate between PD patients and control subjects.  
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The most widely used odour identification test, the UPSIT, consists of 40 items, whereas 
we used a 16-item odour identification subtest of the “Sniffin’ Sticks” test battery. 
Therefore, in chapter 6, we used extended versions of the odour identification and 
discrimination parts of the “Sniffin’ Sticks” to determine whether this would increase 
diagnostic accuracy of olfactory testing in PD. We found that adding more items within a 
single olfactory modality did not results in a better discrimination between PD patients 
and control subjects. These findings do not necessarily imply that the diagnostic potential 
of the identification part of the “Sniffin’ Sticks” is superior to the 40-item UPSIT. In order 
to reliably assess this, a direct comparison between the two tests is necessary, preferably 
in both healthy controls and PD patients. Additionally, since the UPSIT and “Sniffin’ Sticks” 
do not consist of identical odorants, item analyses for the odour identification tests could 
result in a set of odours that increases the diagnostic accuracy of this test further. 
However, this type of analysis would most likely be influenced by cross-cultural 
differences 
130
 and therefore yield different sets of odours depending on the population 
tested, limiting its practical use.  
In chapter 6 we also demonstrated that, in contrast to the lack of effect of adding more 
items to a test of a single olfactory modality, combining different olfactory modalities did 
increase the diagnostic accuracy of olfactory testing in PD. The combination of an odour 
identification and a detection threshold task turned out to be the best in differentiating 
between PD patients and control subjects. It would be quite interesting to apply this 
combination of olfactory tests in a prospective study, to assess whether this combination 
is also the most useful to distinguish healthy controls from subjects in the presymptomatic 
phase of PD. Observations in an ongoing prospective study in a cohort of asymptomatic PD 
relatives 
236
 surprisingly suggest that performance on an odour discrimination task was the 
best predictor for developing PD. This finding, however, may be related to the small 
number of subjects developing PD in this study. In fact, analyzed separately, worse 
performance on each olfactory test (including also odour detection and odour 
identification) was associated with an increased risk of future PD.  
 
The accuracy of the clinical diagnosis of PD is 90% at most.
237
 Among the cases of clinically 
misdiagnosed PD, the most frequent causes are multiple system atrophy,
86;237-239
 
progressive supranuclear palsy,
86;92;237;239
 and Alzheimer’s disease (AD).
239
 Although we did 
not provide direct data on the potential of olfactory testing as a tool for differential 
diagnosis in this thesis, testing of odour recognition memory may prove useful in 
distinguishing between PD patients and AD patients, since odour recognition memory 
appears to be impaired in AD,
98;240
 even when corrected for odour detection 
thresholds,
198-200
 and not in PD (chapter 5). This might be of particular value in screening 
for presymptomatic cases, when a definite diagnosis of AD or PD is not yet offered. Future 
studies directly comparing groups of PD and AD patients are necessary to confirm this. 
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Furthermore, in chapter 4 we confirmed the previous observation that PD patients with a 
Parkin mutation have normal odour identification scores 
168
 and extended this observation 
by showing that the same may hold for PD patients with a DJ-1 mutation. These 
observations suggest that odour identification performance may be useful for 
differentiating between idiopathic PD and certain genetic forms of PD.  
Although odour discrimination performance does not appear to play a significant role in 
distinguishing between PD patients and control subjects (chapter 6), this does not imply 
that this specific olfactory test could not be of significant value in distinguishing between 
different neurodegenerative disorders. Future studies will have to determine which 
combination of olfactory tests is most useful in the differential diagnosis between PD and 
other parkinsonian syndromes, such as multiple system atrophy and progressive 
supranuclear palsy. 
 
 
NEUROPHYSIOLOGICAL STUDIES OF OLFACTORY FUNCTION 
 
One of the aims of this thesis work was to explore the potential of recording olfactory 
event-related brain activity by means of MEG to serve both as a biological marker of 
impaired olfactory function in PD and as a means to study the pathophysiology of these 
olfactory deficits. As described in chapter 7, we first determined the number of 
chemosensory stimuli needed to obtain an optimal signal-to-noise (S/N) ratio for studying 
olfactory event-related responses by means of an olfactometer and EEG in healthy 
controls. The S/N ratio of olfactory and trigeminal ERP significantly improved up to 60-80 
stimuli, mainly due to a reduction of the noise level with increasing numbers of responses 
averaged and a concomitant decrease of signal amplitudes. We then performed a pilot 
study applying our EEG results to MEG. In previous studies in healthy controls, olfactory 
event-related magnetic fields had been reported, albeit with a source distribution that 
varied from one research group to another.
72;74-76;241
 In our pilot study in 23 PD patients 
and 22 controls, we were unable to obtain consistent olfactory event-related magnetic 
fields in each individual, not even in healthy subjects (unpublished observations). Possibly 
the orientation of olfactory sources is more radial than tangential to the skull surface. 
Since MEG is relatively less sensitive to radial sources, this would make EEG more suitable 
to detect olfactory event-related magnetic fields than MEG.
70
 At the time of our pilot 
study, parallel studies in PD patients using time-series analysis MEG data had revealed 
important changes in functional interactions between brain areas in the resting state.
111;242
 
Therefore, we chose to shift focus of our studies of olfactory event-related brain activity 
towards time-series analyses of MEG data as a means to gain more insight in the 
neurophysiological basis of olfactory information processing deficits in PD.  
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In chapter 8 we showed for the first time that time-series analysis of MEG data, including 
spectral power and synchronization likelihood, can be used to detect odour-induced 
changes in brain activity in healthy subjects. At present it is unclear whether these 
changes are specifically associated with olfaction, represent non-specific task-related 
effects of sensory processing, or are merely arousal-induced. With respect to spectral 
power, we found changes in the theta, beta and alpha1 band. Event-related 
desynchronization in the alpha and beta bands, similar to that in our findings, is generally 
interpreted as an electrophysiological correlate of activated cortical areas involved in 
processing of sensory or cognitive information.
243
 Klimesch suggested that alpha and theta 
power respond in different and opposite ways, with alpha power decreasing in a task 
condition, and theta power increasing,
244
 a pattern that corresponds to our findings during 
olfactory stimulation. An interesting focus for additional olfactory MEG research would be 
to localize the observed odour-induced changes in spectral power and functional 
connectivity by means of a beamforming technique (for a review and detailed description 
on beamforming techniques, see 
245
), to determine whether they are confined to 
anatomical olfactory areas or have a distribution compatible with non-specific task-
induced changes.  
In other mammals, high-frequency gamma oscillations have been recorded from the 
olfactory bulb.
246
 We were not able to detect changes in the gamma band, most likely 
because MEG is most suitable to detect activity from (tangential sources in) the cortex and 
provides limited information on activity from deep-lying structures such as the olfactory 
bulb.
70
  
A slowing of resting-state oscillatory brain activity in PD patients has previously been 
described by means of spectral power analysis on MEG data.
109;110
 Since the response in 
EEG or MEG to a stimulus depends on the level of ongoing activity, these resting-state 
changes might have an influence on task-related data obtained during olfactory 
stimulation in PD patients: The decrease in spectral power in control subjects during the 
olfactory stimulus might correspond to the decrease in power in a (s)lower frequency 
band in PD patients. However, those resting-state data were obtained in an eyes-closed 
condition, and are therefore not directly comparable to our task-related data from 
subjects with their eyes open, since eye-opening significantly influences the power 
spectrum.
247
 The absence of a significant difference in odour-induced changes in spectral 
power between PD patients and control subjects in this thesis corresponds to the results 
of a previous study by Gori et al. that failed to find any alterations in the EEG of PD 
patients after olfactory stimulation compared to control subjects.
228
 Spectral power 
analysis apparently is not a suitable method to study differences in olfactory information 
processing between PD patients and controls. 
In addition, in chapter 8, differences in odour-induced brain activity were found between 
PD patients and controls using analysis of SL. These differences may reflect olfactory 
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dysfunction and abnormal olfactory information processing in PD patients. Apparently, in 
addition to the changes in functional connectivity in the resting state,
111
 PD patients also 
have a defective functional coupling within hemispheres in a stimulus condition. Future 
olfactory imaging studies in otherwise healthy subjects with olfactory deficits unrelated to 
PD could reveal whether the observed changes in functional connectivity in PD patients 
are associated with olfactory dysfunction in general or, instead, related specifically to 
olfactory dysfunction in PD. 
As SL measures statistical interdependencies between sensors within or across regions of 
interest (ROI), it is fundamentally different from spectral power within a ROI; spectral 
power within a ROI is an average of the local field potentials measured at each individual 
sensor within that ROI and reflects the synchronous activity of underlying populations of 
neurons. It is therefore not surprising that spectral power showed a different pattern of 
changes during odour stimulation compared to SL, in both PD patients and healthy 
controls. 
 
In the study described in chapter 8, we used a ‘passive’ odour-delivery method, based on 
odour perception only. To further investigate the neurophysiological correlates of 
olfactory information processing, and in particular its dysfunction in PD, it would be 
interesting to perform similar experiments with the addition of several more complex 
olfactory tasks, such as odour identification or discrimination. This has been done 
previously in healthy controls by means of positron emission tomography (PET),
42;44;45
 
showing that olfactory functions are differentially mediated by task-specific regions in the 
brain. As argued above on the basis of the results of the studies presented in this thesis, 
odour identification deficits are presumably present in the early stages of PD, whereas 
odour discrimination performance may develop later in the course of the disease. Future 
MEG studies could reveal differential patterns of task-related connectivity changes during 
performance of these different olfactory tasks. Subsequently, a longitudinal approach 
could provide more insight in the (sequential) involvement of different brain regions 
and/or networks underlying olfactory dysfunction in PD. 
 
 
CONCLUSIONS 
 
In short, based on the studies presented in this thesis, the following conclusions can be 
drawn: 
The impairment of olfactory function in PD involves multiple, but not all, olfactory 
modalities: Odour recognition memory is not independently impaired in PD. 
Approximately 25% of PD patients do not have any impairment of olfactory function.  
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With the exception of odour discrimination, which is associated with disease duration, 
olfactory dysfunction in PD is not related to motor or (other) non-motor characteristics, 
indicating that olfaction is a largely independent feature of the disease process in PD. 
Adding more items to a test of a single olfactory modality does not improve its 
diagnostic value in discriminating between PD patients and controls. By contrast, 
combining tests of different olfactory modalities improves the diagnostic accuracy of 
olfactory testing in PD. A combination of an odour detection threshold task and a 16-item 
odour identification test best distinguishes between PD patients and controls.  
Time-series analysis of MEG data is a suitable method to study odour-induced changes 
in brain activity. In addition, this method can detect differences in odour-induced changes 
in brain activity between PD patients and controls using analysis of functional connectivity, 
but not of spectral power.  
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Olfactory deficits in Parkinson’s disease (PD) were first empirically documented in 1975 by 
Ansari and Johnson. Over the ensuing years it has become clear that most PD patients 
have olfactory disturbances that are not restricted to a single functional modality. Even in 
early stage, untreated PD patients, deficits in olfactory function have been demonstrated, 
which is supported by recent neuropathological studies demonstrating that the olfactory 
bulb and anterior olfactory nucleus structures may be among the induction sites of PD 
pathology. In later pathological stages, the olfactory bulb and tract are among the brain 
regions where Lewy bodies and Lewy neurites, the characteristic neuropathological 
features of PD, are particularly abundant. Since impairments in the sense of smell may 
even precede the development of overt motor symptoms, olfactory testing could prove 
valuable in establishing an early diagnosis of PD when other clinical (motor) symptoms are 
not apparent yet. Also in the early clinical motor stages of PD, olfactory testing may be 
useful as a diagnostic tool, both for distinguishing between PD patients and controls, and 
in differentiating between PD and other neurodegenerative disorders. Furthermore, the 
pathophysiology underlying the olfactory deficits in PD is far from being elucidated. 
 
The following research questions were addressed in this thesis: 
• What is the prevalence and nature of impairments in the different specific olfactory 
modalities in PD and how do they relate to other (motor and non-motor) disease 
characteristics?  
• Which (combination of) olfactory test(s) is best in discriminating PD patients from 
control subjects? 
• Is it possible to explore the neurophysiological basis of olfactory (dys)function by 
means of magnetoencephalography (MEG) in healthy controls and PD patients? 
 
 
Prevalence and nature of olfactory deficits in PD 
The “Sniffin’ Sticks” is a multimodal olfactory test battery that can be used to assess three 
different aspects of olfactory function: odour identification, discrimination and detection, 
each consisting of 16 items. 
In chapter 1, we provided age-specific normative values for the Dutch population (over 45 
years of age) for the two culture-dependent components of the “Sniffin’ Sticks” test 
battery: odour identification and odour discrimination. In chapter 3, we used these age-
dependent normative values to study the prevalence of deficits on the odour 
identification and discrimination task in a large population of Dutch PD patients from two 
university medical centres. The prevalence of an olfactory deficit in PD patients on any of 
the two tasks in this study was 73%. In chapter 2, we assessed the prevalence of olfactory 
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deficits (odour identification, discrimination and detection threshold) in PD in a large 
sample of PD patients from three populations in Australia, Germany, and the Netherlands. 
When we applied age-independent criteria for hyposmia, only 3.3% out of a total of 400 
PD patients were normosmic. However, when applying age-specific criteria, as we did for 
the Dutch cohort in chapter 3, 25.5% of patients were normosmic. From these data we 
concluded that, apparently, a significant minority of PD patients does not suffer from 
olfactory dysfunction.  
The results in chapter 3 further demonstrate an impairment in odour identification in 65% 
of PD patients relative to the performance of controls, and an impairment in odour 
discrimination in 42% of patients. The results described in chapter 5 indicate that PD 
patients have a slight impairment of odour recognition memory that appears to be fully 
accounted for by an increase in odour detection threshold. Taken together, these findings 
argue against the notion that the olfactory impairments in PD would be based on a single 
common underlying deficit, such as an increased odour detection threshold, but suggest 
that olfactory dysfunction in PD entails a disturbance of multiple, but not all, olfactory 
modalities. 
 
Relationship between olfactory (dys)function and other disease characteristics 
Since approximately 25% of PD patients do not appear to have olfactory deficits (see 
above), olfactory function might contribute to the phenotypic characterization of PD 
patients. Therefore, we wanted to determine the relationship between the different 
olfactory modalities and other PD characteristics. 
The results described in chapter 3 show that odour identification performance in PD is 
related to age and sex, but independent of disease duration or stage. By contrast, odour 
discrimination performance was found to decrease with disease duration in PD.  
Chapter 4 addresses the relationship between olfactory impairment and other aspects of 
phenotypical heterogeneity among PD patients. Apart from the above-mentioned 
association between odour discrimination deficits and disease duration, there were no 
other significant correlations between olfactory function and motor or (other) non-motor 
symptoms in PD, such as cognitive status, psychiatric complications, sleep or autonomic 
function. Moreover, there were no significant differences in olfactory test scores (either 
measured as a combined test score or each of three olfactory modalities separate) 
between patients with different motor phenotypes (tremor-dominant, akinetic-rigid, 
postural instability gait difficulty or mixed (chapters 2 and 4).  
 
Diagnostic value of olfactory testing in PD 
The results of the studies described in chapters 2 and 3 show that odour identification is 
more frequently impaired in PD than odour discrimination and odour detection, and that 
an odour identification test allows a better differentiation between patients and controls. 
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Odour recognition memory, was not independently impaired in PD (chapter 5), and is 
therefore not useful as a diagnostic tool to differentiate between PD patients and control 
subjects.  
In chapter 6, we used extended versions of the odour identification and discrimination 
parts of the “Sniffin’ Sticks” and found that adding more items within a single olfactory 
modality does not improve the diagnostic accuracy of these tests. By contrast, combining 
different olfactory modalities did increase diagnostic accuracy. A combination of an odour 
identification and a detection threshold task turned out to be the best in differentiating 
between PD patients and control subjects.  
 
Neurophysiological studies of olfactory function 
In chapter 7, we determined the number of chemosensory stimuli needed to obtain an 
optimal signal-to-noise (S/N) ratio for studying olfactory event-related responses by 
means of an olfactometer and electroencephalography (EEG) in healthy controls. The S/N 
ratio of olfactory and trigeminal event-related potentials significantly improved up to 60-
80 stimuli, mainly due to a reduction of the noise level. However, in a pilot study involving 
both healthy controls and PD patients, applying our EEG results to MEG, we were unable 
to obtain consistent olfactory event-related magnetic fields (unpublished observations). 
Therefore, we changed focus towards time-series analyses of MEG data instead, as a 
means to gain more insight in the neurophysiological aspects of olfactory information 
processing in healthy controls and the pathophysiology of olfactory dysfunction in PD. 
Chapter 8 describes the results of a study in which we were able to show for the first time 
that time-series analysis of MEG data, including spectral power and synchronization 
likelihood (a general measure of functional connectivity between brain areas), can be used 
to detect odour-induced changes in brain activity in healthy subjects. In addition, we 
found differences in odour-induced changes in brain activity between PD patients and 
controls using analysis of functional connectivity, but not of spectral power. These 
differences in functional connectivity may reflect abnormal olfactory information 
processing in PD patients that leads to the clinically observed olfactory impairments.  
 
General discussion 
In the general discussion, the data presented in the various chapters of this thesis were 
combined and a consideration of the potential implications as well as future research 
perspectives was provided. The most striking observations from the first two sections of 
this thesis are A) that apparently approximately 25% of PD patients do not suffer from 
olfactory dysfunction, B) that the impairment of olfactory function in PD entails a 
disturbance of multiple, but not all, olfactory modalities, and C) that a combination of an 
odour detection threshold test and an identification test is the best in distinguishing PD 
patients from controls. Furthermore, differential characteristics of the odour identification 
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and discrimination deficits in PD suggest that these olfactory modalities involve at least 
partly differential components of the olfactory information processing system.  
From the last section, we can conclude that time-series analysis of MEG data is a suitable 
method to study odour-induced changes in brain activity. In addition, differences in odour-
induced functional connectivity were found between PD patients and controls. The results 
obtained may be used in future olfactory neuroimaging studies to further investigate the 
pathophysiology of olfactory dysfunction in PD, in particular moving beyond the mere 
administration of odorants to the use of more complex tasks, such as odour identification 
or discrimination.  
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De eerste beschrijving van een reukstoornis bij de ziekte van Parkinson (ZvP) dateert uit 
1975. Sindsdien is het duidelijk geworden dat Parkinson-patiënten reukstoornissen hebben 
die niet beperkt blijven tot een enkele modaliteit. Zelfs in de vroegste en onbehandelde 
stadia van de ziekte zijn reukstoornissen aanwezig, wat in overeenstemming is met de 
resultaten van recente post-mortem studies. De voor de ZvP kenmerkende 
neuropathologische veranderingen (Lewy lichaampjes en neurieten) worden als eerste 
waargenomen in het olfactoire systeem en het verlengde merg en breiden zich in de loop 
van de ziekte volgens een vast patroon uit over de hersenen. Omdat een afname van het 
reukvermogen vooraf kan gaan aan de motorische symptomen van de ZvP, kunnen 
reuktests een belangrijk onderdeel vormen van een toekomstige screeningbatterij voor de 
vroege (presymptomatische) detectie van de ZvP. Ook in vroege klinische stadia van de 
ZvP zouden reuktests kunnen bijdragen aan het onderscheid tussen patienten met de ZvP 
en gezonde controles, en aan het onderscheid tussen de ZvP en andere 
neurodegeneratieve aandoeningen. De pathofysiologie van olfactoire disfunctie bij de ZvP 
is echter nog verre van opgehelderd. 
 
De volgende onderzoeksvragen komen aan de orde in dit proefschrift: 
• Wat zijn de prevalentie en kenmerken van stoornissen van de verschillende aspecten 
van het reukvermogen bij de ZvP, en hoe zijn deze gerelateerd aan andere (motorische en 
niet-motorische) ziektekarakteristieken? 
• Welke (combinatie van) reuktest(s) is het meest geschikt om patiënten met de ZvP te 
onderscheiden van gezonde controles? 
• Is het mogelijk de neurofysiologische achtergrond van olfactoire (dis)functie te 
onderzoeken bij gezonde controles en Parkinson-patiënten, met behulp van 
magnetoencefalografie (MEG)? 
 
 
Prevalentie en kenmerken van reukstoornissen bij de ziekte van Parkinson 
De “Sniffin’ Sticks” is een multimodale olfactoire testbatterij, die gebruikt kan worden om 
drie verschillende aspecten van het reukvermogen te meten: geuridentificatie, -
discriminatie, en -detectie, allen bestaande uit 16 items. 
In hoofdstuk 1 hebben wij leeftijdsafhankelijke normaalwaarden vastgesteld voor de 
Nederlandse populatie (van 45 jaar en ouder), voor de twee cultuur-afhankelijke 
onderdelen van de “Sniffin’ Sticks” testbatterij: geuridentificatie en geurdiscriminatie. 
Vervolgens zijn deze leeftijdsafhankelijke normaalwaarden in hoofdstuk 3 gebruikt om de 
aanwezigheid van een stoornis van het geuridentificatie of -discriminatievermogen te 
meten in een grote groep Nederlandse Parkinson-patiënten uit twee academische 
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ziekenhuizen. Een stoornis op een van beide reuktaken kwam voor bij 73% van de 
patiënten.  
In hoofdstuk 2 hebben wij bij een grote groep Parkinson-patiënten uit drie landen 
(Australie, Duitsland en Nederland) vastgesteld dat, op basis van leeftijdsonafhankelijke 
normaalwaarden, slechts 3.3% van de 400 Parkinson-patiënten een normaal 
reukvermogen heeft. Bij gebruik van leeftijdsafhankelijke normaalwaarden bleek 25.5% 
van de patiënten een intact reukvermogen te hebben. Uit deze resultaten concluderen wij 
dat blijkbaar bij een significante minderheid van de patiënten met de ZvP het 
reukvermogen intact is. 
De resultaten in hoofdstuk 3 laten zien dat 65% van de Parkinson-patiënten een stoornis 
heeft van het geuridentificatievermogen, terwijl 42% van de patiënten slecht scoorde op 
de geurdiscriminatietaak. De resultaten beschreven in hoofdstuk 5 maken duidelijk dat 
Parkinson-patiënten een geringe afname hebben in hun vermogen om geuren te 
onthouden en herkennen ten opzichte van gezonde controles, maar dit blijkt volledig te 
verklaren te zijn door een verhoogde geurdetectie drempel. 
Uit bovenstaande resultaten kunnen we concluderen dat de stoornis van het 
reukvermogen bij de ZvP blijkbaar niet op één gemeenschappelijk onderliggende factor 
berust, zoals een verhoogde geurdetectie drempel, maar verschillende, doch niet alle, 
aspecten van het reukvermogen behelst. 
 
Relatie tussen reukstoornissen en andere ziekteverschijnselen 
Aangezien ongeveer 25% van de patiënten met de ZvP geen reukstoornissen heeft (zie 
bovenstaande), zou het reukvermogen kunnen bijdragen aan de fenotypering van 
Parkinson-patiënten. Om deze reden hebben we gekeken naar de relatie tussen de 
stoornissen van verschillende aspecten van het reukvermogen en overige 
ziekteverschijnselen. 
Het vermogen om geuren te identificeren bleek bij Parkinson-patiënten gerelateerd te zijn 
aan leeftijd en geslacht, maar onafhankelijk van ziekteduur of ernst. Het vermogen om 
geuren te onderscheiden bleek echter wel gerelateerd te zijn aan ziekteduur (hoofdstuk 
3).  
Hoofdstuk 4 beschrijft de relatie tussen reukstoornissen en overige aspecten van de 
fenotypische heterogeniteit bij Parkinson-patiënten. Behalve de hierboven beschreven 
relatie tussen stoornissen van het geurdiscriminatievermogen en ziekteduur, zijn er geen 
significante relaties tussen het reukvermogen van Parkinson-patiënten en andere 
ziekteverschijnselen gevonden, zoals cognitieve stoornissen, psychiatrische complicaties, 
slaap, autonome functie of motorische functie. Bovendien bleken er geen significante 
verschillen te zijn in reukscores tussen patiënten met verschillende motorische fenotypes 
(tremor-dominant, akinetisch-rigide, houdings- en balansstoornissen (hoofdstuk 2 en 4). 
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Diagnostische waarde van reuktests bij de ziekte van Parkinson 
In hoofdstuk 2 en 3 is aangetoond dat het geuridentificatie vermogen vaker is aangedaan 
bij de ZvP dan het geurdiscriminatie- of geurdetectievermogen, en dat een 
geuridentificatietest beter onderscheid maakt tussen Parkinson-patiënten en gezonde 
controles. Het vermogen om geuren te onthouden en herkennen blijkt niet onafhankelijk 
gestoord te zijn bij de ZvP (hoofdstuk 5), en heeft dan ook geen waarde voor het 
onderscheiden van Parkinson patiënten en controles.  
In hoofdstuk 6 hebben wij verlengde versies van de geuridentificatie- en 
geurdiscriminatietaken van de “Sniffin’ Sticks” gebruikt. Uit de resultaten kwam naar 
voren dat het toevoegen van meer items binnen een test van een enkele reukmodaliteit 
geen significant effect heeft op de diagnostische waarde van de test. In tegenstelling 
hiermee heeft het combineren van taken die verschillende aspecten van het 
reukvermogen testen wel een positieve invloed op de diagnostische waarde. Een 
combinatie van een geurdetectietaak en een geuridentificatietaak bleek het best in staat 
Parkinson-patiënten van gezonde controles te onderscheiden. 
 
Neurofysiologisch onderzoek van het reukvermogen 
In hoofdstuk 7 hebben wij door middel van electroencefalografie (EEG) bij gezonde 
controles het aantal chemosensorische stimuli bepaald dat nodig is voor een optimale 
signaal-ruis verhouding. Deze signaal-ruis verhouding van zowel olfactoire als trigeminale 
‘event-related potentials‘ verbetert significant tot 60-80 stimuli, voornamelijk dankzij een 
afname van het ruisniveau als resultaat van het middelen van meer waarnemingen. 
Vervolgens zijn deze resultaten gebruikt in een pilot MEG studie bij gezonde controles en 
Parkinson-patiënten. Het bleek echter niet mogelijk om consistente veranderingen in 
magnetische velden te meten onder invloed van de aangeboden geurstimuli. 
Derhalve hebben wij ons vervolgens gericht op het analyseren van locale synchronisatie 
van hersenactiviteit (frequentie-analyse) en functionele connectiviteit binnen en tussen 
hersengebieden (synchronization likelihood), om op deze manier meer inzicht te krijgen in 
de neurofysiologische processen die betrokken zijn bij het verwerken van olfactoire 
informatie bij zowel gezonde controles als patiënten met de ZvP (hoofdstuk 8). De 
belangrijkste en nieuwe bevinding van deze studie was dat zowel frequentie-analyse als 
berekening van synchronization likelihood bruikbaar zijn om geur-geïnduceerde 
veranderingen in de hersenen te meten. Bovendien werden verschillen gevonden in 
functionele connectiviteit, maar niet in frequentie-inhoud, onder invloed van geurstimuli 
tussen Parkinson-patiënten en gezonde controles. Deze verschillen in functionele 
connectiviteit vormen wellicht een afspiegeling van de verstoorde verwerking van 
olfactoire informatie bij de ZvP die leidt tot de objectief en subjectief aanwezige 
reukstoornissen. 
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Discussie 
In de discussie wordt een overzicht gegeven van de resultaten van de diverse studies 
beschreven in dit proefschrift en worden suggesties voor toekomstig onderzoek gedaan. 
De meest opvallende bevindingen uit de eerste twee secties van dit proefschrift zijn dat A) 
ongeveer 25% van de Parkinson-patiënten geen reukstoornis hebben, B) dat de stoornis 
van het reukvermogen bij de ZvP verschillende, doch niet alle, aspecten van het 
reukvermogen omvat, en C) dat een combinatie van een geurdetectietaak en een 
geuridentificatietaak het best in staat is Parkinson-patiënten van gezonde controles te 
onderscheiden. Bovendien suggereren de verschillen in reukstoornissen bij de ZvP dat 
deze aspecten van het reukvermogen verschillende componenten omvatten van hoe 
reukinformatie in de hersenen wordt verwerkt. 
Uit de laatste sectie van dit proefschrift is gebleken dat bepaalde MEG analyse methodes 
geschikt zijn om geur-geïnduceerde veranderingen in de hersenen te meten. Bovendien 
bleken verschillen in geur-geïnduceerde functionele connectiviteit tussen Parkinson-
patiënten en gezonde controles aantoonbaar. Aan de hand van deze eerste resultaten 
kunnen vervolgstudies met behulp van MEG of andere beeldvormende technieken 
worden opgezet om de pathofysiologie van reukstoornissen bij de ZvP verder te 
onderzoeken, in het bijzonder door hersenactiviteit te meten tijdens meer complex 
reuktaken, zoals geuridentificatie en geurdiscriminatie.  
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LIST OF ABBREVIATIONS 
 
AD   Alzheimer’s Disease 
AUC   Area Under the Curve 
CAMCOG CAMbridge COGnition examination 
CO2  carbondioxide 
CSERP  ChemoSensory Event-Related Potential 
DIS  Discrimination task 
EEG  ElectroEncephaloGraphy 
ERP  Event-Related Potential 
fMRI  functional Magnetic Resonance Imaging 
H&Y  Hoehn and Yahr 
H2S  hydrogensulphide 
ID  Identification task 
ISI  InterStimulus Interval 
LUMC  Leiden University Medical Center 
MEG  MagnetoEncephaloGraphy 
MMSE  Mini Mental State Examination 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI  Magnetic Resonance Imaging 
OERP  Olfactory Event-Related Potential 
OI  Olfactory Impairment 
PD  Parkinson’s Disease 
PEA  PhenylEthyl Alcohol 
PET  Positron Emission Tomography 
ROC  Receiver Operating Characteristic 
ROI  Region Of Interest 
S/N  Signal to Noise 
SL  Synchronization Likelihood 
TDI  sum score of Threshold, Discrimination and Identification task 
THR  Threshold task 
UPDRS  Unified Parkinson’s Disease Rating Scale 
UPSIT  University of Pennsylvania Smell Identification Test 
VUMC  VU University Medical Center 
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